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ASSESSMENT OF HEMOGLOBINOPATHY TRAIT NOTIFICATION IN WESTERN 
PENNSYLVANIA NEWBORN SCREENING 
 
Caitlin Elizabeth Russell, MS, MPH 
 





Background: Newborn Screening (NBS) is a state-run public health program, which 
screens infants at birth for congenital conditions that may cause significant disability or death 
without prompt intervention. Carriers of sickle cell disease (SCD) are incidentally identified in 
the screening process yet are generally considered to be healthy. States’ policies regarding the 
incidental finding vary. Sharing the result challenges the traditional scope of NBS, and the 
history of sickle cell screening in the United States cautions against the program’s potential 
harms. States’ programs that do disclose positive sickle cell trait (SCT) status are primarily 
motivated by its reproductive implications. These programs notify stakeholders through a variety 
of means. This study sought to evaluate the impact of SCT notification on families in 
Pennsylvania, who are informed via a mailed letter. 
Methods: Parents in Western Pennsylvania who received the SCT notification letter within 
the past year were surveyed regarding their understanding of SCD, anxiety related to the 
notification, and anticipated sharing of the health information. 
Results: Ninety-four of 434 notified families completed the survey by mail and telephone. 
Over 36% of respondents were unclear of the inheritance pattern of SCD, and 29% incorrectly 
answered that SCT could develop into SCD. The greatest misunderstanding was found regarding 
Hemoglobin C trait and specific reproductive risks. The letter elicited anxiety in approximately 
   
 v 
one-third of parents. Over 90% of respondents planned to discuss the letter with their partner, 
their infant’s primary care provider, and their infant at an older age. 
Conclusions: The current notification letter inadequately conveys the health and 
reproductive implications of SCT and may contribute to anxiety in a meaningful proportion of 
parents. These findings support the utility of follow-up services in promoting understanding and 
minimizing stress related to carrier identification through NBS. Parents appear to appreciate the 
relevance of the information, based on their intent to share it with appropriate family and 
healthcare providers. Further research is needed to clarify additional effects of the program, in 
particular for the infant, who should be a primary beneficiary of NBS.  
Public Health Significance: This study may inform policies regarding disclosure of SCT 
status through NBS. 
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1.0 INTRODUCTION 
Newborn Screening (NBS) is a public health program that aims to diagnose congenital 
conditions in infants, so they may be provided with timely intervention.1 Since 2006, all 50 states 
and the District of Columbia have screened for sickle cell disease (SCD) through NBS.2 SCD is 
an autosomal recessive blood condition with multisystem pathology.3,4 Infants and children with 
SCD have an increased risk of potentially fatal pneumococcal infection, and the condition’s 
inclusion in NBS is based on the significant protection against infection that is conferred by daily 
penicillin started in infancy.5,6 Heterozygous carriers of SCD experience few related health 
consequences.7 However, they may have a baby with SCD if their partner also has a variant 
hemoglobin trait.  
The heterozygote carrier state, more commonly known as having sickle cell trait (SCT), is 
identified incidentally when screening for SCD during NBS. States that disclose the positive 
screening result to families are primarily compelled to do so by the information’s potential to 
inform reproductive decisions.6,8 However, this health information comes prematurely for the 
infant. It may not be recalled at the point in life when it is relevant and threatens their autonomy 
to choose whether or not to undergo carrier screening. While greater reproductive benefit may 
come to the screened infant’s parents, this is outside the traditional scope of the NBS program.9 
There is the additional concern that SCT notification may lead to adverse psychological and social 
harms, many of which were demonstrated in the country’s earliest SCD screening programs.10–13 
Studies of those communities most affected by SCD, which in the United States is primarily 
African American communities, have found that the information that trait notification seeks to 
provide is largely desired.14–18 Professional clinical and prenatal guidelines pertaining to SCD also 
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call for greater awareness of personal trait status and of its reproductive implications.19,20 
Programs’ abilities to achieve this informative benefit of SCT notification  while minimizing harm 
may rest in their execution. Great variation exists in how programs respond to a positive screen 
for SCT.21 Notification and counseling may be provided by the infant’s pediatrician, a specialized 
healthcare provider such as a genetic counselor, or may not be provided at all. Few states actively 
pursue follow-up with families whose infants screen positive for SCT to ensure that they have 
received the information.21  
A 2011 study performed at the Pediatric Sickle Cell Clinic of the University of Pittsburgh 
Medical Center (UPMC) Children’s Hospital of Pittsburgh (CHP) provided evidence that genetic 
counseling for SCT notification is positively received by families.22 Following genetic counseling, 
mothers demonstrated relatively high SCD knowledge scores, reduced anxiety, and a greater 
reported likelihood to share the health information with close family members. While genetic 
counseling is still available to those who request the service, the program for active follow-up of 
SCT NBS results at the Pediatric Sickle Cell Clinic of CHP, which included three calls made to 
the family by a specialized healthcare provider to offer genetic counseling or other educational 
and counseling services over the telephone or through the mail, has not been sustained. As a 
consequence, trait notification occurs solely through a letter and informational brochure for the 
majority of families. The mailing, which is sent within two weeks of the infant’s positive screen, 
also includes contact information for the Pediatric Sickle Cell Clinic. No additional services are 
provided through the NBS program unless the family actively pursues them. 
This study seeks to characterize the experience of families who are notified of their infant’s 
positive NBS screen for SCT through the mail. A survey was administered to families living in 
Western Pennsylvania who received the notification letter for either Sickle S trait or Hemoglobin 
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C (HbC) trait. The Pediatric Sickle Cell Clinic of CHP is contracted with the Pennsylvania 
Department of Health to follow-up on positive NBS results for hemoglobinopathies and to notify 
families for hemoglobinopathy traits in 19 counties.23 As this is the same region from which 
families were recruited for the previous studies of genetic counseling following SCT notification, 
this current study may inform both the understanding of how the genetic information is received 
through the letter alone, as well as how additional educational and counseling services may affect 
its impact.22,24 
This study will focus on knowledge of SCD, the letter’s emotional impact on notified 
parents, and disclosure patterns of the health information, as these describe three of the program’s 
potential benefits and harms. The data generated by this study may provide insight into how 
positive SCT results are disclosed through the current NBS program of Pennsylvania, as well as 
potentially by other states’ programs. We anticipate that results of this study will guide revision of 
the NBS trait notification letter currently sent out to families in Western Pennsylvania. 
1.1 SPECIFIC AIMS 
1.1.1  Specific Aim 1 
To assess knowledge levels regarding the health and reproductive implications of SCD 
among mothers who have been notified of their infant’s positive screen for Sickle S trait or HbC 
trait through the current NBS program of Western Pennsylvania, which consists of an 
informational mailing sent within two weeks of the positive screening result. Knowledge will be 
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measured through an eight-question true/false and multiple-choice questionnaire administered 
through the mail or telephone within approximately one year of the infant’s birth. 
1.1.2  Specific Aim 2 
To determine through mail and telephone surveys whether trait notification for SCT 
through the mail results in increased anxiety in notified parents. The survey tools will be the 
PROMIS Short Form 8a Scale of Anxiety (PROMIS) for the mail surveys and a single yes/no 
question for the telephone surveys. 
1.1.3   Specific Aim 3 
To examine the willingness of parents to share their infant’s SCT status with their 
reproductive partner, relevant healthcare providers, and the infant him or herself at an older age. 
This will be measured through both mail and telephone surveys, in which participants will be asked 
if they have shared or intend to share the letter’s health information with the respective individuals. 
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2.0 LITERATURE REVIEW 
2.1 SICKLE CELL DISEASE 
Sickle cell disease (SCD) is a group of inherited blood disorders characterized by 
structurally abnormal hemoglobin.3,4 The condition’s name derives from the physical deformation, 
or sickling, of red blood cells (RBC) that may be observed on blood smears of affected 
individuals.25 Sickled RBCs tend to obstruct blood flow through the vessels and have a decreased 
lifespan.4 These properties of affected RBCs contribute to the pain crises, extensive organ damage, 
and hemolytic anemia that characterize the clinical presentation of SCD.3,4 As one of the most 
common single-gene disorders, SCD represents a significant public health concern both in the 
United States and worldwide.26  
2.1.1  Molecular Genetics  
SCD is a monogenetic disorder that affects hemoglobin, the oxygen-transporting molecule 
of RBCs.3 Hemoglobin is a tetramer composed of two unlike pairs of globin polypeptides. The 
polypeptides are coded for by the globin genes on chromosomes 11 and 16. Differential expression 
of the globin genes allows for the composition of hemoglobin to change throughout development.27  
Fetal hemoglobin (HbF) is the predominant form of hemoglobin at birth.27 HbF consists of 
two alpha subunits, encoded by the HBA gene pair (HBA1 and HBA2), and two gamma subunits, 
encoded by HBG gene pair (HBG1 and HBG2). During fetal development, adult hemoglobin 
(HbA) gradually begins to replace HbF. By six months of age, approximately 97% of the 
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hemoglobin in the blood of individuals not affected with SCD is HbA.27 The HbA tetramer consists 
of two alpha subunits and two beta subunits. The latter are encoded by the HBB gene. For 
individuals with SCD, the transition from HbF to HbA is delayed. HbF levels also remain 
perpetually higher in affected individuals and range between 2% to 20%.28  
The abnormalities in hemoglobin that define SCD arises from mutations in the HBB gene.3 
Causative mutations of SCD lead to either a structurally variant form of the beta globin subunit or 
in diminished or absent HBB protein product. Individuals with SCD possess at least one HbS allele, 
in which a thymine to adenine point mutation results in the substitution of valine for glutamic acid 
at the sixth amino acid of the HBB gene (Glu6Val).29 This is translated into a structurally variant 
beta globin subunit that gives rise to a form of hemoglobin known as Hemoglobin S (HbS), or 
Sickle Hemoglobin. The most common form of SCD is caused by biallelic HbS alleles. This is 
known as HbSS disease, or sickle cell anemia.26 In the United States, HbSS disease accounts for 
approximately 60 to 70% of SCD.30 
While hundreds of hemoglobin variants have been characterized, clinical relevance is 
limited to a smaller subset. Common HBB alleles that contribute to SCD include HbC (Glu6Lys), 
HbD (Glu121Gln), and HbE (Glu121Lys).31 Genotype serves as a significant predictor of clinical 
severity in SCD.32 HbSS disease is typically one of the most severe forms of the condition, while 
HbSC disease, which is characterized by one HbC allele and one HbS allele, is typically more 
mild.33 HbSC disease is the second most common form of SCD in the United States, where it 
accounts for between 18 to 25% of SCD.34 
Pathogenic variants in the HBB gene that affect the quantity of beta globin, rather than its 
structure, can also contribute to SCD. Referred to as β-thalassemia mutations, these are either gene 
deletions or mutations that inhibit HBB gene transcription or mRNA stability and translation.3 The 
   
 7 
clinical significance of a β-thalassemia mutation is based on the degree of residual beta globin 
gene expression. The β+ allele is associated with diminished protein product, whereas the β0 allele 
is associated with no protein product. Accordingly, HbS-β0 Thalassemia typically has a severe 
presentation like that of HbSS disease, while those with HbS-β+ Thalassemia are typically more 
mildly affected.32 HbS-β+/0 Thalassemia together account for between 1 to 6% of SCD in the 
United States.34 
2.1.2  Pathophysiology 
The clinical features of SCD arises from the unique chemical properties of HbS. Namely, 
HbS polymerizes in its deoxygenated state.3 Long, stiff protein fibers of polymerized HbS form 
within the RBCs. This deforms the cells from their usual donut shape into the sickle shape that is 
synonymous with SCD.35 HbS polymerization lessens the integrity of the RBC cytoskeleton and 
cellular membrane through repeat sickling.35 This causes the lifespan of circulating RBCs in 
individuals with SCD to average 20 days, as compared to the 120 day lifespan of unaffected RBCs. 
In some affected individuals, the sickled RBCs may circulate as few as five to seven days.35 The 
shortened lifespan of RBCs in SCD results in hemolytic anemia, one of the condition’s primary 
features.3 
Sickled RBCs are also less elastic and more prone to adhere to one another and to other 
circulating cells.4 These qualities stimulate heterocellular aggregation of the sickled RBCs with 
other circulating components, such as leukocytes and platelets. Blood flow through the 
microvasculature can be obstructed by these aggregates, as they also demonstrate greater 
adherence to the vascular endothelium. When the blood flow is obstruction in the microvasculature 
in this way, this is known as vaso-occlusion. Vaso-occlusion can lead to ischemia, infarction, and 
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tissue death.35 The widespread effects of recurrent vaso-occlusion events account for many of the 
multisystemic manifestations of SCD. 
Pain Episodes: Vaso-occlusive episodes result in ischemic tissue injury from prolonged 
oxygen and nutrient deprivation.35 This is commonly experienced as acute pain. Pain crises are the 
hallmark clinical feature of SCD.3 The events often come on unpredictably and may be precipitated 
by environmental factors, such as dehydration or hypoxia arising from physical exertion.36 In 
infants, pain is most often reported in the extremities; whereas in adolescents and adults, it 
typically presents in the chest, abdomen, back, and head.37 Pain episodes usually last between four 
to six days. In the United States, they are the primary cause of emergency room visits as well as 
hospital admissions related to SCD.38 Dactylitis, or the painful swelling in the hands and feet, is 
another manifestation of vaso-occlusion in the extremities. This is often the first sign of SCD 
observed in infants.4 
Spleen Dysfunction: The spleen is one of the earliest organs involved in SCD.39 Splenic 
dysfunction appears to arise from recurrent vaso-occlusion and infarction and can lead to 
progressive atrophy and/or splenomegaly. By the age of five, approximately 94% of children with 
HbSS disease will have developed functional asplenia.40 
Insufficient splenic filtration of sickled RBCs, bacteria, and other waste products 
contributes to impaired immune response.41 Other common complications of SCD, such as 
impaired antibody production, tissue ischemia, and micronutrient deficiency, exacerbate immune 
dysfunction in affected individuals.44 Infants and young children with SCD are particularly 
susceptible to invasive encapsulated bacterial infections and sepsis. Prior to the implementation of 
effective intervention, infection was associated with between 20%-50% of childhood deaths in 
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SCD in the United States.46 Infection remains the primary cause of death for those with SCD 
around the world.47–49 
Another life-threatening complication of SCD in infants and children related to the spleen 
is acute splenic sequestration crises (ASSC).50 ASSC arises from rapid accumulation of sickled 
RBCs and other circulating blood constituents in the spleen, which results in a sudden onset of 
anemia and threat for hypovolemic shock.4 Acute splenic sequestration crises commonly present 
with severe anemia; lethargy, irritability, abdominal pain and/or distention, and nausea may also 
arise. Without the timely intervention of a blood transfusion, splenic sequestration can result in 
death. Acute splenic sequestration is most prevalent between five months to two years of age and 
is the second leading cause of mortality in children with SCD.42  
Acute Chest Syndrome: The vasculature of the lung is particularly susceptible to 
complications of SCD. A primary manifestation of the disorder’s cardiovascular involvement is 
Acute Chest Syndrome (ACS). ACS is characterized by infiltration of sickled RBCs into the 
pulmonary vasculature.43 It is also associated with increased white blood cell count and 
pneumonia-like symptoms. Often, it is preceded by a vaso-occlusion crisis, and in children, it is 
commonly precipitated by infection or asthma.36 ACS presents typically presents with shortness 
of breath (tachypnea) and hypoxia, as well as potentially chest pain, fever, pain in the arms, legs, 
and sternum. It is the second most common cause for SCD-related hospitalization in adults.36  
Neurological involvement: Vaso-occlusive events in the larger arteries of the brain can 
lead to ischemic strokes. Without transfusion therapy, the risk of recurrence in affected children is 
at least 67%.44 Cognitive and physical impairment is a serious complication of such events. Silent 
cerebral infarctions, which are defined as abnormal brain magnetic resonance imaging findings in 
the absence of a history of neurological deficits, occur in over one-third (35%) of children with 
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HbSS disease.45 These events can cause lasting brain injury. The risk for hemorrhagic strokes is 
also increased with SCD, with the events primarily occurring in adulthood. While more rare than 
ischemic strokes, hemorrhagic strokes are associated with a 24-65% mortality rate in SCD.46 
2.1.3  Sickle Cell Trait 
SCD is an autosomal recessive condition.47 Its carrier state is commonly referred to as 
sickle cell trait (SCT). Approximately three million individuals in the United States are estimated 
to be heterozygous for the HbS allele., also known as Sickle S trait30 In these individuals, HbS 
concentration in the RBCs ranges from between 20 to 45%.48 This is sufficiently low to preclude 
hemoglobin polymerization under normal physiological conditions. Consequently, the RBCs of 
carriers of the HbS allele do not tend to undergo sickling in vivo and do not experience the clinical 
complications of SCD except under extreme sickling conditions.35,48 
Clinical Manifestations: SCT has historically been confused as a more mild form of 
SCD.10,13 However, while a number of complications have been associated with the carrier state, 
the great majority of individuals with SCT remain asymptomatic.7,49 A 2018 evidence-based 
review by Naik et al. aimed to clarify the extent to which SCT affects health. From an initial screen 
of 7,083 articles published between 1970 to 2018, the review’s authors evaluated 41 observational 
control studies for their support of an association between SCT and an increased risk for clinical 
outcomes in six categories.7 The majority of studies were cohort (n = 16) and case-control (n = 16) 
studies.  
The review found high-strength evidence for an increased risk of three complications for 
carriers of the HbS allele: pulmonary embolism (PE), proteinuria, and chronic kidney disease 
(CKD). One high-quality study of PE risk found a prevalence of 5.2% in those with SCT compared 
   
 11 
to a prevalence of 2.5% in those without; this represents a hazard ratio (HR) of 2.24 (95% CI = 
1.28 to 3.95) associated with SCT.50 Regarding proteinuria, risk for the renal complication was 
found by one high-quality study to be 1.86-times higher (95% CI = 1.49 to 2.31) in African 
Americans with SCT compared to those without. Finally, the risk for chronic kidney disease 
associated with SCT was found to be 1.57 times greater (19.2% versus 13.5% prevalence) by one 
high-quality study and 1.89-time higher (1.59 to 2.23) by a second high-quality study.51 The review 
also found an increased risk for exertional rhabdomyolysis supported by a moderate-level of 
evidence. For the remaining complications examined, which comprised the majority, low-strength 
or insufficient evidence was found in support of an association with SCT. 
Exertion-related Events: A potential complication of SCT that has received much 
attention both medically and in the media is the risk for exertion-related injury. Extreme physical 
exertion may cause significant changes in pH, oxygen availability, temperature, and RBC 
hydration, which could potentially lead to RBC sickling and acute vaso-occlusion events in those 
with SCT.52 Particularly in the setting of dehydration and hypoxemia, these metabolic changes 
have been postulated to contribute to potentially fatal events of rhabdomyolysis, heat illness, 
cardiac arrhythmia, or renal failure as a result of intense exercise or other physical exertion. 
Reports of sudden death owing to extreme exertion in those with SCT first appeared in 1970s and 
focused on sudden death in military recruits performing boot camp drills.53,54 More recently, case 
reports have implicated SCT as the cause of sudden death in college and professional athletes as 
well.52,53  
In their 2018 review, Naik et al. reviewed the risk for exertion-related complications, 
namely splenic infarction, exertional rhabdomyolysis, and sudden death associated with SCT.7 No 
evidence was found to support an association of splenic infarction with SCT. Two studies were 
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reviewed for evidence regarding a risk of exertion-related rhabdomyolysis.55,56 The first, a 15-
subject case-control study, provided low-quality evidence in support of an increased risk owing to 
SCT due to its small size and lack of adjustment for confounders.55 The second study provided 
moderate-quality evidence for this increased risk.56 This 2016 study was funded by the NHLBI 
and Uniformed Services University of the Health Sciences and reviewed events of exertional 
rhabdomyolysis and death as they occurred between 2011 and 2014 among African American 
soldiers enlisted in the US Army. Of the 47,944 individuals, 3,564 were positive for SCT. A key 
strength of this study was that trait status was established in all subjects through laboratory testing, 
rather than self-report or medical history, ensuring validity to this variable. Three-hundred and 
ninety-one events of exertional rhabdomyolysis were found among the 1.61 million person-months 
analyzed. Forty-two events occurred among individuals positive for SCT (1.2%), compared to 349 
among those without SCT (0.8%). SCT was consequently found to be associated with a 
significantly increased risk of exertional rhabdomyolysis, with a HR of 1.54 (p-value = 0.008).56  
The study contextualized its results by analyzing the risk for these medical events in 
relation to reported characteristics besides SCT status, including body-mass index (BMI), tobacco, 
statin, and antipsychotic use.56 The increased risk of rhabdomyolysis associated with SCT was 
nearly identical in magnitude to that associated with tobacco use (HR = 1.54, p < 0.001). The HR 
associated with SCT was also similar to that associated with having a higher BMI, defined as 30.0 
or greater. Compared to a BMI less than 25.0, the HR associated with higher BMI was 1.39 (p = 
0.03). Finally, use of statins or antipsychotic agents were found to be associated with a greater risk 
of rhabdomyolysis than was having SCT, with HR of 2.89 (p = 0.001) and 3.02 (p = 0.008), 
respectively. Overall, Naik et al. determined that moderate-quality evidence supports a higher 
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relative risk, yet low absolute risk, for exertion-related rhabdomyolysis associated with positive 
SCT status.  
Lastly, Naik et al. found low-strength evidence in support of an increased risk for sudden 
death arising from extreme exertion in those with SCT.7 This conclusion was drawn from 
consideration of two studies, both of which providing moderate quality evidence. The first was a 
1987 retrospective review by Kark et al. considered to be seminal in establishing the connection 
between SCT and exercise-related death.54 The study evaluated for the relative risk of sudden 
unexplained death among 466,300 African Americans undergoing military basic training between 
1977 and 1981.7 Using prevalence measures, the risk of sudden death among those with SCT was 
found to be 15-fold higher than those without (95% CI = 6 to 38). Thirteen total deaths occurred 
among those with SCT (0.03%), compared to ten among those who did not have SCT (0.0002%). 
Naik et al. found no association between SCT and “non-battle-related death” after adjusting for 
variables such as sex, age, rank, BMI, and smoking.7 The second study examined by Naik et al. 
was the 2016 study which was also considered for rhabdomyolysis risk.56 In this case, ninety-six 
deaths, battle and non-battle-related, were recorded. Seven of these deaths were among individuals 
with SCT (0.2%), and 89 deaths were among those without SCT (0.2%). From these mortality 
rates, no significant increased risk of death was found to be associated with positive SCT status 
(HR = 0.99, p = 0.97). 
In spite of the weak connection between SCT and sudden death due to extreme exertion, 
multiple groups, including the United States armed forces and collegiate and professional sports 
associations have instigated screening programs for SCT.57–59 In 2007, the National Athletic 
Trainers’ Association (NATA) put forth the consensus statement “Sickle Cell Trait and The 
Athlete,” which recommended screening and precautions for athletes with SCT, while supporting 
   
 14 
their participation in all sports.60 Additionally, it recommended education for both coaches and 
athletes regarding how to appropriately respond to the potential complications of SCT. However, 
the recommendations were not evidence-based and were not supported by many professional 
groups, including the Sickle Cell Disease Association of America, American Society of 
Hematology, and the Secretary’s Advisory Committee Heritable Disorders in Newborn and 
Children (SACHDNC).58,61,62 
While the United States’ army ceased its screening program in 1996 in favor of universally 
applied precautions, both the Air Force and the National Collegiate Athletic Association (NCAA) 
continue to require screening for SCT.59 These programs have been met with criticism for being 
litigious in nature, at the cost of potential stigmatization and loss of privacy for participants.49,59 
SACHDNC does not endorse the NCAA screening program. Rather, the Committee’s 
recommendation is for all SCT  screening to be performed in an individual’s medical home with 
the assurance of privacy.58 As a primary prevention strategy, SACHDNC advises education and 
the use of universal precautions such as proper hydration, accommodation of rest and recovery, 
and heat acclimation. 
Reproductive Risk: With the majority of clinical manifestations of SCT being rare and 
presenting only under extreme conditions, the most significant implication of having SCT is 
largely considered to be its reproductive risk.3 Specifically, those with SCT have a 25% chance 
with each pregnancy to have a child with SCD if their partner also carries SCT or another variant 
hemoglobin trait that contributes to HbS polymerization in the deoxygenated state.47  
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2.1.4  Demographics 
SCD is the most common inherited blood condition in the world.26 Its prevalence is highest 
in those of African, Indian, Middle Eastern, Southeast Asian, Mediterranean, Latin American, and 
Caribbean descent. In the United States, between 72,000 and 98,000 individuals are estimated to 
have SCD.34 The majority are African American. SCD is estimated to occur in approximately one 
in every 400 African American, one in every 36,000 Hispanic, and one in every 80,000 Caucasian 
births.30  
About 8% of African Americans are carriers of the HbS allele. The prevalence increases to 
10% when other variant hemoglobin traits, such as Hemoglobin C and ß-Thalassemia, are 
included. The three most common forms of SCD in the United States are HbSS disease, HbSC 
disease, and HbS-β0/+ Thalassemia.34 
2.1.5  History in the United States 
In the United States, the minority population that SCD disproportionally affects has shaped 
the condition’s social and political narrative. The first observations of SCD in the country occurred 
exclusively in those of African ancestry, which fed the belief that SCD was a “race specific 
disease” whose “occurrence depends entirely on the presence of Negro blood.”63 Dating from the 
mid 19th century, the first written accounts of SCD in the United States report of characteristics 
suggestive of the condition in African slaves.64 The sickle-shaped RBCs that are now iconic of the 
disease were first described in 1910 in the blood of an anemic dentistry student from Grenada 
named Walter Clement Noel. The Chicago physician, James Herrick, is credited with discovering 
SCD through his detailed report of this observation made in Noel’s blood sample.65 By 1923, a 
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number of similar findings led to the condition being named sickle cell anemia.25 For 
asymptomatic individuals whose blood was observed to sickle in vitro, the term “sicklemia” was 
coined in 1926.66 This is what is now known be the carrier state, or SCT.  
Scientific advancements throughout the mid 1900s helped clarify the mechanism of SCD 
inheritance. In 1923, two Johns Hopkins physicians, Taliaferro and Huck, published their study of 
SCD that they had traced through multiple generations of a Virginia family.67 Their paper correctly 
established SCD to be passed down as a single-gene Mendelian trait, yet it erroneously presented 
the condition as following an autosomal dominant mode of inheritance. The autosomal recessive 
nature of SCD was clarified in 1949 by James Neel.47  
Experiments carried out in the mid 1900s helped to elucidate the molecular basis of SCD. 
In 1927, E. Vernon Hahn and Elizabeth Gillespie observed that anoxia stimulated the sickling of 
RBCs.68 Electrophoresis migration studies carried out by Linus Pauling in 1949 determined that 
the hemoglobin molecules of affected and unaffected individuals differed in their electric 
charges.69 This experiment was notable in that it was the first to directly connect a protein’s 
chemical properties to disease pathology, and the resulting paper “Sickle Cell Anemia: A 
molecular disease” made SCD the first so-termed molecular disease. Sequencing of the HBB gene 
by Vernon Ingram and J.A. Hunt in 1957 traced the origin of this chemical difference in 
hemoglobin to the single glutamine to valine amino acid substitution.29 
Despite this scientific progress, SCD continued to be associated with a high mortality rate 
throughout the early 20th century.64 The average life expectancy for affected individuals remained 
under 20 years old into the 1970s.70 With the high prevalence of infectious disease at this time, 
SCD-related deaths were often attributed to pneumonia or tuberculosis, with little attention given 
to the underlying genetic cause.71 The high childhood mortality rate associated with SCD 
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disproportionately affected African American communities, thereby aggravating racial disparities 
in health that were gaining national attention.64 
SCD grew as a public health and justice concern under the sociopolitical climate of the 
1960s. National attention of the issue peaked in 1970, with the publication of the editorial “Health 
Care Priority and Sickle Cell Anemia.”72 Its author, the hematologist Robert B. Scott, argued that 
the amount of federal funding allocated to SCD was significantly less than other childhood genetic 
disorders, such as cystic fibrosis, muscular dystrophy, and phenylketonuria, relative to the 
population size it affected. Through reframing the shortage of funding devoted to the condition as 
a matter of civil rights, Scott, who himself was African American, rallied for increased public and 
federal backing of SCD research, screening, early diagnosis, and disease management.  
Scott’s paper is largely credited with stimulating the creation of SCD screening, clinical 
care, and education programs nationwide.64,72,73 The year following its publication, the National 
Association for Sickle Cell Disease was established as the first national organization dedicated to 
SCD research, education, and funding.74 Formed from the union of fifteen independent 
community-based SCD organizations, it persists today under the name Sickle Cell Disease 
Association of America. Also in 1971, President Nixon brought national attention to the issue in 
his Presidential Message to Congress, which highlighted deficiencies in SCD funding.75 His speech 
spoke of SCD as a neglected disease and echoed Dr. Scott’s concerns for an increased need for 
federal support for the condition. Congress responded by passing the Sickle Cell Anemia Control 
Act in 1972.75,76 This legislation was the first federal program to target a specific genetic disorder.64 
Acknowledging SCD as a significant public health concern, it allocated ten million dollars for 
SCD screening, counseling, treatment, education, and research programs, thereby providing a ten-
fold increase in funding from what had previously been available.75 One important product of this 
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funding was the Hemoglobinopathy Reference Laboratory, which is based at the Centers for 
Disease Control and Prevention (CDC) and serves as a national reference library for state health 
departments, Sickle Cell Clinics, and Sickle Cell centers that test for SCD.2 The Control Act also 
funded the creation of the National Sickle Cell Disease Program, as well as the establishment of 
41 SCD treatment centers throughout the country.2,49 These centers continued to expand with 
funding that was renewed in 2003 through the Sickle Cell Treatment Act.77 
As funded by the Control Act, The National Heart, Lung, and Blood Institute established a 
Sickle Cell Branch for research into SCD natural history and therapy in 1973.75 Under this group, 
the multicenter Cooperative Study for Sickle Cell Disease (CSSCD) was formed in 1977. The 
CSSCD was a prospective study of SCD, which aimed to better understand the condition’s natural 
history as well as factors that influence its morbidity and mortality.78 3,800 participants were 
recruited from twenty-three institutions between 1978 and 1988. One of the most well-known 
studies to come out of the project was the Prophylactic Penicillin Study (PROPS) Trial, which 
demonstrated the effectiveness of penicillin prophylaxis in decreasing invasive pneumococcal 
disease in children with SCD.5 The results of the PROPS I trial were published in the New England 
Journal of Medicine in 1986, prompting the National Institutes of Health (NIH) Consensus 
Committee, cosponsored by Health Resources and Services Administration (HRSA), to 
recommend universal newborn screening for hemoglobinopathies in 1987.6 The NIH statement 
specified that state laws should provide voluntary universal SCD screening for all newborns, in 
order to allow for the timely initiation of oral penicillin to all those diagnosed. 
Significant increases in the life expectancy for those with SCD have been made in the three 
decades following the NIH recommendation. This has largely been attributed to the introduction 
of penicillin prophylaxis along with pneumococcal vaccination and parental education, as enabled 
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through universal newborn screening for SCD.79 In 1973, the estimated average life expectancy 
associated with SCD was just over 14 years.80 Over 20% of deaths occurred prior to the age of 
two, with the majority due to invasive pneumococcal infection. In 1989, two years after the 
recommendation for universal NBS for SCD, initial results from the natural history study of the 
CSSCD demonstrated significant improvement in mortality rates.70 The study, which included 
2,824 participants under age 20 to represent 14,670 person-years of follow-up, found that 85% of 
those with HbSS disease and 95% of those with HbSC disease survived past the age of twenty 
years old. Additionally, the study’s mortality rate of 0.5 deaths per 100 person-years (2.6%) in 
individuals under age 20 was found to be significantly lower than that of previous reports. Namely, 
the authors cited a study from 1975 where a mortality rate of 1.7 deaths per 100 person years 
(7.3%) was found among affected individuals under the age of 23.81 Survival rates in SCD have 
continued to increase, and the majority of individuals with SCD currently live into adulthood (over 
18 years old).79  
2.2 NEWBORN SCREENING 
The substantial reduction in SCD-related morbidity and mortality has largely been gained 
through timely intervention for affected infants that lowers their infection risk.3 In the United 
States, this proceeds through newborn screening (NBS). NBS is a public health program that aims 
to detect within the first days of life congenital conditions for which early intervention can improve 
long-term health outcomes.1,82 It has been deemed by the Centers for Disease Control and 
Prevention as one of the ten most successful United States’ public health programs.1 Since its 
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inception in the early 1960s, the NBS program has facilitated screening for over 150 million 
newborns.1 
NBS primarily evaluates for genetic, metabolic, endocrine, and hematological conditions 
through a blood sample collected between 24 to 72 hours following birth.83 The purview of NBS 
extends beyond the initial screen tests to the coordination of responding to out-of-range results, 
offering follow-up diagnostic testing, and providing treatment for infants diagnosed through 
screening.84–86 Ongoing education of those who carry out the programs’ services, as well as 
program evaluation are also crucial components of NBS.87 The varied actions covered by NBS 
require the participation of a wide set of stakeholders, which include clinicians, the newborn’s 
family, hospital staff, clinical laboratories, and policy makers. 
A biochemical assay developed in 1961 by physician Robert Guthrie provided the initial 
basis for population-level newborn screening.88,89 His method utilized a blood sample that was 
collected and dried onto filter paper to test for the high serum levels of phenylalanine that are 
characteristic of the genetic condition phenylketonuria (PKU). Studies published in 1953 had 
demonstrated that intervention via a low-phenylalanine diet successfully minimized the 
condition’s severe neurological damage, thereby providing the impetus to diagnose affected 
infants prior to the onset of symptoms.90 In 1963, Massachusetts became the first state to mandate 
universal newborn screening for PKU. By the end of that year, 29 states as well as Puerto Rico 
offered screening for PKU to all infants upon birth.91  
Growing participation in NBS provided motivation to develop screening programs for 
other conditions whose effects may be mitigated by early treatment. Throughout the 1960s and 
1970s, states began screening for other disorders that were primarily metabolic in nature. 
Screening panels continued to expand as advancements in technology allowed. With the 
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introduction of Mass Spectrometry to NBS in the 1990s, this push to grow became particularly 
relevant. Utilization of the technology, which allows for the rapid characterization of numerous 
metabolites from a single blood spot, quadrupled the number of disorders that could be affordably 
and efficiently detected in NBS through a single screening method.92 
Mass Spectrometry technology remained unavailable to many states due to limited funding 
and access. This exacerbated disparities between programs, although they have been a defining 
characteristic of NBS since its inception.93,94 Much of this variation arises from the state-run nature 
of NBS in the United States. Legislature is determined by state health officials, the state board of 
health, or a dedicated advisory committee specializing in NBS or genetics; these entities typically 
partner with state laboratories and/or other experts to review the available evidence prior to making 
recommendations.93 As a consequence of this structure, differences are present in nearly all aspects 
of the programs, including screening follow-up, funding mechanisms, and whether parents can 
opt-out of the screening.109  
Inconsistencies are particularly conspicuous in terms of the number of conditions included 
on a state’s panel. In 1995, states’ panels ranged from zero to eight conditions. By 1999, the 
difference had grown to between four and fifty conditions.91 In this year, concern over such 
growing disparities prompted HRSA to appoint the American Association of Pediatricians (AAP) 
NBS Task Force to develop national standards for NBS panels.95 As part of this effort to increase 
uniformity, the Maternal and Child Health Bureau commissioned the American Committee of 
Medical Geneticists (ACMG) in 2002 to devise a list of core NBS conditions to be a guide for 
states. In their evaluation of 81 conditions, the ACMG considered incidence and severity, as well 
as evidence regarding the efficacy of the currently available screening and treatment.9 The ACMG 
specifically proposed three minimum criteria for a core condition: First, it must be detectable 
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within 24 to 48 hours of birth and prior to when it could otherwise be recognized by a physician; 
second, a sufficiently specific and sensitive screen for the condition must exist; and lastly, early 
detection and intervention must result in evidence-based benefit. This led to creation of the 
Recommended Uniform Screening Panel (RUSP).96 As originally created by ACMG, the RUSP 
included 29 core conditions. An additional 25 conditions that may be incidentally identified during 
a core condition’s screening yet present unclear benefits for screening and do not satisfy the 
screening criteria alone were named to a secondary list. While ACMG recommends that states 
mandate reporting of secondary conditions, it has received criticism for not providing clear, 
evidence-based guidelines for how to respond to a positive screening result for these conditions.94  
The RUSP continues to grow in its number of included conditions. In 2003, the SACHDNC 
was formed by the United States Department of Health and Human Services (HHS) to advise the 
HHS Secretary in the process of evaluating candidate conditions for the RUSP, as well as other 
services relating to NBS.97 In their evaluation, SACHDNC uses an evidence-based decision model 
similar to that initially used by ACMG that considers factors such as incidence, anticipated benefits 
of screening, availability of treatment and program feasibility. SACHDNC considers conditions 
that have been nominated by groups comprised of parents, advocacy groups, clinicians, and 
researchers. As of April 2019, the RUSP includes 35 core conditions and 26 secondary 
conditions.96  
2.2.1  Newborn Screening for Hemoglobinopathies 
Three forms of SCD, HbSS disease, HbSC disease, HbS-β 0/+ Thalassemia, have been 
included as primary conditions on the RUSP since its introduction in 2006.9 However, population-
based screening for SCD and SCT was available in individual states much earlier than this. Large-
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scale screening for hemoglobinopathies was first suggested in 1970 by the development of a rapid 
and high-throughput screen for SCD that used dithionite to stimulate sickling of RBCs.98 In 1972, 
the political and financial support brought about by the Control Act spurred implementation of 
screening programs across the United States. Funding from the Control Act contributed to 
technological advances made in 1973 that allowed for hemoglobinopathies and hemoglobinopathy 
traits to be screened for from the standard blood spot samples collected during NBS.99 By 1974, 
ten states had mandatory screening programs, and another four states had voluntary screening 
programs.2 New York became the first state to mandate universal newborn screening for HbSS 
disease in April 1975.100 Over the following decade, four additional states added 
hemoglobinopathies to their NBS panels.2  
SCD screening in the 1970s and early 1980s was not supported by a treatment that could 
be provided to those who the programs identified to have SCD. A contemporary editorial in the 
New England Journal of Medicine published in 1974 criticized this shortcoming, claiming that 
programs were “introduced before evidence that [they were] needed, desired or in the best interest 
of the affected community.”10 Rather, screening was argued for on the bases that it provided an 
opportunity to promote awareness and knowledge of sickle cell in “high-risk” populations.10 
However, these programs garnered widespread criticism for perpetuating misinformation and 
causing confusion and unwarranted anxiety.11–13,101 The difference between SCT and SCD was 
often poorly communicated.12 Educational materials provided to screening participants presented 
SCT as a milder form of SCD and did not clarify the health implications of SCT.13 Consequently, 
parents restricted their children’s activities and changed their diets when found to have SCT, 
despite no clear medical indication.11,13 Other information provided to screening participants over-
dramatized the pain and high mortality rate of SCD. The condition was described as “the killer 
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disease” by one promotional poster, and as “the black scourge” by a public service announcement 
published by the Red Cross.10Another brochure described the pain episodes of SCD as “caus[ing] 
the patient to scream and cry and assume odd postures in an attempt to get relief.”10 Through such 
histrionic portrayals of SCD, programs were criticized for aggravating anxiety while being unable 
to effectively alleviate the symptoms of those identified to have SCD.120 
Racial controversy compounded these failings of early programs, with many explicitly 
targeting African Americans. In one 1974 study, the presence of a program in a state was found to 
be significantly associated with the proportion of its population that was African American.102 
Nine of the ten states with mandatory screening programs had total African American populations 
of over 200,000, resulting in more than 40% of the nation’s African American population being 
subject to such programs. Screening policies existed for newborns, school-age children, couples 
applying for marriage licenses, and inmates.10 In some states with mandatory screening laws for 
African Americans, children could be denied entry to school and couples denied marriage licenses 
if they refused screening. Many programs lacked safeguards for maintaining confidentiality. Cases 
of job discrimination against those identified to have SCT were common, in particular in the 
military.103 Individuals also reported being denied health or life insurance after they screened 
positive for SCT, despite its lack of significant health effects.103 Premarital and prenatal counseling 
were key features of many programs. Such counseling was accused of being coercive, rather than 
promoting informed choice. This led to aspersions of eugenics and dissent among targeted 
communities. Surveys of African Americans performed in the 1970s demonstrated a strong 
objection to the genetic counseling services that were offered to those with SCT.”11 
With growing controversy, many of the early programs were abandoned. However, 
renewed interest in SCD screening was brought about by findings of the PROPS study in 1986, 
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which was followed by the endorsement of the NIH for universal newborn screening for 
hemoglobinopathies in 1987.6 By 1988, SCD was included in the NBS programs of 16 states, with 
another 14 states offering targeted screening. All but nine states had universal NBS for 
hemoglobinopathies by 1994.2 In 1996, NBS for hemoglobinopathies was recommended by the 
American Academy of Pediatrics.104 By 2006, all 50 states as well as the District of Columbia 
were offering NBS for hemoglobinopathies. New Hampshire became the last state to add the 
conditions to their NBS panel in this year.2 This was prompted by inclusion of hemoglobinopathies 
on the RUSP, which was published earlier that year (Table 1).9  
 
Table 1. Uptake of NBS for Hemoglobinopathies 
State or Territory Universal Screening Required or Available State/Territory 
Universal Screening 
Required/Available 
Alabama Jan 1, 1987 Montana Jul 1, 2003 
Alaska Oct 1, 2003 Nebraska Nov 1, 1996 
Arizona Jan 1, 1988 Nevada July 1, 1990 
Arkansas Oct 1, 1988 New Hampshire May 1, 2006 
California Feb 7, 1990 New Jersey Apr 1, 1990 
Colorado Jan 1, 1979 New Mexico Oct 10, 1995 
Connecticut Jan 1, 1990 New York Apr 1, 1975 
Delaware July 1, 1985 North Carolina May 2, 1994 
District of Columbia Jan 1, 1986 North Dakota Apr 1, 2003 
Florida Jan 1, 1989 Ohio Jul 1, 1989 
Georgia Oct 1, 1998 Oklahoma May 1, 1991 
Hawaii Jul 1, 1997 Oregon Feb 1, 1995 
Idaho May 19, 2004 Pennsylvania Sep 28, 1992 
Illinois Feb 1, 1989 Rhode Island May 1, 1990 
Indiana Jul 1, 1985 South Carolina Jul 1, 1987 
Iowa Feb 5, 1988 South Dakota Jun 1, 2005 
Kansas Jul 1, 1993 Tennessee Jan 1, 1988 
Kentucky Jan 1, 1995 Texas Nov 1, 1983 
Louisiana Jan 1, 1992 Utah Sep 24, 2001 
Maine Jul 1, 2001 Vermont Feb 4, 1996 
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Maryland Jul 1, 1985 Virginia Jul 1, 1989 
Massachusetts Mar 26, 1990 Washington Nov 1, 1991 
Michigan Jul 1, 1987 West Virginia Jul 1, 2003 
Minnesota Jan 1, 1988 Wisconsin Oct 31, 1988 
Mississippi Jan 1, 1990 Wyoming Jan 1, 1987 
Missouri Apr 1, 1989   
 From Kavanagh et al. (2008) 21    
In Pennsylvania, HbSS disease was introduced to the NBS panel in April 1992. Under the 
Newborn Child Testing Act (35 P.S. § 621, et. seq.), all newborns are required to receive screening 
unless their parent or legal guardian refuses on the basis of religious objection.105 There is no fee 
for NBS in Pennsylvania.105 The program occurs under the oversight of the Pennsylvania 
Department of Health, which contracts with commercial laboratories to perform the testing.23 
Follow-up in response for a positive screen for a hemoglobinopathy or hemoglobinopathy trait is 
determined by the Division of Newborn Screening and Genetics Bureau of Family Health under 
the Pennsylvania Department of Health.23 Screening results must be reported to the Department of 
Health’s Newborn Screening and Follow-up Program, the infant’s primary care provider (PCP) 
listed on the filter paper, and the birthing facility. In the case of an abnormal result, the PCP is 
most commonly responsible for notifying the infant’s parents and ensuring completion of the 
necessary follow-up, referral, and/or diagnostic procedures. However, hemoglobinopathies are an 
exception, with follow-up tasked to the SCD centers. Currently, hemoglobinopathies account for 
the highest proportion of disorders identified by the states’ NBS program.106 The most commonly 
identified form of SCD in both Pennsylvania, as well as in the United States, is HbSS disease, 
followed by HbSC disease, HbS-β0 Thalassemia, and HbS-β + Thalassemia.23 
Through the current NBS technology, SCT is identified incidentally through screening for 
SCD. However, SCT does not require immediate care for the infant, and no consensus currently 
exists regarding appropriate follow-up in response to the positive NBS result.21,73,107 While 
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identification of SCT does not clearly align with the public health program’s stated intent, the 
decision of many states’ NBS programs to share this information with families was largely shaped 
by a statement put forth by the Institution of Medicine (IOM) in 1994.1,8 In its report entitled 
“Assessing Genetic risk,” the IOM argued that although SCT status was not purposefully sought 
out during screening, the state was obligated to share this genetic information, as it belonged to 
the infant and his or her family.21  
To guide physicians in responding to a positive screen for SCT, the ACMG published an 
ACTion (ACT) sheet for SCT in 2012.108 The ACMG makes ACT sheets for all NBS conditions 
to serve as instructions for physicians in their follow-up for a positive screen. Specific actions 
depend on the condition but typically include prompt notification of the family, further diagnostic 
evaluation, and treatment for affected newborns. For an abnormal hemoglobin trait, providers are 
directed to perform confirmatory testing, report the screening results to the state, and offer family 
members referral for personal hemoglobinopathy screening and genetic counseling. The SCT ACT 
sheet also advises physicians to inform families of the good prognosis for SCT and to reassure 
them that infants with SCT do not have the clinical symptoms of SCD. The clinical considerations 
for SCT specified by the ACT sheet include the reproductive risks for carriers, as well as risks for 
renal complications, namely hematuria in older children and adults, and potentially other 
complications in the case of extreme exertion, dehydration, and hypoxia.  
There remains significant variation among programs in how the information regarding a 
positive SCT screen through NBS is disseminated to families.21 A PCP or specialty provider often 
receives the initial notification from the laboratory, and in few states is contact with the family 
aggressively pursued. In a report from the National Newborn Screening and Genetics Resource 
Center in 2009, about 15% of infants with a positive screen for SCT were found to receive follow-
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up diagnostic testing; however, this follow-up testing is not universally recommended by all SCD 
centers.109 Another study performed in 2007, which was one year following inclusion of SCD in 
the RUSP, surveyed NBS program coordinators regarding their follow-up protocols in response to 
a positive screen for SCD or SCT.21 The questionnaire asked which stakeholders were directly 
notified following a positive screening result, by what means they were informed, and how it was 
ensured that this notification was received. Over one-third of programs did not report having any 
protocol for follow-up for a positive SCT screen. Among those programs that did, significantly 
fewer stakeholders were directly notified following a positive NBS for SCT as compared to SCD 
(2.4 versus 3.4, p < 0.0001). Only 37% of programs reported a process for directly notifying 
families regarding SCT results. Finally, while all programs reported directly notified the infant’s 
pediatrician regarding a positive NBS for SCD, 88% of programs notified pediatricians in the case 
of SCT. Based on these findings, the study’s authors called for resources and guidelines to be 
developed for provider regarding communication about SCT screening through NBS.21  
2.2.2  Screening Guidelines 
The substantial variation in NBS programs’ policies regarding SCT results compounds 
uncertainty about the program’s true appropriateness. As it exists in public health generally, an 
ethical challenge exists for the program to balance public benefit with individual liberties.110 A 
number of criteria and systems have been developed to guide these considerations in the 
implementation of public health screening programs. They may be applied to an evaluation of the 
appropriateness of disclosing positive SCT status identified through NBS.  
As commissioned by the World Health Organization (WHO) in the mid 1960s, the Wilson-
Jungner criteria remain one key set of guiding principles (Table 2).111 The ten criteria describe 
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characteristics of a condition and its method for testing, diagnosis, and treatment needed to justify 
screening. The criteria also consider cost, availability of resources, and public reception to the 
screening program.  
 
Table 2. Original Wilson-Jungner Criteria 
1 The condition sought should be an important health problem. 
2 There should be an accepted treatment for patients with recognized disease. 
3 Facilities for diagnosis and treatment should be available. 
4 There should be a recognizable latent or early symptomatic stage. 
5 There should be a suitable test or examination. 
6 The test should be acceptable to the population. 
7 
The natural history of the condition, including development from latent to declared 
disease, should be adequately understood. 
8 There should be an agreed policy on whom to treat as patients. 
9 
The cost of case-finding (including diagnosis and treatment of patients diagnosed) should 
be economically balanced in relation to possible expenditure on medical care as a whole. 
10 Case-finding should be a continuing process and not a “once and for all” project. 
 
 
The Wilson-Jungner Criteria remain widely regarded as the “gold standard” for public 
health screening.112 United States policy makers are generally guided by the criteria in their 
evaluation of potential additions to their states’ NBS panel; however, political pressure, 
availability of technology, and financial considerations may also factor into their decisions.113 A 
2006 review of international NBS practices criticized the wide variability in how the Wilson-
Jungner criteria were being interpreted and applied throughout the United States.114 The authors 
largely attributed this lack of consistency to rapidly advancing technological capabilities for 
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screening that were outpacing policy-maker’s ability to evaluate the programs’ appropriateness. 
An updated set of Wilson-Jungner criteria was published in 2008 in recognition of this challenge 
(Table 3).112 The revised criteria seek to have greater applicability to genetic medicine and place 
greater emphasis on the contemporary medical values of equity, access, and scientific evidence. 
They also acknowledge that certain legal, ethical, logistical, and social factors may obviate a 
particular screening program.  
 
Table 3. Modified Wilson-Jungner Criteria 
1 The screening program should respond to a recognized need. 
2 The objectives of screening should be defined at the outset. 
3 There should be a defined target population. 
4 There should be scientific evidence of screening program effectiveness. 
5 
The program should integrate education, testing, clinical services and program 
management. 
6 
There should be quality assurance, with mechanisms to minimize potential risks of 
screening. 
7 The program should ensure informed choice, confidentiality and respect for autonomy. 
8 
The program should promote equity and access to screening for the entire target 
population. 
9 Program evaluation should be planned from the outset. 
10 The overall benefits of screening should outweigh the harm. 
 
 
In 2011, four past and present members of the U.S. Preventive Services Task Force 
(USPSTF) proposed an alternative strategy for evaluating screening programs.115 The USPSTF is 
a panel of national experts, which makes evidence-based recommendations regarding screening 
and other clinical preventative services.116 The publication by Harris et al. reviewed the experience 
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of the USPSTF in evaluating screening programs in the United States from 1997 to 2011 to put 
forth criteria that addressed stated shortcomings of the Wilson-Jungner criteria. Their system, 
which aimed to better capture the methods found useful by the USPSTF for program evaluation, 
contrasted the Wilson-Jungner criteria’s “checklist” system in favor of a “Balance Approach.” 
Using this latter system., a screen’s anticipated benefits are weighed against its anticipated harms 
with regard to current scientific evidence and available resources in order to determine its 
appropriateness (Table 4).115 The authors also emphasize that the particular cultural needs of the 
communities being screened should be considered.  
 
Table 4. Summary of Considerations for Estimating a Screening Program’s Benefits and 
Harms 
  
Magnitude of Potential Benefits Magnitude of Potential Benefits 
1 Probability of an adverse outcome without screening 1 Frequency of false-positive screening tests 
2 
Degree to which screening identifies 
all people who suffer the adverse 
outcome 
2 Experience of people with false-positive results 
3 
Magnitude of incremental health 
benefit of earlier versus later treatment 
resulting from screening 
3 Frequency of over diagnosis 
4 Experience of people who are over diagnosed 
5 Frequency and severity of harms of workup and treatment 
 
2.2.3  Potential Benefits of Sickle Cell Trait Notification 
In an evaluation of the program’s appropriateness, a primary argument for sharing SCT 
NBS results concerns reproductive choice.8,117 Namely, programs that notify parents of the 
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incidental NBS finding seek to inform the prenatal decisions of the infant and their family members 
who may have an increased chance of having a pregnancy affected with SCD. Professional 
guidelines recognize that informed reproductive decisions regarding SCD are aided by an 
awareness of one’s personal trait status along with an understanding of the condition’s inheritance 
pattern.19,20 Studies that have been carried out in the United States to assess this knowledge have 
primarily focused on African American and other minority communities, as these are where SCD 
is the most prevalent.30 These assessments have largely determined that the current level of 
relevant knowledge is likely insufficient for informed decision-making. Importantly, these studies 
have also found that the affected communities view this lack of SCT awareness to be a significant 
concern.  
Sickle Cell Knowledge: Medical guidelines recommend screening and counseling to 
clarify personal SCT status and provide education about SCD inheritance. Current American 
College of Obstetricians and Gynecologists (ACOG) guidelines recommend hemoglobinopathy 
screening through a complete blood count with RBC indices for all women who are either pregnant 
or considering pregnancy; for those whose RBC indices indicate a low mean corpuscular 
hemoglobin or mean corpuscular volume indicative of a hemoglobinopathy, as well as women of 
high-risk ancestries, hemoglobin electrophoresis should also be performed.20 Hemoglobinopathy 
screening is also central to the reproductive counseling outlined in current consensus guidelines 
for SCD. Developed by the National Heart, Lung, and Blood Institute (NHLB) of the National 
Institutes of Health (NIH), the guidelines specify that hemoglobinopathy screening should be 
offered to clarify the SCT status of the other individual in a couple where one is known to have 
SCT or SCD.19 Additionally, at-risk couples should be offered genetic counseling to discuss the 
potential for an affected pregnancy. Couples are recommended to make a “reproductive life plan” 
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that relates to their desires either to have or to not have children. Both contraceptive and 
preconception counseling, including pre-implantation genetic diagnosis and prenatal diagnostic 
testing following spontaneous conception, are included in the guidelines, which emphasize 
individual choice. 
A number of survey and interview-based studies have sought to assess knowledge levels 
regarding SCD inheritance and personal SCT status, primarily among high-risk demographics 
(Table 5). These studies have recruited participant through a variety of means and locations and 
have utilized different questionnaires and survey methods. However, they have generally found 
that while participants are aware of the congenital nature of SCD, they have a poorer understanding 
of its particular inheritance pattern. Additionally, there is a consistent lack of awareness regarding 
personal trait status, in spite of professional guidelines and programs that promote screening.  
In 1994, Wright et al. interviewed 147 African American between the ages of 18 and 50 
who visited the emergency room of a large urban medical hospital for minor injuries.118 Nearly all 
individuals (98%, 144/147) had heard of SCD, and about three-quarters (73%, 107/147) were 
aware of its genetic basis. However, knowledge of personal trait status was not as high, with only 
thirty-one percent (46/147) knowing whether or not they had SCT. Women were more likely to 
know their trait status than men, as were patients with a family history of SCD or SCT compared 
to those with no known family history.  
A telephone survey of African American women of reproductive age (between 18 and 30 
years old) was carried out in 2005 in St. Louis, Missouri, where universal NBS for SCD has been 
available since 1989.119 Boyd et al. used random-digit dialing to recruit participants, yet one-third 
of the 241 women contacted had to be excluded from the survey, as they had not heard of SCD. 
Next, an assessment of SCD knowledge was administered over the telephone to those who were 
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aware of SCD. While 91% of the women understood that individuals were born with and could 
not later develop SCD, less than 10% were able to correctly describe its inheritance pattern. The 
remaining 90% of women answered that SCD “skipped generations” and could occur in a 
pregnancy where one parent had neither SCT nor SCD. Knowledge of personal trait status was 
relatively high compared to other studies, yet this finding was calculated after excluding the nearly 
one-third of women contacted for the study who had not heard of SCD. Ninety percent of 
participants confirmed that they knew whether they did (14%) or did not (76%) have Sickle S trait. 
However, awareness of carrier status was not as great for other variant hemoglobin traits. Twenty-
seven percent of women stated that they knew whether or not they were a carrier of HbC trait, and 
10% of women knew their ß-thalassemia trait status.  
In 2006, Treadwell et al. interviewed 316 men and women of reproductive age (ages 18 to 
44 years old) in an ethnically diverse, urban community of northern California.120 California has 
required universal SCD screening through NBS since 1990.2 Unlike the majority of studies of 
either exclusively or majority African American participants, only 36.4% (115/316) of participants 
surveyed by Treadwell et al. identified as African American. When asked if both parents must 
have SCT to have a child with SCD, nearly nine out of ten surveyed individuals (86.2%, 261/316) 
answered correctly. However, a relatively small proportion, 15.9% (45/316), reported knowing 
whether or not they had SCT. Lower knowledge of personal SCT status in spite of higher general 
knowledge may be related to the more racially diverse population of the study. As the current 
ACOG guidelines recommend hemoglobinopathy screening only to those of certain ancestries, a 
smaller proportion of this study’s participants may have been covered by the screening guidelines 
as compared to other studies. 
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In 2007, Gustafson et al. administered an anonymous questionnaire on health beliefs and 
knowledge relating to SCD to 101 African American women over 18 years of age at an Obstetrics 
and Gynecology clinic of a large women’s hospital in Pittsburgh, Pennsylvania.121 Over three-
quarters (79.2%, 80/101) of women knew that SCD was genetically inherited, yet only half (49.5%, 
50/101) recognized that a gene mutation had to come from both parents for their child to have 
SCD.  
In a 2009 study, Acharya et al. recruited 53 African American individuals who either had 
SCT themselves or had a child with SCD or SCT from a sickle cell clinic and sickle cell non-profit 
organization in Chicago, Illinois.122 Hemoglobinopathies have been included in the Illinois NBS 
program since 1989.2 At the time of the study, parental SCT notification proceeded through a letter 
sent either from the birth hospital or from the Sickle Cell Disease Association of America under 
state contract with the Illinois Department of Health.122 Participants answered an anonymous, 
validated questionnaire on SCD genetics and screening. Despite all participants having personal 
experience with SCT or SCD, their responses showed significant misunderstanding of the 
condition’s inheritance. Nearly all knew that SCD was a genetic condition (89%, 47/53) and not 
transmitted via physical contact (89%, 47/53). However, less than half (40%, 21/53) were aware 
that both parents needed to have SCT or SCD for their child to be affected with SCD. Sixty-eight 
percent (36/53) of respondents answered all ten knowledge questions correctly. Mean knowledge 
score was significantly lower for those parents who did not have a child with SCD, as compared 
to those who did (78% versus 58%, p = 0.002).  
Finally, a study carried out by Lang et al. in 2009 interviewed 387 post-partum women in 
Chicago hospitals in order to determine their attitudes and understanding of NBS screening for 
SCD.18 At the time, the Illinois NBS program notified parents of their infant’s positive SCT 
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screening result through a letter that was mailed shortly after their infant’s birth.18 Approximately 
73% (282/387) of participants were African American, and 8.8% (34/387) reported having SCT. 
One individual had SCD. Ninety-six percent of women in the study had heard of SCD. A trained 
interviewer asked these individuals a set of knowledge questions regarding SCD. Sixty percent 
(232/387) of respondents believed SCT could develop into SCD, and 71% (275/387) believed that 
an individual with SCD could have a child with SCD even if their partner was not a carrier of a 
variant hemoglobin trait. The mean knowledge assessment score of 66% was deemed by Lang et 
al. to indicate a “significant knowledge gap” regarding the health and reproductive implications of 
SCT in this population.18  
A lack of SCD knowledge persists in many of those communities at greatest risk for SCD. 
A number of studies, which have examined trait status awareness in relation to access to prenatal 
and general medical care, show that such care for high-risk communities is deficient and when 
present, may still insufficiently ensure that individuals are aware of their SCT status. In a 2010 
study by Lang et al., 100 Chicago-area mothers notified of a positive NBS result for SCT through 
a mailing within the past year were surveyed over the phone or in person (93% and 7%, 
respectively).17 Participants were 95% (95/100) African American, with a mean age of 26 years 
old. Sixty-two percent reported not having a personal doctor other than an obstetrician, and 83% 
reported having no insurance. Less than half (40%) reported knowing their SCT status prior to this 
pregnancy, even though it was not their first pregnancy for over two-thirds (69%) of participants. 
However, Lang et al. did not report whether a greater awareness of personal SCT status was more 
likely to be found in those who had previously been pregnant.  
A similar lack of awareness of SCT was found among African American men and women 
recruited from a community-based health organization in Pittsburgh, Pennsylvania, in spite of 
   
 37 
greater reported access to prenatal and medical care.16 Forty-two percent (14/33) of participants 
were not aware of their personal SCT status, and the majority (74%) did not know the SCT status 
of their partner. This relatively low awareness of personal SCT status was found even though 97% 
of participants had health insurance and 83% did not report having difficulty accessing medical 
care due to its cost, indicating the presence of other barriers to SCT awareness besides access to 
healthcare among at-risk communities.  
Table 5. Summary of Sickle Cell Knowledge Studies 
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1 Question assessed participant’s understanding that SCD was a health condition an individual is 
born with, and is not contagious 
2 Question assessed participant’s understanding that a genetic contribution had to come from both 
parents for a child to have SCD 
 
Transmission of Sickle Cell Knowledge: Generally low knowledge levels regarding 
sickle cell that persist in spite of medical guidelines intended to promote awareness. This suggests 
that more effective strategies are needed to ensure transmission and retention of this health 
information. Personal connections have been found to be central to the promotion of health 
   
Table 5 Continued 
   
 39 
knowledge in African American communities, where family, friend, and community resources are 
looked to as primary resources.16,122–124 While Treadwell et al. found that only 16% of participants 
knew their SCT status, for over half of those who did (53%), this knowledge had been gained 
through discussions with family members.120 When Acharya et al. asked participants about their 
personal SCT status and general SCD knowledge, those who did not have a child with SCD most 
often designated family members to be their source of information, as well.122 The study also found 
relatively high awareness of personal trait status (94%), but substantial confusion about SCD 
inheritance: 60% incorrectly responded to the question regarding autosomal recessive inheritance. 
In the focus groups held by Long et al., “reliance on personal experience” was identified as a 
prevalent theme in participants’ discussion of their perceptions and knowledge of SCD.16 
However, similar to those findings of Acharya et al., this theme was found to be associated with 
greater confusion and misconceptions about SCD inheritance. It was postulated that this was due 
to participants trying to make sense of patterns of SCD inheritance observed in their own family.122 
In sum, these findings indicate that social networks may be especially effective at promoting 
awareness of personal SCT status but less so at disseminating more general information regarding 
the condition and its inheritance. 
Surveys of disclosure patterns of parents notified of their infant’s positive SCT status 
through NBS indicate that the program promotes sharing of the health information within familial 
networks. The great majority of parents report that they intend to discuss their child’s positive trait 
status and its implications with their son or daughter at an older age. In one telephone survey of 
300 families who were seen at a pediatric Sickle Cell clinic in Pittsburgh, Pennsylvania for genetic 
counseling following identification through NBS of an abnormal hemoglobin trait, 91% (104/114) 
responded that they planned to inform their child about the NBS result following counseling for 
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the screening results.22 Additionally, when Lang et al. surveyed mothers notified about their 
infant’s positive SCT result through a letter sent through the Illinois NBS program, 99% (99/100) 
expressed that trait status should be shared with the infant.17 Thirty-eight percent of respondents 
indicated they planned on informing their infant when he or she was a teenager or young adult. 
The remainder specified a younger age, with a mean specified age of sharing to be 8.6 years.  
Studies indicate that families are inclined to share this information with other close family 
members as well. In the study by Lang et al., mothers of infants found to have SCT through NBS 
were asked which individuals they felt should know this health information about their child. 
Ninety-seven percent expressed that they intended to speak about this information with their 
partner.17 Greater than 90% of mothers also stated that they felt first-degree relatives should also 
have this information: 92% planned to share this information with their siblings, 97% with their 
parents, and 93% with their infant’s siblings. There was less consensus that “other relatives” 
should know about their infant’s SCT status, with 63% of participants reporting that they would 
share this information with more distant family members. Among those who said that they would 
not share this information with the specified individual, the majority (31%, 31/100) responded that 
this was because this information was not relevant to them, rather than that they did not want them 
to know that their baby had SCT (6%, 6/100). In the greater context of the study, Lang et al. 
interpreted these disclosure patterns to demonstrate that the notified mothers possessed a good 
understanding of who should also know the trait letter’s information. Lang et al. called for further 
research in order to determine whether mothers did actually share this information, and if so, when 
and how this information was imparted.  
As Lang et al. indicates, reported intentions to share SCT status may not accurately 
represent true disclosure patterns. This highlights a primary shortcoming of the NBS program, 
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which is that the health information it provides comes prematurely for the infant. Those who 
receive SCT screening through NBS must be told their positive trait status at an older age for the 
program to have this benefit. For those who are relayed the information, they may not remember 
their carrier status or appreciate its implications by the time they are of reproductive age. This 
timing has been criticized by professional organization, including the ACMG, the American 
Society of Human Geneticists (ASHG), and the AAP.125–127 Statements from these groups present 
carrier screening in infants and children as threatening their autonomy to choose whether or not  
to pursue carrier screening for SCT while presenting them with no true health benefit.  
Ideally, carrier screening is offered prenatally, when the information is most relevant to the 
individual.19 While it is not the case for the infant, trait notification through NBS often comes at 
an opportune time to inform the reproductive decisions of the infants’ parents, for at least one 
parent must also have SCT. If the other partner also has SCT of SCD, the couple has a chance for 
a future pregnancy of theirs to be affected with a clinically significant hemoglobinopathy.  
NBS may serve to inform parents of their own positive SCT status at equivalent rates to 
prenatal screening. When Acharya et al. asked mothers how and when they learned of their SCT 
status, approximately equal proportions named prenatal screening and NBS: 36% (19/100) of 
women reported they had learned prenatally, while 26% (14/100) reported they had learned after 
their child’s NBS and 11% (6/100) from their own NBS.122  
Evidence supports that NBS results may provide information for the parents at a higher 
rate than they do for the child. The reproductive benefit of parents and other close relatives has 
been posited as a main justification for NBS trait notification, yet a question exists whether this is 
consistent with the current aims of NBS. This goal of informing parents’ reproductive choice 
extends beyond the program’s traditional scope, which is to provide interventions to affected 
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infants in a timely manner to significantly improve their health outcomes.1,111 However, 
reproductive benefit has been gaining increasing support as a reason for NBS programs.117,126 In 
one 2007 survey of healthcare providers, 78% agreed that one purpose of NBS is to provide an 
infant’s carrier status to their parents. The majority of providers (68%) also agreed that NBS should 
inform parents about their own reproductive risk.128 In another study examining ethical issues in 
pediatric genomics, 90% of American PCPs surveyed agreed with the statement, “an important 
goal of newborn screening is to identify and counsel parental carriers before the next 
pregnancy.”129  
Whether the NBS results are more salient for the infant or for his or her family members 
may be made less of concern when greater SCD awareness in general has been identified as a 
priority by African American communities. This is an important consideration in light of criticism 
that early screening programs were undesired by those they targeted.49,103  A consideration of the 
NBS program’s appropriateness must heavily weigh the views of the communities it most affects. 
This is highlighted by contemporary ethical guidelines that emphasize community reception and 
cultural sensitivity in determining the appropriateness of a screening  program.112,115 Under  this 
criterion, NBS for SCT is supported by findings that increased awareness of SCD is desired by 
African American communities.14–16,120 Furthermore, this knowledge appears to contribute to more 
accurate risk perception and greater reception of screening in these communities.16,130 
Community-based studies have provided the support for the receptiveness of at-risk 
communities to SCD educational programs. In 2016, Housten et al. offered hemoglobinopathy 
education and screening in St. Louis, Missouri to African American men and women between 14 
and 60 years old who were recruited from Qualified Health Centers, as well as community health 
events at churches and public libraries.15 The program was driven by requests from an advocacy 
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group comprised of members of an African American Fraternity as well as a SCD treatment and 
education team, both of which were based at the local university. When members of these 
organizations were polled, 100% agreed that SCD knowledge and personal SCT status should be 
made a priority for adolescents and adults in St. Louis who are at the greatest risk for having a 
pregnancy affected with SCD. Both organizations expressed that SCD education was needed to 
empower individuals to make informed decisions about their reproductive health. Similarly, in an 
open-ended survey of 300 African American men and women aged 18 through 35 years old who 
did not know their SCT status, Mayo-Gamble et al. asked participants their beliefs and perceptions 
about SCT and SCT screening.131 Perceived lack of knowledge about SCT and perceived health 
benefits of SCT screening were both identified as major themes through qualitative thematic 
analysis of the discussion transcripts. 
Similar concerns have been identified in more targeted studies of those who are aware of 
their SCT status. When focus groups of African American adults who either had SCT or SCD were 
asked about their beliefs regarding reproductive choice in relation to sickle cell, a major concern 
of participants was the lack of understanding about SCD inheritance and personal trait status and 
how this affected reproductive choice.132 The groups specified three pieces of information to be 
clarified for people of reproductive age in their community: 1) the genetic transmission of SCD, 
2) the distinction between SCD and SCT, and 3) that SCD could not be transmitted like a cold or 
a sexually transmitted infection. Participants agreed that SCT status should be established before 
pregnancy in order to inform couples about their chance of having an affected pregnancy. 
Additionally, they noted that a key barrier to screening was an insufficient understanding about 
how an infant could be born affected with SCD, as well as an under-appreciation for the relevance 
of knowing one’s personal SCT status.132  
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The value of screening and genetic testing for hemoglobinopathies and hemoglobinopathy 
carrier status was specifically addressed in focus groups held by Long et al.16 The 35 participants, 
who were majority female (91%, 32/35) with a mean age of 53, were recruited from a community-
based health program focusing on racially segregated neighborhoods affected by poverty and 
chronic disease in Pittsburgh, Pennsylvania. Moderator-led discussions sought to more fully clarify 
the attitudes and perspectives of African American individuals on SCD and barriers to awareness. 
Through qualitative thematic analysis, a value of awareness brought about by genetic testing was 
identified as a major theme. Knowledge about a genetic condition was recognized as allowing for 
understanding of recurrence risks and permitting one to modify related behaviors.  
With a similar aim as  that of Long et al., Asgharian et al. interviewed 34 African and 
African Caribbean women with SCT to gain insight into how knowing one’s carrier status 
influenced reproductive decisions.130 The authors also identified a theme of understanding the 
genetic transmission of SCD to be important for making informed choices regarding pregnancy.  
Finally, in their study about SCD health beliefs and knowledge of reproductive-age African 
American women, Gustafson et al. found a high perceived benefit to hemoglobinopathy screening 
and counseling among participants.121 Participants were asked to rate on a five-point Likert scale 
their perceived usefulness of knowing their SCT status and knowing their partner’s status for 
planning for pregnancy. Scores of 4.32 and 4.43 respectively indicated that the participants viewed 
this information to be valuable for reproductive decisions. A higher average SCD knowledge score 
was significantly associated with a greater perceived benefit of screening, yet not with a higher 
perceived risk of having a child affected with SCD. However, A higher perceived risk of having 
an affected child did significantly correlate with a greater understanding of recessive inheritance 
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and SCD inheritance patterns. In this finding, Gustafson et al. emphasized the importance of 
promoting understanding of the mode of SCD inheritance in counseling and education.  
2.2.4  Potential Risks of Sickle Cell Trait Notification 
As they exist in any screening program, a number of risks may be realized by SCT 
notification through NBS. These include the potential for psychological, social, and/or emotional 
harm from impaired self-image, stigmatization, discrimination, and undue parental anxiety. Many 
of these risks pertain to screening for SCT, as well as for SCD and for genetic screening programs 
more generally. The relative weight of these harms as compared to the benefits must be considered 
when SCT does not pose an immediate health concern for the infant.  
Providing genetic information can alter how an individual is seen by others and also how 
they see themselves. This may result in stigmatization, where the perception of an individual as 
undesirable leads to their devaluation as well as possible discrimination and altered behavior 
toward them.133–135 A genetic diagnosis may cause one to feel shame, distress, secrecy, isolation, 
and damage to self-perception.134 In the medical context, both stigmatization and emotional harm 
can lead to the additional harm of causing a person to mistrust or under-utilize healthcare 
services.134 Both the infants and their family members are vulnerable to such harms in NBS 
programs which notify families of positive SCT results.  
Historical precedent exists for this concern. One major criticisms of the initial sickle cell 
screening programs was that they led to stigmatization of sickle cell carriers.10,11,49 Studies that 
have aimed to assess the burden of stigma associated with SCT have generally found that stigma 
associated with SCT may be anticipated more than actually felt by individuals with SCT. 
Additionally, those with SCT have not been found to view themselves or their health more 
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negatively on account of their carrier status. Consistent with this first point, a fear of stigma 
directed toward SCD and medical conditions in general has been identified as a barrier to 
hemoglobinopathy screening and related follow-up services among at-risk communities.  
 Dating from the early 1980s, one of the earliest studies on the topic found minimal 
evidence that the self-perception of sickle cell carriers was harmed by their awareness of having 
SCT. In this study, African American individuals with SCT were asked to respond to a Health 
Orientation Scale (HOS).136 The HOS survey consisted of 12 pairs of opposing adjectives (Good 
– Bad; Sad – Happy; Sick – Health; etc.), which participants were asked to assign to how having 
SCT made themselves or others feel. Responses were rated on a five-point Likert scale. The HOS 
survey was also administered to study participants who were also African American but did not 
have SCT. This latter group was more likely to report a negative attitude toward individuals with 
SCT than those who did have SCT.  
In 2009, Acharya et al. administered the same HOS-based survey to 53 African American 
or non-Hispanic adults with SCT from the Chicago area.122 Participants answered the survey as it 
related both to their perception of themselves, as well as how others perceived them. The average 
score on the HOS scale was 3.8, indicating an overall positive self-image possessed by those with 
SCT. This average score was higher than that found previously in the earlier study, which had also 
concluded that sickle cell carriers do not view their health negatively impacted by having SCT.136 
Acharya et al. interpreted these findings to indicate that sickle cell carriers’ self-image had 
improved since the initial days of screening programs, while admitting that the unavailability of 
raw data from the earlier study precluded statistical testing to determine if this increase was 
statistically significant. Similar to the earlier study’s findings, Acharya et al. also found that 
participants who did not have SCT themselves reported viewing SCT more negatively than those 
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who knew that they were carriers (p < 0.05). This was the case for overall score (3.8 versus 3.2, p 
< 0.05), as well as with ten of the 12 individual questions (p < 0.05).  
Acharya et al. additionally measured stigma with a questionnaire originally developed in 
the late 1990s for a similar purpose for HIV.137 Participants were asked to rate eight statements on 
a one to five scale, with five representing the highest stigma. The mean score was 1.6, indicating 
low stigma. For all but one of the eight statements, less than five percent of responses indicated 
any degree of perceived stigma. All study participants disagreed with the statement “I worry about 
people discriminating against me” on account of having SCT. Acharya et al. concluded that those 
with SCT did not feel stigmatized on account of their carrier status. The authors did note the limited 
generalizability of their data, given that stigma may differ based on sex and socioeconomic class. 
This is an important limitation of all studies that survey one population in order to more generally 
characterize a community’s perceptions, attitude, and beliefs toward sickle cell screening. 
Evidence supports that among African American communities, there is a perception that 
those with SCT are viewed as undesirable or unhealthy.16,120 Even in the context of positive self-
image, this fear may engender secrecy about one’s positive trait status and serve as a deterrent for 
hemoglobinopathy screening in those of un-clarified trait status. Effective SCT screening requires 
notified families to feel comfortable seeking follow-up testing, education, and counseling from 
their providers. It also calls for notified individuals to share the health information with close 
biological relatives who may also be at greater risk for having a pregnancy affected with SCD. 
Fear of stigmatization that inhibits such helpful sharing not only diminishes the utility of the health 
information, but also may impede the newborn’s care and harm familial dynamics.  
A desire for secrecy due to perceived stigma has been identified as a barrier to effective 
SCT follow-up with medical providers among African American communities. In their focus 
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groups, Treadwell et al. elicited the perceptions of participants on how screening and other medical 
services for hemoglobinopathies could be improved.120 A theme of stigma was identified as a 
barrier to following up on a positive screening result for SCT in two of the three focus groups: 1) 
that of individuals who had a first-degree relative with SCD or SCT or who themselves had SCT 
or SCD, and 2) that of African American men and women from the surrounding community. Terms 
such as embarrassment, taboo, stigmatization, fear, and ostracism were prevalent in both groups 
when discussing SCT. One participant remarked, “children…face stigmatization, fear and 
ostracism” and another that “people…with sickle cell are embarrassed; being unhealthy is taboo.” 
Stigmatization was not identified in the discussion of the third focus group, which consisted of 
healthcare providers who regularly worked with individuals affected with SCD. From this, 
Treadwell et al. posited that providers may not appreciate how related anxiety may be impeding 
families to pursue follow-up in response to a positive screen for SCT. Trait notification could 
thereby hinder the establishment of an effective alliance between families and their child’s 
provider in a crucial time of the infant’s care. Gaps in communication between the African 
American population and healthcare providers have been well-characterized and a contribute to 
race-based health disparities in the United States.101,138,139 Trait notification could exacerbate such 
differences. 
The disclosure of a newborn’s SCT status may also jeopardize familial relationships. 
Parents may experience guilt or shame in response to their child’s positive SCT screen or blaming 
the other parent if they believe them to have passed on SCT to the child.11,135 Trait notification 
may also expose non-paternity or contribute to distress over a potential future pregnancy being 
affected with SCD.11,82 The potential for these harms were demonstrated in one study, in which 
interviews of 34 African and African Caribbean women with SCT were conducted to gain insight 
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into how their carrier status influenced reproductive decisions. Participants expressed that a fear 
of rejection inhibited them from discussing SCT status with their partners.130  
The theme of shame and stigma associated with disease in a family was similarly identified 
as a barrier to effective sharing of knowledge in the focus groups held by Long et al.16 The study 
utilized qualitative thematic analysis to elucidate the attitudes and perspectives of African 
American individuals on SCD and barriers to education and awareness. A feeling of shame about 
personal and family health history, which discouraged open communication within families, was 
identified as an impediment to greater knowledge of SCD. However, one participant remarked that 
she thought, “more families are talking about it. It’s not seen as you have to be ashamed of it,” 
indicating that this concern may be diminishing in younger generations. This temporal shift is 
supported by previously presented findings, which indicate that most parents notified of their 
infants’ SCT status via NBS intend to share this information with close relatives.  
Parents may experience guilt over their child being born with SCT yet there is little support 
that they blame their partners. In the study of Kladny et al. carried out in the Pediatric Sickle Cell 
Clinic of Children’s Hospital of Pittsburgh (CHP), 114 families who received genetic counseling 
following a positive hemoglobinopathy trait screen via NBS were anonymously surveyed about 
their feelings regarding the screening.22 Nineteen percent of families reported a feeling of guilt or 
of being upset over their child having SCT. However, only 4% reported that they believed their 
partner blamed them for their child’s trait status. Participants were not asked whether they blamed 
their partner for their child’s SCT status. Additionally, blame was not identified when Gallo et al. 
held focus groups to elicit the beliefs and emotions of individuals with SCD or SCT regarding 
informed reproductive decision-making.132 Participants either had SCD themselves, or they were 
a parent of a child with SCD and at least 36 years of age. This age group was selected, as they 
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were more likely to have already made reproductive decisions. While many individuals expressed 
a sense of blame associated with a child’s inheritance of SCD, this was not the case for SCT. 
Another primary risk of screening for parents is the anxiety that can arise in response to 
receiving a genetic diagnosis for one’s child. Previous studies that have looked at the disclosure 
of carrier status identified through NBS to parents show that confusion regarding the information 
may lead to excessive worry about the infant’s health, impaired bonding, and unnecessary 
medicalization of the child.82,140,141 The term “non-disease” has been used to describe SCT 
identified through NBS, as the carrier state has few significant health implications for the infant 
yet can lead to adverse psychological effects for the infant’s parent.102 Feelings such as anxiety 
and depression have been reported by parents in response to learning that their child is a carrier 
for sickle cell or cystic fibrosis.140–142 
Genetic testing may lead to the social harm of discrimination. This was a documented issue 
of early screening programs of the 1970s and 1980s, with cases of both job and insurance 
discrimination occurring due to SCT status.10,103 Since this time, a number of federal laws have 
been developed to protect the confidentiality of personal health information and safeguard against 
employer discrimination and other forms of discrimination on the basis of genetic testing results. 
The Genetic Information Nondiscrimination Act (GINA) is a federal law passed in 2008, which 
dictates that genetic information cannot be used to determine eligibility or premiums for health 
insurance for individuals who do not show signs of the disease.143 Genetic information includes 
both family health history and genetic test results. Under GINA, it is also illegal for employers to 
base hiring, firing, promotion, or pay on genetic information. There are limitations to the protection 
afforded by GINA, as it does not apply to life, disability, or long-term care insurance, nor does it 
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cover healthcare coverage provided by the government such as Tricare Military Insurance or the 
Veteran’s Administration.143 
With such legislature in place, concern for genetic discrimination may be diminished for 
current screening programs. When Acharya et at. administered in-person questionnaires to parents 
who had SCT themselves or had a child with SCT or SCD, none of the 47 respondents reported 
that they worried about discrimination related to SCT.122 Additionally, no one expressed that they 
felt they had been rejected for a work position based on their SCT status. Two of the 47 respondents 
(4%) did report that they had experienced health insurance discrimination based on SCT status.  
In spite of such findings, study participants from minority backgrounds have expressed 
fears about future insurability or abuse of genetic testing results. A 2007 interview-based study by 
Kass et al. provided grounds for this concern in relation to SCD and other single gene disorders.144 
Five hundred and ninety seven participants who were either affected with or at risk for a genetic 
or other chronic health condition or had a similarly affected child were surveyed about their 
experiences and beliefs regarding health insurance. Approximately 17% (99/597) of participants 
were affected with SCD or had a child affected with the condition. Individuals with SCD or cystic 
fibrosis (CF), another mendelian disorder, were twice as likely to report having been denied health 
insurance or offered it at a cost-prohibitive rate than individuals with conditions that were non-
genetic in nature. Additionally, those with SCD were less likely to report that they had a choice 
when they were transitioning between insurance plans. These findings, although they may be 
explained by the fact that GINA does not apply to those already manifesting signs or symptoms of 
the condition, suggest that individuals receiving a genetic diagnosis through NBS may face genetic 
discrimination in health insurance.143 Further studies are needed to clarify how this applies to a 
genetic diagnosis of SCT, which does not acutely impact health as does SCD. 
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2.2.5  Execution of Newborn Screening Programs for Sickle Cell Trait  
Whether the potential risks and benefits of NBS for SCT are realized largely depends on 
how a program follows up on the positive screening results. Effective communication with families 
is central to ensuring that a program “does more good than harm:” That is, that the information is 
effectively imparted and utilized, and that any psychological and social complications are 
minimized.142 The means by which the message is first disclosed to families warrants particular 
examination. Its impact may carry undue weight, as individuals appear to be better able to recall 
the first message compared to the information discussed later on in a counseling session.142  
Disclosure of SCT status is often the responsibility of the infant’s pediatrician or PCP. 
However, the ability of these providers to notify families of this information has been criticized.145–
147 One primary concern regards education. While the physician must help parents understand the 
reproductive and health implications of SCT, PCPs have been found to have a limited 
understanding about NBS and genetics in general.148–150 In spite of this, counseling from general 
healthcare providers has been shown to contribute to increased patient knowledge. For example, 
in the study of Mayo-Gamble et al., women with SCT who reported having received 
hemoglobinopathy counseling from their PCP had significantly better scores on the SCD 
questionnaire than those who reported never having received counseling (p < 0.05).131 
Results disclosure must also attend to the emotional needs of the family. Providing such 
support helps to minimize undue parental anxiety and contribute to the formation of an alliance 
between the PCP and parents. However, fault has been found with the psychological support 
provided by PCPs communicating SCT results, as they struggle to achieve a balance between 
concern and reassurance.142 PCPs have also been shown to have difficulty identifying and 
responding to patient’s emotions.142,151,152 In the focus groups of Treadwell et al., participants 
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expressed a need for “compassion” and “love and nurturing” from physicians during SCT results 
disclosure.120 These themes were not identified in the third focus group made up of providers, 
which identified education and community outreach as the primary keys to support. This 
discordance indicates that PCPs may not fully recognize and attend to the emotional needs of 
parents during disclosure of the SCT results. 
Direct analysis of PCP’s communications with parents support this impression that trait 
status disclosures generally lack emotional support. When 116 randomly selected interactions 
between patients and PCPS were audiotaped and transcribed, PCPs were found to miss 79% of 
opportunities to positively respond to the patients’ emotional queues.152 Similarly, when Bradford 
et al. assessed the social support behaviors of PCPs during SCT disclosures to standardized 
patients, they found a lack of emotional support.153 In their analysis, Bradford et al. used a 
framework that defined five major categories of support. These were designated as either action-
facilitating types of support (tangible aid support and information support) or nurturing types of 
support (esteem support, emotional support, and social network support).154 In the 125 
conversations analyzed, less than 10% featured emotional support, which was defined as the 
physician acknowledging the patient’s emotions and expressing empathy. Less than 2% of 
conversations provided esteem support, defined as engendering feelings of self-efficacy through 
encouragement. Physicians primarily used social network support and information support. The 
former, which can be described as expressing the intention to maintain an ongoing supportive 
alliance, was found in over half (61.6%, 77/125) of interactions; it primarily manifested as 
physicians emphasizing the ongoing follow-up care to be provided in future appointments. The 
availability of educational materials for parents was largely credited for the physician’s use of 
informational support, which was present in 38.4% (48/125) of their conversations. Bradford et al. 
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acknowledged the important limitation of their findings due to the study’s artificial scenario yet 
discussed its unclear effect.153 As their conversations were being evaluated, providers may have 
felt an additional drive to succeed. On the other hand, they may have been less motivated to provide 
support to individuals who were not their real patients.  
Relying on PCPs to disclose NBS results and provide counseling for SCT may inadequately 
address the educational and psychological needs of families. Studies have demonstrated that when 
trait notification is facilitated by specialized healthcare provider such as a genetic counselor, it has 
positive effects on families both in terms of understanding as well as of reducing parental 
anxiety.22,147,155,156 In spite of such findings, genetic counseling appears to be rarely utilized by 
those notified of their infant’s positive NBS result for SCT when the services are offered. One 
assessment performed in northern California in the early 2000s found that less than 18% of families 
who were notified of their infant’s trait status through the state’s NBS program accepted free 
genetic counseling.120 More aggressive follow-up of families for the NBS results may be needed 
to increase the proportion who see a genetic counselor for SCT. However such protocols have been 
criticized, as they may unduly magnify anxiety in families.157 
In 2003, Kladny et al. addressed this critique by testing whether a flexible and accessible 
means of follow-up for SCT notification would increase utilization of genetic counseling services 
and be received positively by families.24 Convenience for the families, as well as their general 
interest in receiving genetic counseling, were also considered. The intervention was carried out at 
the Pediatric Sickle Cell Clinic of CHP, which is contracted with the Pennsylvania Department of 
Health to follow-up on positive hemoglobinopathy and hemoglobinopathy trait NBS results in 
Western Pennsylvania.23 In both this study and currently, a letter explaining the infant’s positive 
screening result serves as the initial means of trait notification in the Pediatric Sickle Cell Clinic’s 
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program. The letter, which is sent to the family within two weeks of the positive screen, is 
accompanied by an educational brochure regarding the specific hemoglobinopathy trait’s health 
and reproductive implications. In the study by Kladny et al., notified families were also contacted 
on the telephone following receipt of the letter and offered the opportunity to schedule an in-person 
genetic counseling session at the Sickle Cell Clinic.24 Parents who declined were offered the 
opportunity to speak with a board-certified genetic counselor over the telephone and also to be 
sent an educational video.  
When three or more attempts made to contact each family, 53% percent of families 
(362/679) were reached by telephone by Kladny et al.24 The majority (61%, 222/362) declined in-
person genetic counseling. Among the 39% who did express interest, slightly under half (47%) 
successfully scheduled appointments. This resulted in 18% (66/362) of families who were reached 
by telephone secured genetic counseling appointments. The show-rate for these families was not 
reported. 
A significantly greater proportion, 92% (333/362) agreed to receive telephone genetic 
counseling.24 While no quantitative means of assessing of understanding gained through this 
session was performed, families confirmed verbally that they understood the information 
following the session. Additionally, Kladny et al. reported that all families were able to explain 
the general concepts back to the counselor prior to completion of the session.  
Over one-quarter (27%, 99/362) of families contacted by Kladny et al. requested the 
educational video.24 A seven question SCD knowledge questionnaire was administered to 43 of 
these mothers after they had watched the video. Relatively high knowledge scores were interpreted 
to indicate high efficacy of the video in imparting SCD knowledge, yet this conclusion is limited 
by the absence of a pre-video questionnaire to assess participants’ prior knowledge. The 
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questionnaire found a relatively high understanding of autosomal inheritance in comparison to 
other studies, with 90.6% (39/43) of respondents agreeing that both parents had to have SCT in 
order for their child to be affected with SCD. The lowest average score was found in the question 
regarding the reproductive implications of HbC: “If one parent has sickle S trait and one parent 
has hemoglobin C trait, could they have a baby with disease?” Fifty-eight percent (25/43) of 
mothers answered this question correctly, while 16% answered incorrectly (7/43), and 26% (11/43) 
were unsure. This finding along with that of Boyd et al., where only 27% of African American 
women interviewed knew whether or not they were a carrier for HbC trait, supports an overall 
poorer understanding and awareness of variant hemoglobin traits beyond Sickle S trait.119  
Kladny et al. also examined other parameters indicative of the impact of genetic counseling 
on the notified families. The emotional impact of the trait notification process was assessed by 
asking participants if they felt less anxious after watching the video. The majority (93%, 40/43) 
reported that they did feel less anxious.24 For the remaining three individuals, it was not asked 
whether they felt more anxious, maintained their level of anxiety, or never felt anxious regarding 
their infant’s SCT status. When sharing patterns of the health information were evaluated, 79% 
(34/43) of parents responded that they did intend to share their infant’s SCT status with other 
family members. The study concluded that an intensive follow-up for SCT featuring multiple 
service modes increases utilization of genetic counseling for SCT, and that the majority of families 
are receptive to receiving these services by telephone. 
To better understand the reception of the in-person genetic counseling for SCT identified 
through NBS, a follow-up study by Kladny et al. evaluated 114 of the 300 in-person genetic 
counseling sessions held at the Pediatric Sickle Cell Clinic from June 2003 to December 2009.22 
All of the 114 participants reported that the session had been educational, and 113 out of the 114 
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participants agreed that all of their questions had been answered by the session. Eight-two percent 
of participants stated that they felt less anxious after the session. Genetic counseling was also 
concluded to contribute to increased sharing of SCT status between reproductive partners. 
Specifically, 21% of participants reported that they discussed SCD with their partner prior to or 
during pregnancy. This rate significantly increased following the genetic counseling session, with 
81% reporting that they would discuss this information with their partner. The reported 21% rate 
of sharing prior to genetic counseling is relatively low compared to other studies, yet the majority 
of these other studies report intentions of parents to discuss the information, rather than actualized 
sharing. Thus, the rate of 21% found by Kladny et al. may more accurately reflect true disclosure 
rates. In this case, the noted improvement in sharing rates, from 21% to 81%, derives from a 
comparison of past sharing (21%) to intended sharing (81%) and thus may be inflated. 
Additionally, it was not asked whether partners who did not discuss this information during 
pregnancy had been aware at that time that SCT was a chance for the pregnancy. Consistent with 
other studies, the great majority of respondents (91.2%, 104/114) expressed that they intended to 
share the infant’s trait status with the infant him or herself at an older age.  
In Pennsylvania, SCT notification remains a feature of the NBS program and continues to 
be facilitated by the mailing of a letter and informational brochure within two weeks of birth 
(Appendix B and Appendix C). The Pediatric Sickle Cell Clinic of CHP still offers in-person 
genetic counseling to families living within Region 6 of Western Pennsylvania. However, there is 
no longer the intensive follow-up as described by Kladny et al. due discontinuation of grant 
funding through HRSA.22,24 Consequently, the letter serves as the only consistent form of 
communication to families about their infant’s NBS results.  
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Genetic counseling for SCT is unavailable or under-utilized in many NBS programs.21,73 A 
passive means of notification, such as through the mail, is the experience for a large proportion of 
parents in states whose programs directly notify parents.21 While current literature has examined 
SCT notification facilitated by both PCPs and genetic counselors, it fails to directly address how 
trait notification through a mailing impacts families. By surveying parents who have received trait 
notification through this means, this study seeks to better characterize the harms and benefits of 
the NBS program for SCT experienced by a meaningful proportion of families. As this current 
study will draw from notified families living in the same regions previously recruited by Kladny 
et al., it will also allow for further evaluation of the additional services for trait notification that 
were the focus of these two previous studies.  
This study will evaluate the effectiveness of the letter and informational brochure that is 
currently sent in Western Pennsylvania to notify families of their infant’s positive screen for SCT 
in three categories: 1) disseminating relevant SCD knowledge 2) inducing parental anxiety, and 3) 
promoting sharing of the health information. As these three metrics characterize major benefits 
and harms of trait notification, this assessment will provide insight into the appropriateness of the 
public health program. This study plans to utilize what it learns from parents to revise the SCT 
notification letter sent in Western Pennsylvania. It may also potentially inform the NBS policies 
of Pennsylvania’s and other states’ programs. 




Sickle cell disease (SCD) refers to a group of inherited blood disorders characterized by a 
variant form of hemoglobin, whose sickling in the deoxygenated state contributes to severe pain, 
organ damage, and chronic anemia.3,4 In the United States, SCD affects approximately 100,000 
individuals.34 SCD is an autosomal recessive disorder.47 Its heterozygous carrier state, which is 
also known as sickle cell trait (SCT), is more prevalent in those with ancestry from malaria-
endemic regions. This includes Southeast Asia, Indian, Africa, Latin American, and the Middle 
East and the Mediterranean. In the United States, the prevalence of SCT is highest among African 
Americans, where the carrier rate is approximately one in 12.34 SCT is considered to be generally 
benign.7 Its primary relevance to health is its reproductive risk, as individuals with SCT may have 
a child with SCD if their partner also carries a variant hemoglobin trait or disease.  
Prior to the development of effective intervention, pneumococcal infection contributed to 
childhood mortality rates that were close to 30% for those with SCD in the United States.70 This 
high mortality rate aggravated racial disparities in health that began gaining national attention in 
the 1960s.64 In 1972, significant federal funding was devoted to SCD research and public health 
programs through the Sickle Cell Anemia Control Act.76 This funding sponsored the multi-center, 
prospective Cooperative Study for Sickle Cell Disease (CSSCD) to study the natural history of 
SCD.78 As one of the most influential projects to come from the CSSCD, the Penicillin Prophylaxis 
in Sickle Cell Disease (PROPS) trial was a double-blind, randomized control trial that 
demonstrated that penicillin prophylaxis provided significant protection against infection-related 
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morbidity and mortality in infants with SCD.5 In response, the NIH sponsored a conference entitled 
“Newborn Screening for Sickle Cell Disease and Other Hemoglobinopathies,” in 1987, after which 
a consensus statement was put forth recommending universal SCD screening of all newborns.6 
New York was the first state to adopt universal NBS for SCD, with subsequent uptake by other 
states. As of 2006, all 51 state and district programs include SCD in Newborn Screening (NBS).2 
NBS is a state-based public health program that screens for congenital conditions in 
newborns so that those affected may receive treatment to improve their long-term health 
outcomes.1 Relevant legislation is primarily made at the state-level, with each state determining 
its own screening panel as well as means for follow-up.93 In 2006, in response to significant 
variability between states, the American College of Medical Genetics, as commission by the 
Maternal and Child Health Bureau under the Health Resources and Services Administration, 
published the Recommended Uniform Screening Panel (RUSP).9 The RUSP provides guidance 
for the formation of states’ screening panels. Hemoglobinopathies were included on the original 
RUSP. SCT is identified incidentally through the screening process, an in 1994, the Institute of 
Medicine published a report in support of sharing SCT status with parents. Their position stated 
that carrier status, even identified incidentally, is genetic information belonging to the infant, and 
by proxy to their parents.8 However, states continue to vary significantly in their policies regarding 
SCT notification. In a survey of NBS programs carried out in 2008, approximately one third of 
states reported means for notifying parents of positive SCT screening results.21  
 No universally accepted policy currently exists regarding parental notification of SCT 
identified through NBS.21,73,107 A number of ethical, as well as evidence-based systems, have been 
developed to guide the determination of the appropriateness of screening programs in public 
health.111,112,115 In general, a public health program’s potential benefits may be weighed against its 
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potential risks. Arguments for reporting SCT focus on the reproductive implications of the 
information, both for the newborn and their parents.8,158 In particular, knowledge deficits regarding 
SCD and personal SCT status persist among at-risk communities and also are a stated concern of 
these communities.17,18,118–120,122 If increased awareness and understanding of SCT can be achieved 
through NBS, this may promote informed reproductive choice. 
A number of potential risks for SCT notification also exist. These include the possibility 
of stigmatization, discrimination, and adverse psychological impact.103,133,135 Many of these have 
been borne out in past screening programs for SCD and have the potential to exacerbate, rather 
than improve, health disparities if screening is haphazardly implemented. In the 1970s, population-
based screening programs for SCD failed to effectively communicate the generally benign nature 
of SCT and distinguish it from SCD.12,103 The resulting confusion perpetuated fear, stigma, and 
discrimination.10,11,13,49 These programs were also criticized for coercive reproductive counseling, 
rather than promoting informed choice and autonomy.159 NBS notification for carrier status in 
current programs has been found to result in emotional distress and anxiety as it regards both sickle 
cell and cystic fibrosis.135,140,147 The risk for these potential psychological harms caused by SCT 
notification must be considered in respect to proposed benefits in the program’s implementation. 
Effective trait notification must adequately impart SCT awareness and knowledge to 
relevant stakeholders without causing undue emotional distress. Previous studies have 
demonstrated that genetic counseling following SCT notification is received positively by families 
and promotes understanding and communication among family members 22,24,147,155,156 However, 
resources limit the availability of genetic counselors’ and other specialists’ services.21 Follow-up 
more often falls to PCPs, who have been found to be inadequately prepared for this role.149,150,153,160 
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Even when discussion with a specialized healthcare provider is available, it is not routinely sought 
out by families following trait notification.22,24 
A common strategy of NBS programs is to notify families of their infant’s positive screen 
for SCT through a letter. In the Pennsylvania NBS program, families are sent a letter and 
educational brochure within two weeks of the hemoglobinopathy referral center’s notification of 
the result.106 The mailing, which is specific to the particular hemoglobin trait identified, also 
includes a telephone number for the Pediatric Sickle Cell Program of CHP. The Pediatric Sickle 
Cell Program receives funding by the state’s Department of Health to send the notification letters 
for positive NBS results for hemoglobin variant traits, as well as performs follow up for 
hemoglobinopathy results. The program also offers genetic counseling to families whose infant 
screens positive for SCT; however, the great majority of families do not attend an in-person genetic 
counseling session. 
This study seeks to evaluate the ability of the current SCT notification letter sent in Western 
Pennsylvania to covey knowledge about the reproductive and health implications of SCD, as well 
as to promote emotional wellbeing and communication of the results to appropriate family 
members and health care providers. The literature, while it has explored SCT results disclosure by 
genetic counselors and PCPs, inadequately addresses the effects of trait notification facilitated by 
a mailed letter. As the trait notification letter is the only follow-up received by many families 
regarding the NBS results, a study of its impact in absence of follow-up counseling and educational 
services is particularly warranted.12 The results of this study have the potential to inform policy 
regarding SCT disclosure for both Pennsylvania’s NBS program as well as other states’. 
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3.2 METHODS 
The University of Pittsburgh Institutional Review Board (IRB) approved this study under 
IRB # PRO 18060433 (Appendix A). 
3.2.1  Participant Selection 
This study was conducted through the Pediatric Sickle Cell Clinic at CHP. The clinic is 
one of six regional specialty centers that are contracted with the Pennsylvania Department of 
Health and receives funding through the Maternal and Child Health Bureau under HRSA to follow-
up on positive NBS results for hemoglobinopathies and hemoglobinopathy traits.106 The Pediatric 
Sickle Cell Clinic covers Region 6, which includes 19 counties in the western portion of the state 
(Figure 1). 
 
Figure 1. Division of Newborn Screening and Genetics Hemoglobin Trait Map 
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As one of two laboratories contracted with the Pennsylvania Department of Health to 
perform the biochemical screening for NBS, PerkinElmer Genetics, Inc. tests for 
hemoglobinopathies. The laboratory maintains a database of infants who have screened positive 
for a hemoglobinopathy or hemoglobin variant trait, which can be accessed by region. The names 
and demographic information of infants who screen positive for a variant hemoglobinopathy trait 
within Region 6 are queried every two weeks and entered into the Sickle Cell Database (SCDB), 
which is an electronic database saved on a secure University of Pittsburgh Medical Center (UPMC) 
server. The SCDB contains information on all active and past patients seen by the Pediatric Sickle 
Cell Clinic since 1999, as well as on all infants who have screened positive for a hemoglobinopathy 
or hemoglobinopathy trait through NBS since this date.  
In October 2018, the SCDB was queried for the names of all infants who had received a 
positive screen for Sickle S trait or HbC trait in Region 6 from four to 56 weeks prior to this date. 
The study’s population was limited to these variant hemoglobin traits, as they are the most common 
structural hemoglobin variants that contribute to SCD in the United States. Thalassemia traits were 
excluded because their inheritance and clinical implications are more complex.4,34  
For each infant identified from the SCDB, a number of additional demographics were also 
retrieved. This included the mother’s surname, date of birth, sex, filter paper number, date of 
specimen collection, hemoglobinopathy profile, birth hospital, mother’s first and last name, 
mother’s address, mother’s phone number, physician’s name, and physician’s phone number. In 
the case that a mother was represented by more than one entry, either due to multiple births or a 
repeated NBS screen on the same infant, only one entry was retained. This was done to ensure that 
each family was sent only one survey. Each entry was assigned a unique number in sequential 
order, and surveys were coded in a corresponding fashion. This allowed for survey responses from 
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returned mail surveys to be matched to the corresponding notified family. This collection of coded 
demographic information served as the codebook and was stored on a secure server maintained by 
CHP.  
3.2.2  Mailed Surveys 
Each mailing was comprised of 1) a waiver for signed informed consent, 2) a generic copy 
of the NBS trait notification letter for “Baby Male Doe” with date of birth March 1, 2017, 3) a 
copy of the informational brochure provided with the original trait notification, 4) the 20-question 
survey, and 5) a paid-return envelope addressed to the Pediatric Sickle Cell Program of CHP 
(Appendix B-Appendix E). The letter, brochure, and survey were specific to the variant 
hemoglobin trait (Sickle S trait or HbC trait) identified through the screening. The letter was 
addressed to the mother of the infant specified by the NBS bloodspot, as this is how the original 
trait notification letters are addressed. Respondents were asked to confirm that they were over 18 
years of age in order to participate in the study. No compensation was offered. The survey 
introduction noted that one goal of the study was to improve the current notification letter. 
The surveys were designed to evaluate three potential consequences of trait notification: 1) 
general SCD knowledge (Knowledge), 2) emotional impact on parents (Anxiety), and 3) disclosure 
of infant’s positive SCT status with relevant family members and healthcare providers (Sharing). 
The eight-question SCD knowledge questionnaire developed for Part 1 (“Knowledge”) was 
adapted from the questionnaire administered by Kladny et al. to families following an SCD 
educational video.22,24 The first seven questions were identical to this previous survey, except it 
specified the letter, rather than the video, in one question. Participants were provided with three 
checkboxes (Yes, No, and Unsure) on the mail survey to record each answer. An additional 
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question was added to the end of the knowledge questionnaire, which asked the specific chance of 
having a baby affected with SCD if both parents had SCT. For this question, respondents were 
provided with the answer choices of 0%, 25%, 50%, 100%, and Unsure. 
 Part Two of the mail survey examined the psychological impact of the letter, focusing on 
anxiety. The Patient-Reported Outcomes Measurement Information System (PROMIS) Short 
Form 8a Scale of Anxiety was adapted for this aim. PROMIS is a validated survey tool developed 
by the NIH to measure emotional distress through self-report with a high degree of reliability and 
precision.161 The PROMIS Short Form 8a for Anxiety may be used in the general public and uses 
universal measures of the symptoms of anxiety: fear (fearfulness, panic), anxious misery (worry, 
dread), hyper-arousal (tension, nervousness, restlessness), and somatic symptoms (racing heart, 
dizziness). Responses range from 1 (“Never”) to 5 (“Always”). Scores are transformed to compare 
to a normalized curve of scores derived from the general American public with a mean of 50 and 
a standard deviation of 10. For the purpose of this study, participants were asked if they 
experienced the specified symptoms of anxiety in response to learning about their infant’s positive 
SCT status. The time frame of the PROMIS survey was modified from “the past week” to assess 
participants’ anxiety since receiving the trait notification letter.  
In the third part of the survey, respondents were asked about the individuals with whom 
they had already shared or planned share their infant’s trait status. Four individuals were specified: 
the respondent’s partner, the infant’s doctor, the respondent’s own doctor, and the infant when he 
or she was older. The choices provided were Yes, No, and Unsure. 
The final part of the survey asked for additional thoughts or feelings about the notification 
letter. A blank space under the question was left for participants’ responses. 
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3.2.3  Phone Surveys 
Two months following the mailing of the surveys, telephone calls were initiated to 
administer the survey to parents who had not returned the mailed survey. The calls were made on 
weekdays during the months of December and January, between the hours of 9am and 6pm. At 
least two call attempts were made for every working number in the codebook. No voicemails were 
left, but a voicemail was counted as one call attempt. Calls and telephone survey responses were 
recorded on individual tabs of the codebook. 
Two genetic counseling Masters students, who had previous experience in the Sickle Cell 
clinic and training by a boarded hematologist, administered the telephone surveys A telephone 
script along with training of one interviewer by the other ensured consistency (Appendix F). 
Parents were first asked if they recalled receiving a letter about SCT a few months to one year ago. 
Those who reported that they did not recall receiving the letter were asked if their pediatrician or 
other provider had talked to them about their infant’s NBS result for SCT. If they were aware of 
their infant’s positive screen, the parents were assured that the call did not regard their child’s 
health and was for a research study. As the survey sought to evaluate the mail notification process, 
individuals who did not report recalling the letter were noted in the codebook but were not eligible 
to participate in the survey. For parents who neither remembered receiving the letter nor expressed 
awareness of their infant’s positive screen, the interviewer disclosed the positive screening result 
for SCT. The parent was assured that their infant was healthy and did not have SCD. SCT was 
explained as a generally benign carrier status with normal lifespan and normal fertility. Its 
implications for reproduction, both for the child as well as for the parents, were discussed, along 
with the potential for the health complications of traumatic hyphema, hematuria, and a mildly 
elevated risk for rhabdomyolysis in the setting of exertional heat illness. Parents were given the 
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opportunity to ask questions or follow-up with a board-certified genetic counselor or hematologist 
if they desired. The number to the Pediatric Sickle Cell Program that was included NBS letter was 
also given to them at the end of the call in the case they thought of questions at a later time.  
Parents who confirmed receipt of the original trait letter and/or the mailed survey were 
offered the opportunity to participate in the survey over the telephone. The survey took between 
five to ten minutes to administer, with additional time for follow-up questions and education as 
needed. The first eight questions, which were the knowledge-based questions, were administered 
verbatim from the mail survey. Mothers were encouraged to answer “yes” or “no” to the questions, 
but an answer of “unsure” was accepted if they refused. No correction or confirmation of answers 
was given until the completion of the entire survey.  
Participants were informed that for the second half of the survey, there were no right or 
wrong answers, as the questions concerned their emotions and opinions about the letter’s 
information. The PROMIS survey, which was used to assess anxiety in the mail survey, is not 
designed to be administered over the telephone. Thus, a single question was asked for this section 
of the telephone survey. The interviewer asked participants if they had felt “nervous, fearful, or 
anxious” about their infant’s SCT status since receiving the notification letter. Responses were 
recorded as either “yes” or “no.” Any reply other than “no” or “not really” was coded as “yes.” 
Elaboration on the question was transcribed with the participant’s survey responses.  
For the last section (Sharing), parents were again reminded that there were no right or 
wrong answers in order to encourage honest reporting of with whom they had shared or planned 
to share the letter’s information. Participants were again encouraged to respond with “yes” or “no”, 
but an answer of “unsure” was accepted. At the end of the survey, participants were asked if they 
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had any additional thoughts or questions regarding the screening letter or information that was 
discussed. With the participant’s permission, these remarks were transcribed.  
Following completion of the survey, the interviewer asked the participant for permission 
to review the answers to the knowledge questions. Additional information was also given if the 
participant expressed confusion or asked further questions. If the information requested was 
outside of the comfort level of the interviewers to impart, participants were given the number of 
the Hemoglobinopathy RN Coordinator, who is trained to counsel parents regarding SCT NBS 
results, and referred to the Hematology clinic as needed. 
3.2.4  Data Analysis 
All responses to the mail and telephone surveys were recorded in Microsoft Excel. For Part 
1 (Knowledge) and Part 3 (Sharing), descriptive statistics were calculated for the mail and 
telephone survey responses separately, as well as combined. Descriptive statistics were also 
calculated for the responses to the telephone survey for Part 2 (Anxiety). For Part 2 of the mail 
survey, which used the adaptation of the PROMIS short form, responses were summed and scored 
as instructed by PROMIS Anxiety Scoring Manual. The mean of the participants’ raw scores was 
transformed into a T-score, with a mean of 50 and a standard deviation of 10, using the provided 
score conversion table (Appendix G). 
R Studio for Mac Version 1.1.456 was used for statistical tests. Specifically, chi-squared 
analysis was performed to compare the knowledge scores of this survey with those of Kladny et 
al.24 
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3.3 RESULTS 
3.3.1  Survey Responses 
Four hundred and forty-one positive NBS screening results for Sickle S trait and HbC trait 
from Region 6 were downloaded from the SCDB using a one-year time span ranging from four to 
56 weeks prior to the date the data of download. Following the removal of seven entries, which 
represented either multiple births or repeat screens for the same infant, results for 434 unique 
mothers remained (Figure 2). Three hundred twenty-nine (75.8%) of these were for Sickle S trait 
and 105 (24.2%) were for HbC trait. The majority of mothers (72.6%) reported a home address in 
Allegheny County, which is the county where the Pediatric Sickle Cell Program of CHP is located. 
The second highest representation, with 12.2% of mothers, came from Erie County, which is 
approximately 120 miles from the clinic. Less than 10% representation came from the remaining 
11 counties. 
Over the five weeks after mailing out the surveys, thirteen (3.0%) completed mail surveys 
were returned to the Pediatric Sickle Cell Program. An additional 40 (9.2%) surveys were mailed 
back as undeliverable. This represents a mail response rate of 3.3% (13/394). 
Two months after the surveys had been mailed out to families, telephone calls were made 
to all parents who had not returned a completed mail survey. Of the 421 numbers attempted, 98 
(23.3%) were no longer in service. A voicemail or busy tone was reached on both call attempts for 
145 (34.4%) of numbers. For the remaining 178 (42.8%) telephone numbers, an individual was 
reached by telephone. The interviewer was informed that the number was incorrect or that the 
mother could no longer be reached at that number for 24 (5.7% total) of these telephone numbers. 
Fourteen of the parents who were reached were ineligible for the survey, as they either did not 
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speak sufficient English (n = 2, 0.5%) or reported that they did not recall receiving the trait 
notification letter originally or with the survey (n = 12, 2.9%). In three of these latter cases, the 
parent also reported not knowing about their infant’s positive NBS result. After confirmation that 
their demographic information matched those of the NBS results reported on the NBS bloodspot, 
the results were disclosed over the telephone. Fifty-nine (14.0%) of the parents who were contacted 
over the telephone either declined participating in the survey or asked to be called back but could 
not be reached at a later time. Eighty-one (19.2%) of parents contacted by telephone completed 
the survey. 
By matching the mailed surveys that had been returned as undeliverable to the 
corresponding parent on the call log, it was found that the interviewers had reached sixteen of these 
intended recipients. Only one parent reported that she did not recall receiving the original mailed 
notification letter. Among the other 15 parents who were reached by telephone, five consented for 
the survey and 10 declined the survey. The remaining 24 parents whose mail survey was returned 
as undeliverable could also not be reached by telephone: three telephone numbers were reported 
to be wrong numbers, eight were disconnected, and 13 went to voicemail on both call attempts. 
Subtracting out the 281 total telephone numbers dialed where the parent could not be 
reached over the telephone or were ineligible, the response rate for calling was 57.8% (81/140). 
This resulted in a total of 94 completed mail and telephone surveys, representing 21.7% (94/434) 
of parents whose infant screened positive for Sickle S or HbC trait within Region 6 in the past 
year.  
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Figure 2. Flowchart of Survey Administration 
3.3.2  Aim 1: Sickle Cell Knowledge 
On the first section of the survey (Knowledge), the mean total correct score was 70.5%. By 
mail, the mean total score was 75% (n = 13) and by telephone, it was 69.8% (n = 81). Appendix 
H contains a breakdown of correct response rate by survey type. 
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Over 95% of parents reported that the notification letter clearly distinguished SCT from 
SCD (Table 6, Question 1). However, 28.7% of participants responded incorrectly that SCT could 
develop into SCD, or that they were uncertain whether it could, indicating confusion over the 
distinction between SCD and its carrier state (Question 2). 
The highest correct response rate was obtained for the question regarding whether or not 
SCD is contagious. All those surveyed through both mail and the telephone responded that SCD 
could not be “caught like a cold” (Question 7). Thus, participants appeared to generally appreciate 
the congenital nature of SCD. There was less understanding regarding how SCD is inherited, with 
only 63% of survey participants correctly answering that both parents need to possess an abnormal 
hemoglobin trait for their baby to be affected with SCD (Question 3). Scores were lower in the 
context of how HbC trait contributed to reproductive risk. When parents were asked whether a 
couple in which one individual has Sickle S trait and the other individual has HbC trait could have 
a child with SCD, just over half of respondents (53.2%) answered correctly (Question 4). When 
this question was broken down by NBS result, significantly higher scores were found among those 
mothers whose infant screened positive for HbC trait, compared to those for Sickle S trait: 71.4% 
(20/28) versus 45.5% (30/66), p = 0.02.  
Responses to two additional questions further underline the lack of clarity among surveyed 
parents regarding the way SCD is inherited. First, over one quarter (25.6%) of parents responded 
that their brother or sister could not also have SCT if they themselves did (Question 5). When 
participants were asked to select the percentage chance that a child would be born with SCD if 
born their parents had SCT, the correct percentage (25%) was given by 14.9% of mothers. This 
resulted in the lowest average score among questions in the knowledge section of the survey, 
although importantly, this was not a true/false question but presented four options for a response. 
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The most common response given by participants was 50%, which represented 51.1% of total 
responses. This was followed by 25.5% of parents who responded that if both parents had SCT, 
their child would have a 100% chance of having SCD. 
 
Table 6. Knowledge Questionnaire Scores 
Question (Answer) Percent Correct 
1. Did the letter make it clear that there is a difference between 
sickle cell trait and sickle cell disease? This is not a question that 
can be answered correctly or incorrectly (Yes) 
95.20% 
2. Can a child with sickle cell trait ever develop sickle cell 
disease? (No) 71.30% 
3. Do both parents have to have sickle cell trait for a baby to be 
born with sickle cell disease (Yes) 63.80% 
4. If one parent has sickle S trait and one parent has hemoglobin 
C trait, could they have a baby with disease? (Yes) 53.20% 
5. If you have sickle cell trait, could your brother or sister also 
have sickle cell trait? (Yes) 74.50% 
6. Can you choose which genes are passed onto your children? 
(No) 93.60% 
7. Can you “catch” sickle cell disease like a cold? (No) 100% 
8. If both parents have sickle cell trait, what is the chance that 
their child will have sickle cell disease? (25%) 14.90% 
Average Score 70.50% 
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3.3.3  Aim 2: Anxiety 
Potential anxiety elicited by the notification letter was measured through two different 
methods depending on survey format. The eight-question PROMIS short form was used to 
measure anxiety and emotional distress in the mail surveys. All 13 mail survey respondents 
completely filled out the PROMIS form. The mean raw score was 13.5. Using the conversion table 
for the Adult Anxiety short form and rounding up, this corresponds to a T-score of 50.8 with a 
standard error of 2.2 (Appendix G). This value is not significantly different from the general 
population mean of 50.0, suggesting that on average, the mail survey participants did not 
experience increased anxiety or emotional distress due to carrier identification.  
Individual scores for the mailed surey PROMIS scores were not normally distributed and 
indicated that a proportion of parents were made anxious by the notification, however. A density 
plot of scores shows a bimodal distribution (Figure 3). Approximately one-third (30.7%, 4/13) of 
participants’ rounded individual scores were at least one standard deviation above the general 
population mean (60.0 or greater). This suggests that these parents experienced a significant level 
of anxiety from the trait notification. The two mail survey participants who provided feedback in 
the final section of the survey emphasized an initial negative reaction to the letter: 
 
“I checked sometimes in those 3 boxes because that is how I felt when I first found out she had the 
trait. But now that I learned about it and read about it I feel much better.” 
 
“The letter made me feel generally uncertain…about the present and the future. I could tell it was 
intended as notification and tried to reassure me that nothing is wrong, but it is still very 
intimidating to be contacted by the Hematology/Oncology department of Children's Hospital...” 
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Figure 3. Range of Transformed PROMIS Scores (n = 13) 
 
In the telephone surveys, parents were asked if they felt “nervous, fearful, or anxious” 
about their baby’s positive screen for SCT in the time since receiving the letter. The rate of anxiety 
demonstrated by these responses was similar to that observed through the mail, in spite of the 
different survey modes and measurement tools. Specifically, just under one-third (30.9%, 25/81) 
of the eighty-one telephone survey respondents confirmed they had been emotionally distressed 
by the letter, compared to 30.7% (4/13) of the mail survey recipients. 
While no formal qualitative analysis was performed on the additional remarks made by the 
telephone survey participants, their elaboration provided additional insight into their emotional 
reaction to the letter (Appendix I). Parents who denied experiencing any anxiety commonly evoked 
personal experiences with SCT that were in line with its generally minimal effect on health. The 
reflections of those who did report a negative reaction commonly included a feeling of fear or 
nervousness from receiving a letter from CHP regarding their infant. Often, it seemed this reaction 
had subsided within a few days to a week.  
Fraction 
Respondents 
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Many parents discussed how they had grown reassured through gaining better 
understanding of the letter’s information. Highlighting the relevancy of the knowledge sections’ 
first two questions, which concerned the distinction between SCT and SCD, parents’ anxiety 
seemed to be often relieved by clarifying that the letter regarded trait rather than SCD. Parents 
reported that they sought clarification through re-reading the mailing or through speaking with a 
health care provider, who was primarily their infant’s PCP, or a family member. A small, but not 
quantified number of parents did speak of lingering worry about their child when he or she was 
ready to have children, or fears that he or she would not be able to do sports. 
3.3.4  Aim 3: Sharing Patterns 
Both survey modes demonstrated a relatively high degree of anticipated sharing of the 
letter’s information. Over 95% of participants expressed that they had discussed or planned to 
discuss their child’s positive SCT status with the family members named by the survey (Table 7). 
Specifically, 96.5% of parents reported feeling comfortable discussing the information with their 
reproductive partner, and 98.9% planned to share their infant’s trait status with him or her at an 
older age.  
A smaller proportion, yet still the majority of parents, reported that they would or had 
already discussed this information with healthcare providers: 90.4% with their child’s physician 
and 71.3% with their own physician. Telephone respondents who answered that they had not and 
did not plan on discussing SCT with their own physician often indicated that this was because it 
was their partner who was responsible for their infant having SCT. In these cases, it was not 
clarified whether either partner had received hemoglobinopathy testing to determine that this 
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report was accurate and also that respondent was not also a carrier of a variant hemoglobinopathy 
trait. 
 
Table 7. Reported Disclosure Patterns 
Have you or do you plan on 
sharing the letter’s information 
with your: 
Yes No Unsure 
Partner 96.8% 3.2% 0% 
Child 98.9% 0% 1.1% 
Child’s Doctor 90.4% 6.4% 3.2% 
Own Doctor 71.3% 25.5% 3.2% 
3.4 DISCUSSION 
This study examined the impact of SCT identification in an NBS program which directly 
notifies families through a letter. Parents who had received the letter for either Sickle S or HbC 
trait within the past year were surveyed through the mail and over the telephone. The survey 
addressed the three specific areas of 1) sickle cell knowledge, 2) emotional distress elicited by the 
notification letter, and 3) anticipated disclosure of its information, as these characterize potential 
benefits and harms of trait notification. 
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3.4.1  Aim 1: Sickle Cell Knowledge 
Disclosing positive NBS results for SCT may promote the understanding of genetic 
information that has great relevancy for reproductive decisions. An increased awareness of this 
information has been called for by the communities most directly impacted by SCD, and is also 
outlined by current clinical and prenatal guidelines.14–16,19,20,120 This study aimed to evaluate the 
effectiveness of one NBS program at disseminating this knowledge to at-risk families. 
Answers to the knowledge assessment’s first two questions suggest that the current trait 
notification letter fails to clarify the health consequences of SCT for a substantial proportion of 
notified parents. While over 95% of participants stated that the notification letter made the 
difference between SCT and SCD clear, more than one-quarter (28.7%) reported that the carrier 
state could develop into SCD. Previous studies, which have similarly assessed understanding 
gained through trait notification facilitated by a letter, have also found high rates of confusion 
among its population regarding the distinction between SCD and SCT. In one such study, Lang et 
al. surveyed mothers who had first been notified of their infant’s positive screen for Sickle S trait 
by an informational mailing sent through the Illinois NBS program. Forty-four percent of mothers 
answered the equivalent question incorrectly, replying that “over time, carriers of SCD (people 
with SCT) can develop SCD.” Forty-one percent of mothers responded that “people who are 
carriers of SCD (people with SCT) have a mild form of SCD,” which is also false.17  
While this current study found a lower rate of misunderstanding between SCT and SCD 
than was found in mothers similarly notified through the Illinois NBS program. its finding that 
over one-fourth of parents believe that SCT could turn into SCD is particularly concerning among 
individuals who have just learned of their newborn’s positive screen for SCT.17 An inability to 
distinguish SCD from its generally benign carrier state may contribute to an erroneous view of 
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their infant’s poor health and increase anxiety. An exaggerated perception of the health 
consequences of having SCT appears to persist among African American communities.120,122,136 
This may be attributed to both historical and contemporary events. For four decades following 
James Herrick’s initial publication of SCD, SCT was thought to be a more mild form of the 
condition.47,65 The initials sickle cell screening programs propagated this misconception among 
the general public.13 Contemporary SCT screening programs of some military branches and the 
NCAA have also been criticized for over-emphasizing the personal health implications of SCT, 
thereby conflating SCT with a more clinically significant condition.58,61,62 This study’s findings 
indicate that the current trait notification process may also inadequately establish the difference 
between SCD and SCT for a meaningful proportion of parents of whose infants screened positive 
for SCT. This is one potential harm of the program. 
The reproductive implications of SCT motivate programs to share the screening results 
with families. However, responses to this study’s survey demonstrate that the current letter does 
not adequately impart to parents how having SCT may lead to having a child with SCD (Table 6; 
Questions 3, 4, and 8). This is consistent with other similar knowledge assessments, which have 
found that in spite of a relatively high appreciation for the condition’s hereditary nature, there is 
poorer understanding of its specific mode of inheritance (Table 5). Over one-third (36.2%) of this 
current study’s participants did not recognize that both parents must have SCT for their child to 
have SCD. This incorrect response rate is similar to that found by Lang et al., who found that 33% 
of notified Illinois mothers incorrectly confirmed that “you can be a carrier of SCD (have SCT) 
even if neither parent has disease or trait.” In responding to this question over the telephone, a 
number of this study’s parents articulated the common misconception that SCD “skips 
generations.” 
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Such confusion over how SCD is inherited was further highlighted by the last question of 
this survey’s knowledge assessment, which specifically inquired about the reproductive risks 
associated with autosomal recessive inheritance. This question received the lowest scores of Part 
One (Knowledge). A greater proportion of participants (25.5%) responded that a carrier couple 
would have a 100% chance of having a child affected with SCD than those who gave the correct 
chance of 25% (15%). While reviewing the answers, a number of participants expressed disbelief 
that the chance was “only 25%.” In light of studies that have largely found their African American 
participants have a low perceived personal risk of having a child with SCT, this finding is 
particularly surprising.16,17,120,122 In particular, it contrasts those of Gustafson et al., where a higher 
perceived personal susceptibility was found to significantly correlate with an understanding of 
autosomal recessive inheritance.121 This may indicate that a lack of understanding of the 
inheritance pattern of SCD is not the greatest barrier to accurate risk perception. Other factors, 
which likely correlate with a specific understanding of the inheritance pattern, may more strongly 
contribute to accurate risk perception. An awareness of one’s partner’s and one’s own trait status, 
an appreciation for the high prevalence of SCT, and having personal or familial experience with 
sickle cell have also been found to influence reproductive decision making in relation to SCD. 
While this study did not evaluate parents’ perceived risk for having a child with SCD, responses 
to this final question of the knowledge assessment suggest that further evaluation is needed to 
clarify what information should be prioritized in order to promote accurate risk perception in this 
population.  
This study found a mean knowledge score of 70.5%. While this is comparable to scores 
deemed to be “insufficient” by other study authors, score interpretation is subjective in 
nature.119,122 Thus, this measurement’s primary utility is in its ability to be compared with other 
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populations to evaluate the effect of interventions. In a previous study by Kladny et al., the same 
knowledge questionnaire used in this study was administered to a similar population who also 
received additional educational services.24 Parents living in Region 6 of western Pennsylvania who 
had been notified through the mail of their infant’s NBS screen for SCT were surveyed about their 
knowledge of sickle cell after watching an information video. The video was concluded to promote 
greater understanding, with all but two families surveyed (95%, 41/43) reporting that the video 
had provided them with additional information about SCT that they had not known previously. 
However, without a pre-video assessment, Kladny et al. was unable to determine what knowledge 
was specifically gained through the video. As this current study utilized the same set of questions 
to assess the SCD knowledge of notified parents living in Region 6 who had only received the 
notification letter, it can provide further insight into the impact of educational services following 
trait notification. 
In comparing the results of this current survey to those of Kladny et al., additional learning 
does appear to have been facilitated by the educational services (Table 8). Significantly higher 
scores were achieved for three of the six knowledge questions asked of both groups by the 
population of parents who had watched the video (p < 0.05).24 For those questions for which the 
additional education did not correspond to significantly higher scores, the scores were greater than 
90% in both groups. This suggest that there is an opportunity to further increase SCD-related 
knowledge after families are initially notified of the NBS results through the mail. However, other 
differences may exist between these two groups, such as the motivation to watch the video, to 
account for the deviations in scores. Support for additional services following trait notification to 
increase understanding of SCD is provided by other studies. Namely, Lang et al. administered both 
pre- and post- intervention knowledge questionnaire to their population of mothers in the Chicago, 
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Illinois area, who had also been notified of their child’s positive NBS screen for SCT through a 
mailing. Participants who attended an in-person sickle cell educational program significantly 
improved their average scores (69% versus 76%, p < 0.01). Following the program, significantly 
higher correct response rates were also found for three of the questions previously discussed: 1) 
Over time, carriers of SCD (people with SCT) can develop SCD, 2) People who are carriers of 
SCD (people with SCT) have a mild form of SCD, and 3) You can be a carrier of SCD (have SCT) 
even if neither parent has disease or trait (p < 0.05). 
Further understanding of SCT has also been identified as a need by notified families who 
seek out additional services after receiving the NBS letter for SCT. When Kladny et al. surveyed 
mothers who attended in-person genetic counseling sessions following trait notification through 
the mail, the majority (52%) reported that their main motivation for genetic counseling was a desire 
to obtain more information.22 Following this was 22% who reported it was due to their physician’s 
recommendation, and then 13% who responded that it was for “peace of mind.”  
In the context of these two earlier studies of Kladny et al., the first of which assessed SCD 
knowledge of families who had received additional educational services following the notification 
letter and the second of which surveyed mothers for their motivation to seek out in-person genetic 
counseling regarding SCT, as well as those of Lang et al., results from the first part of this study’s 
survey indicate that trait notification through the current letter alone inadequately addresses the 
educational needs of families.17,22,24 Additional services appear to increase understanding of the 
health and reproductive implications of SCT following notification by mail; greater understanding 
of SCT also appears to be the primary motivation of a large proportion of families who seek out 
follow-up counseling services. Ensuring families access to such resources will allow for the 
benefits of the NBS program to be more fully realized. Further evaluation is needed to clarify what 
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information most significantly influences reproductive decisions in this population and how to 
most effectively execute these services in Western Pennsylvania specifically. 
 









(n = 43) 
1. Did the letter/video make it clear that there is a 
difference between sickle cell trait and sickle cell 
disease? This is not a question that can be answered 
correctly or incorrectly (Yes) 
95% 93% 
2. Can a child with sickle cell trait ever develop sickle 
cell disease? (No) 
71% 91%* 
3. Do both parents have to have sickle cell trait for a 
baby to be born with sickle cell disease (Yes) 
64% 91%* 
4. If one parent has sickle S trait and one parent has 
hemoglobin C trait, could they have a baby with 
disease? (Yes) 
53% 58% 
5. If you have sickle cell trait, could your brother or 
sister also have sickle cell trait? (Yes) 
75% 91%* 
6. Can you choose which genes are passed onto your 
children? (No) 
94% 95% 





   * Statistically significant increase in score (p < 0.05) 
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3.4.2  Aim 2: Anxiety 
Responses to the first section of this study’s survey (Knowledge) demonstrate that the 
current notification letter fails to fully clarify the distinction between SCT and SCD among parents 
whose infant screens positive for SCT in Western Pennsylvania. Confusion about the health risks 
of SCT was widely propagated by the nation’s earliest SCD screening programs; this contributed 
to undue anxiety among those screened and lead to programs’ early termination.10–13 2 In current 
NBS programs, parental anxiety remains a concern of carrier identification, which occurs not only 
for SCD, but for other conditions such as cystic fibroris..49,140,141 In light of the minimal health 
implications of SCT, any emotional distress caused through notification of families is particularly 
pertinent to the program as a potential harm. 
Despite using different measurement tools, both the mail and telephone surveys found that 
approximately one-third of notified parents were made anxious by the NBS mailing (30.7% and 
30.9%, respectively). Participants’ feedback often suggested that their anxiety was elicited by 
learning this information about their infant’s health that they may not fully comprehend or by 
receiving an official mailing from CHP about their newborn. Thus, their elaborations emphasized 
an initial negative reaction to the letter. Both survey methods measured a sustained emotional 
response to the letter, however, which suggests that the anxiety reported by just under one third of 
notified parents persists. This conclusion is supported by findings of Lang et al. who surveyed 
mothers notified through mail of their infants’ positive screen for SCT through the Illinois NBS 
program: 24% (15/62) of mothers who had received the notification mailing more than one month 
prior to completing survey reported that they still thought about their infant’s positive trait status 
at least once a week.17 
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Although no qualitative analysis was performed on participants’ commentary, several 
observations made by those administering the survey provide further insight into the emotional 
reaction of notified parents. Those surveyed over the telephone often reported that their anxiety 
began to diminish once they felt they had gained a clearer understanding of the letter’s information. 
As many of this study’s telephone participants reported re-reading the letter to feel reassured, the 
initial mode of results disclosure, in this case the letter, appears to be central to minimizing the 
adverse emotional impact of trait notification. Parents also cited sources of additional information 
that they sought out following receiving the notification, indicating that effective educational 
strategies may help minimize the stress experienced by notified parents. Key stakeholders to 
engage include included healthcare providers, namely the infant’s pediatrician, as they were often 
named as a primary reference for families. Other external sources of information included family, 
friends, and coworkers. Only one parent spoke of turning to the internet (“Googling”) for more 
information.  
Personal and familial experience with SCT appeared to both positively and negatively 
influence emotional reaction to the trait notification depending on the nature of the experience. 
Many of those who denied having a negative reaction to the letter explained that they had family 
members with SCT who were generally healthy. In the case that the experience was negative, this 
was often noted in tandem with a self-report of anxiety. Specifically, a number of participants who 
reported being made anxious by the letter spoke of having family members affected with SCD. 
One mother talked about her father who had SCT that “developed into a rare form of SCD,” 
evoking confusion between SCD and SCT.  
These observations are generally consistent with community-based qualitative studies that 
have found familial connections to be central sources of health information in African American 
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communities.16,122–124 They also suggest that education of PCPs and other healthcare providers, as 
well as community outreach may go farther than paper or web-based educational material in 
promoting SCT awareness and understanding among high-risk populations. Community-based 
educational programs have been shown to be effective at promoting SCT awareness and screening 
in at-risk populations.15,120  
As was true for the first part of survey, the results of this section may also inform Kladny 
et al.’s assessment of the ability of follow-up services to reduce anxiety in parents who have been 
notified of positive NBS SCT results through the mail. In this previous study, families were asked 
if they “felt less anxious after watching the video” that was provided to them following trait 
notification.24 Ninety-two percent of families reported that the video decreased their anxiety. In a 
follow-up study by Kladny et al., families who received in-person genetic counseling for SCT were 
asked if they felt less anxious after the session.22 In this case, 82% of families indicated they felt 
less anxious. However, in neither survey were parents asked if they were anxious before the video 
or genetic counseling. Findings from this current study indicate that a substantial proportion of 
parents do experience lingering anxiety due to trait notification and may benefit from these follow-
up services to promote emotional wellbeing.  
Taken together, these studies’ findings provide insight into the criticism that more 
aggressive follow-up for SCT may unnecessarily increase anxiety.49,157 The previous work 
performed by Kladny et al. demonstrates that additional services following trait notification by 
mail reduces anxiety in notified mothers; this study identified a proportion of parents who may 
benefit from access to such services. With thoughtful execution, follow-up for SCT notification 
may minimize the potential emotional harm caused by the NBS program. A prioritization should 
also be placed on making the initial notification clear and reassuring and providing mothers with 
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immediately accessible sources of accurate information. One source that the current letter provides 
is the number to the Pediatric Hemoglobinopathy RN Coordinator. Future assessment must be 
done to determine to what degree this number is utilized and its effectiveness at minimizing initial 
anxiety in notified families. A survey of PCP knowledge in regarding SCT may also help to design 
training and resources for 
3.4.3  Aim 3: Sharing Patterns 
Evidence for stigma related to SCD in African American communities has raised concern 
that parents may not feel comfortable sharing the screening results. This is supported by lower 
rates of SCT status awareness than universal newborn and targeted prenatal screening programs 
would suggest (Table 5).17,119 While individual circumstances vary, discussion of the health 
information with close family members and healthcare providers promotes more full realization of 
the reproductive benefit of SCT notification. The great majority of parents surveyed in this study 
reported their intent to discuss the NBS results with relevant individuals. This high rate of 
anticipated sharing is consistent with the findings of past studies of similar populations.17,18,22,24  
The NBS program’s potential to provide reproductive benefit to the screened newborn 
relies on the health information being shared with him or her at an older age. When parents in this 
study were asked whether they planned to share the letter’s information with their infant at a later 
date, all but one individual confirmed that they did. A substantial proportion of telephone survey 
participants replied emphatically to this question, underlining their intent to share the health 
information. While the age at which they planned to share this information was not asked for, the 
majority of participants who elaborated on the question mentioned the milestones of dating and 
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reproductive age as pertinent to the time of disclosure. This indicates an appreciation for the 
information’s implications.  
This study’s measured rate of reported sharing with the infant exceeds that of Kladny et 
al., in which 91% of mothers who had received genetic counseling for SCT confirmed that they 
planned to tell their infant about the NBS result at an older age.22 This suggests that trait 
notification through a letter alone may be sufficient in promoting sharing with the newborn who 
receives the screening through NBS. However, future studies are needed to determine if such 
discussions actually do occur and how their quality may be impacted by the way families are 
presented with the information. 
The great majority of parents in this study (96.8%) reported that they felt comfortable 
discussing their child’s trait status with their partner. Several telephone survey responses indicated 
that these conversations may be limited. One mother qualified her response by saying that while 
she would discuss SCT, she “wouldn’t want to discuss disease.” Another replied that while she 
was comfortable, her partner would “clam up.” Three other parents who reported feeling 
comfortable discussing SCT similarly indicated that when they tried to bring up the topic, their 
partner had not been receptive. However, this was the minority of parents. Many more indicated 
they were able to discuss SCT comfortably with their partner.  
This rate of reported sharing with one’s partner is similar to that found by Lang et al. among 
notified mothers living in Illinois.17 Similar to this current study, Lang et al. called mothers eight 
to 52 weeks after their infant’s birth to administer a survey regarding awareness and knowledge of 
SCD as well as anticipated sharing patterns. Ninety-seven of the 100 participants (97%) confirmed 
that their partner should also be made aware of their infant’s positive screen for SCT. The survey 
provided additional insight into potential barriers to sharing the information, as participants were 
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presented with three answer choices to the question of whether their partner knew that their child 
had SCT: 1) Yes, they should know, 2) No, it does not matter if they know, and 3) No, I do not 
want them to know. The three mothers who did not respond that their partner should know their 
infant’s positive SCT screen identified that it was because it did not matter whether or not their 
partner knew. No participant replied that she did not want her partner to know. Thus, the mothers 
surveyed by Lang et al. appeared to desire to share this information with their partner if they 
believed it was important. Appreciation for the pertinence of their infant’s positive SCT status may 
serve as a more significant barrier to sharing the information of an infant’s positive screen, rather 
than a desire to not share it. 
Genetic counseling, which was shown by Kladny et al. to provide relevant knowledge and 
reduce anxiety, also appears to affect parents’ rates of sharing with family members. When Kladny 
et al. surveyed notified mothers following a genetic counseling session for SCT, significantly more 
mothers said they planned to discuss SCT with their partner than those who confirmed that they 
had discussed SCT with their partner before or during pregnancy: 81% versus 21%.22 Kladny et 
al. interpreted this rise in sharing rates following genetic counseling to demonstrate that genetic 
counseling promotes sharing of the health information between partners. However, this increase 
may have been influenced by other factors, including notably, a lack of awareness that SCT was a 
possibility for the pregnancy. It may also indicate a difference in the self-reported measure as it 
concerns past sharing versus anticipated sharing, as participants may be unrealistically optimistic 
about their future actions. Lastly, an inability to confirm whether or not these discussions about 
SCD actually do occur, as well as their relative quality, is a significant limitation of both this and 
the previous studies.  
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At 91% and 81% respectively, parents’ reported rates of sharing with one’s infant and one’s 
partner were lower in the studies of Kladny et al. than those reported by parents in both this current 
study as well as that of Long et al.17,22 Genetic counseling itself may reduce sharing rates with 
these relevant individuals. This could be the case if lower anxiety was related to lower sharing 
rates, or if the education provided during genetic counseling informed parents that further 
discussion of the results with these family members was not necessary. Such a finding would be 
an important topic of future research, as lowering rates of sharing with these two individuals is 
generally counter to the goals of a genetic counseling session. A number of other explanations 
exist that are unrelated to the intervention of genetic counseling, however. First, none of these 
studies clarified if the reproductive partner specified by the survey was the other parent of the baby 
or one’s current partner, if these two individuals differed. In the case that they did, varied 
interpretations of parents may have contributed to discordant rates of sharing between the studies. 
Additionally, although it is not clear how it would contribute to lower sharing rates, self-selection 
bias was more heavily implicated in the population of Kladny et al., as participants were required 
to pursue additional follow-up counseling services.  
In this current study, higher rates of sharing were reported with both specified family 
members than with the healthcare providers who were named. Sharing rates may indicate parents’ 
views on the importance of the information for the named individuals; in the case of healthcare 
providers, lower rates of sharing may also reflect a communication gap between medical providers 
and the African American community, which has been well-documented.101,138,162 However, the 
great majority of parents still reported an intent to share the letter’s information with both their 
infant’s doctor, as well as their own. When participants were asked if they intended to share their 
infant’s SCT status with their PCP, over 90% confirmed that they already had or intended to tell 
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them. In many of the telephone responses, parents expressed that it was their infant’s PCP with 
whom they had initially discussed the NBS results. The infant’s PCP would have also received the 
NBS results if they were listed on the NBS blood spot, and parents were not asked whether they 
or the physician had initiated the reported conversation. 
A number of participants surveyed over the telephone expressed that their PCP should 
already know the screening results. This suggests that a decision to not share this information may 
derive from a belief that they are already aware of the results, rather than discomfort over 
discussing the results or a preference for them to not know their infant’s trait status. However, this 
assumption of parents that their infant’s PCP is aware of the screening results may not be true 
under a number of circumstances. First, while the PCP listed on the NBS bloodspot is notified of 
the results in Pennsylvania’s NBS program, this provider may not accurately reflect the infant’s 
actual PCP. In the case that it does not, the infant’s PCP would not receive the results through 
NBS. Additionally, a 2007 survey of NBS programs for SCD found that unlike Pennsylvania, 12% 
of states had NBS programs that did not directly notify the infant’s PCP of a positive screening 
result for SCT.21 This same study also found that among those programs that did include 
notification of the PCP for SCT results, less than half possessed a confirmation mechanism, such 
as a return fax, electronic log, or telephone log, to ensure that the specified provider actually 
received the results notification.21  
The lowest rate of anticipated sharing (71.3%) was found regarding the parent’s own 
physician. This individual was the only specified stakeholder with whom less than 90% of 
participants reported an intent to discuss the screening results. Lower rates of anticipated sharing 
may reflect a lack of clarity among parents regarding the screening result’s relevancy to their own 
potential for having a pregnancy affected with SCD. This interpretation is consistent with the 
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results from the knowledge assessment, which showed a lack of clarity about the specific 
inheritance pattern of SCD. However, a number of parents who reported no intention to discuss 
their infant’s screening results with their own physician responded that their infant’s positive SCT 
status “came from their partner.” While this does demonstrate an understanding of the letter’s 
implications for the parents’ carrier status, the interviewers did not seek to clarify whether this was 
an assumption or had been confirmed by hemoglobinopathy screening. Moreover, if a respondent’s 
partner does have SCT, it is more relevant that the they determine their personal SCT status, which 
may be facilitated through speaking with their physician.20 As previous studies have shown a 
generally low perception of personal risk for having a child with SCD, along with sub-optimal 
uptake of hemoglobinopathy screening, further evaluation of the SCT notification process calls for 
looking at its effect on promoting hemoglobinopathy screening in parents of undetermined SCT 
status.15–18,130,131 
3.4.4  Study Limitations 
This study sought to evaluate the impact of the NBS program on families in Western 
Pennsylvania who had been notified of their infant’s positive result for Sickle S or HbC trait within 
the past year. However, its ability to draw conclusions regarding the overall effect of the program 
are limited by its exclusion of a meaningful subset of families and family members.  
First, while effective trait notification requires the letter to be received and read, parents 
who reported that they did not recall receiving the notification were ineligible for this study, which 
sought to describe the specific effects of the letter. The perspectives of these individuals are 
pertinent to a comprehensive evaluation of the trait notification program, and as a consequence of 
their exclusion, this study does not fully describe the program’s impact. Both its positive and 
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negative effects are likely more acutely felt by those who do receive the notification letter. Thus, 
it likely inflates the program’s impact, both in terms of its harms and benefits. 
This study also largely fails to describe the experiences of fathers with the NBS trait 
notification process. While both fathers and mothers were eligible to participate in the study, the 
great majority of survey participants were mothers. Only two of the 81 telephone surveys were 
completed by fathers. The mail survey did not ask whether it was the mother or father who was 
responding which precludes quantification of how many fathers did participate in the study. 
However, the survey was addressed to the mother, as this is whose contact information is reported 
on the NBS bloodspot. Consequently, it is assumed that the great majority of mail respondents 
were also mothers. A lack of male representation is a common criticism of the current literature 
regarding sickle cell health beliefs and behavior; this study is similarly limited in its 
generalizability to the experiences of parents with the NBS trait notification program and 
represents primarily mothers.  
As another point to consider, sampling bias may have inflated this study’s conclusions 
regarding the NBS program’s impact. This would be the case if those who agreed to participate 
differed from the general population of notified parents in ways that differentially impacted 
measurements. Survey responses were obtained for approximately 22% of parents who should 
have received the notification letter within the past year. When surveyed over the telephone, 81 of 
the 140 eligible participants who were contacted consented to participate. Through the mail, 13 
completed surveys were obtained out of the 394 surveys that were not returned as undeliverable. 
This translates to response rates of 57.8% through the telephone and 3.3% through the mail. These 
rates reflect the magnitude by which sampling bias may impacted the study’s results. Regarding 
its potential effect on knowledge measurements, it is plausible that those who felt more uncertainty 
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regarding the questions did not complete or send back the mail survey. Similarly, those contacted 
by telephone who felt uncertain about their understanding of SCD may have declined to 
participate, as the consent process explained they would be asked a series of true/false and 
multiple-choice questions about SCD.  
The survey sought to measure emotional impact and to gather feedback about the letter. 
This may have implications for sampling bias as well. During the consent process, participants 
were informed that it was a goal of the study to utilize the information it gained to revise the letter, 
so that the notification process could potentially be improved. Parents for whom the letter elicited 
a strong emotional reaction, or who found its information to be especially important, may have 
been more likely to remember the notification and/or to be inclined to participate. Consequently, 
it is plausible that this survey found a magnified impact in its latter two sections (Anxiety and 
Sharing) due to sampling bias. 
A strength of this study is the utilization of both mail and telephone surveys, which allows 
for an examination of the potential effect of reporting bias through comparing the two methods’ 
results. Reporting bias arises in self-reported measures when participants purposefully give false 
information due to their reluctance to report the truth, as it may be perceived as socially 
unacceptable or undesirable.163 Previous studies have sought to assess the impact of different 
survey modes on measurements of health-related quality of life, emotional, and behavioral data. 
These studies have generally found a small yet significant impact in the survey mode. When 
surveyed over the telephone as compared to mail, participants tend to report more positively about 
their mental health and emotions and are less likely to report socially-unacceptable behavior.163–
166 This pattern, which can be attributed to the greater anonymity of the mail format, has 
implications for this study. For example, parents may have been more likely to understate a 
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negative reaction to receiving the letter or to falsely report their intent to share the letter’s 
information with particular individuals. The error in measurements of this data would be expected 
to be greater for the telephone surveys than for the mail surveys based on findings from these 
previous studies. 
Nearly identical rates of emotional distress were found for part two (Anxiety). However, 
the different survey tools (PROMIS survey versus a single question) are likely more relevant than 
survey format and preclude this comparison between mail and telephone survey measurements. 
For the final section of the survey (Sharing), reporting bias would be expected to lead to artificially 
high rates of anticipated disclosure of the SCT results. Again, the influence would likely be greater 
in the case of the telephone surveys, where there was more direct contact between the subject and 
the interviewer. Attempts were made to minimize this bias by reminding participants that there 
was no right or wrong answer, yet a number of participants responded to the question by asking if 
they “should share the information” with the specified individual. For all individuals whom this 
section addressed (the participant’s infant, partner, PCP, and infant’s PCP), the reported rates of 
sharing were equal or higher when measured by the mail, as compared to the telephone (Appendix 
H.2). As this is the opposite pattern as would be expected with reporting bias, this bias likely had 
minimal impact in this third section of the survey (Sharing). More direct measurement is needed 
to ascertain whether this intent to share the trait notification letter’s information does translate to 
it being effectively imparted to important stakeholders. 
3.4.5  Future Research 
Disclosure of SCT status is not a primary goal of NBS, as the carrier state does not 
jeopardize the health of the infant.1,82,111 While it may be argued that promoting parents’ 
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reproductive choice is a potential benefit of the program, states’ decisions to disclose the incidental 
finding are based on a position that the health information belongs to the infant. The screening 
results are shared with their parents only in their capacity as the infant’s guardians.8 As this study 
did not examine the program’s effect on the newborn, it calls for this as a follow-up study to more 
fully describe the program’s appropriateness. 
Data collected through this study will be used to suggest revisions of the current SCT 
notification letter sent to parents in Region 6 of Pennsylvania. A repeat assessment of parents who 
receive the updated mailed information would permit an assessment of how the letter’s 
modifications have impacted parents’ knowledge, anxiety and disclosure patterns through a 
comparison with this study’s data. A number of additional measurements, described below, could 
also be collected at this time to augment the evaluation of trait notification through NBS that this 
current study provides.  
In their evaluation of a systematic follow-up process for SCT results disclosed through the 
mail, Kladny et al. noted that it could not be determined how many of the NBS letters are actually 
delivered to the correct individual, as well as opened and read.192–194 Receiving and reading the 
letter comprise the minimum set of actions required for the trait notification letter to have an effect 
on parents. An inability to ensure that this occurs is one major criticism of the passive means of 
trait notification provided by a letter. Through administering the telephone survey, it was found 
that 2.9% of parents who were reached reported not receiving the notification letter. It is reasonable 
to posit that parents who could not be reached for the telephone survey, either because the number 
was disconnected (23.3% of all attempted calls) or incorrect (5.7% of calls), are also those 
individuals more likely to have not received the notification letter. As this was the only means this 
study had to assess whether parents had received the original trait letter, this study cannot provide 
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an accurate estimate of the rate that the notification letter is received, opened, and then read by 
families. Further evaluation is needed to more determine this. Without such data, the effectiveness 
of the NBS program cannot be fully appreciated. 
The second part of this survey aimed to gauge anxiety as a potential psychological harm of 
trait notification. There are a number of other ways this program may negatively impact the 
emotional and social wellbeing of its targeted population. These include relational distress between 
notified parents due to the future reproductive implications of the information or questioned 
paternity, feelings of guilt or blame, and impaired self-image of those found to have with SCT.10–
13,49 Additional research should explore these risks of trait notification as they relate to the current 
method of a letter in order to better understand the specific program’s impact.  
Finally, as it was deemed a deficit of the studies of Kladny et al, this study also lacked a 
baseline for its measurements. Consequently, this study cannot clarify whether the trait letter alone 
has any effect on SCD knowledge. A number of similar assessments of SCD knowledge, which 
were reviewed earlier in this text, may provide comparisons (Table 5). However, their scores 
demonstrate a great sensitivity to population demographics, specific questionnaire, and survey 
technique. Ideally, pre- and post-notification knowledge surveys would be administered to 
measure any direct effect of the notification process. While this cannot be feasibly performed in 
parents who have not yet been notified of their infant’s positive screen, an opportunity for this 
does exists in a NBS program that does not currently directly notify families of SCT results. 
Assessing SCD knowledge in communities where prevalence of SCT is highest, prior to and then 
after initiation of a trial program, would provide valuable insight into the actual effect such a 
program has on a community’s awareness and understanding of SCD. One component of public 
health services such as NBS is assessment and quality improvement. Such a trial may fill this role. 
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3.5 CONCLUSION 
This study sought to evaluate the impact of SCT notification on the families whose infants 
had been identified through Western Pennsylvania’s NBS program to have a variant hemoglobin 
trait. Its findings suggest that the current notification process does not fully convey to parents how 
this positive hemoglobin trait status impacts health and reproductive risk. Comparison of this 
study’s findings to those of previous work, which also surveyed notified parents living in Western 
Pennsylvania, indicates that follow-up educational and counseling services may help to maximize 
the educational benefits of the NBS program for SCT. These services may also reduce the anxiety 
associated trait notification, with emotional distress being reported by approximately one third of 
this study’s participants. Finally, the great majority of parents surveyed by this study stated their 
intent to discuss their infant’s positive SCT status with relevant family members and healthcare 
providers. This suggests that the notification letter’s health information is generally found to be 
useful by families and that they appreciate its relevance. Notified parents may benefit from 
additional encouragement to discuss the screening results with their own physician in order to 
promote informed reproductive decision making. 
While previous literature has explored the three parameters addressed by this study – SCD-
related knowledge, anxiety regarding carrier status, and openness towards discussing SCT with 
family and healthcare providers – less work has looked specifically at how they may be influenced 
the disclosure of SCT status through NBS specifically. This means of information transmission is 
important to address, as greater awareness of SCD and personal trait status is supported by both 
the lay and medical communities it most concerns; it is the setting of NBS that is primarily 
contended. There is currently no consensus on the appropriateness of sharing newborns’ SCT 
status when incidentally identified through NBS, yet variant hemoglobinopathy traits are the most 
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common screening result in the Pennsylvania NBS program.106 This study’s value lays in part in 
the gap between the high frequency of this NBS result and the little agreement between states’ 
programs in how to handle it. 
This work may contribute to forming a consensus regarding sharing of hemoglobin variant 
trait status through NBS. It increases understanding of one NBS program for SCT notification, 
both as the majority of families experience it, as well as how it may be more ideally carried out. 
In relation to the latter, it augments previous work performed in the same population of notified 
parents in Western Pennsylvania, which examined the impact of genetic counseling services 
following trait notification through the mail.22,24 A comparison of these studies’ results suggests 
that follow-up services may both increase the trait notification’s informative benefits and reduce 
its potential for emotional harm.  
Follow-up educational and counseling services are often unavailable or underutilized by 
families of infants who screen positive for SCT, however.21,73,120 As a consequence, the passive 
means of trait notification that this current study examined likely represents a more common 
experience for notified families. Comparison of this study’s results to those previously obtained 
by surveying mothers who had been notified of their infant’s positive SCT results through a 
mailing sent by the Illinois NBS program further clarifies the common strengths and weaknesses 
of trait notification through a mailing.17 As one key finding, ensuring that parents understand the 
minimal health effects of SCT and the specific inheritance pattern of SCD appears to be a 
significant limitation of trait notification through the mail in general.  
Together, these studies advocate for NBS resources to be devoted to additional educational 
and counseling services for notified families. As limited resources provide a barrier for expanding 
this public health service, further work must be carried out to identify services that are both 
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effective and may be feasibly implemented. Such evaluation should include clarifying what 
specific information should be prioritized to maximize the reproductive benefit of the NBS 
program, for both the parents as well as for the screened infant. Finally, as did this study, future 
work must directly engage with the communities most affected by the NBS program as key 
stakeholders in the NBS trait notification process.  
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4.0 RESEARCH SIGNIFICANCE TO PUBLIC HEALTH AND GENETIC 
COUNSELING 
Evaluation of current services for quality improvement is a central component of the NBS 
program.167,168 This study, which examined the impact of SCT notification on families living in 
Western Pennsylvania, was carried out in part to serve this quality improvement role. Through 
examining the NBS program for SCT notification, this study also fulfills the core public health 
function of assurance, which aims to ensure the accessibility and effectiveness of public health 
interventions.169 There are a number of other ways that this work may provide assurance in the 
public health program as well. Through gathering data to guide revision of the current SCT letter 
sent in Western Pennsylvania NBS, this survey of parents provided insight that may be used to 
improve the trait notification process. Measurements obtained through the survey may also provide 
a baseline for evaluation of the revised letter and potentially inform the assessments of other states’ 
programs. With the goal of being relevant to such future assessment roles, this study was guided 
by models of public health program evaluation that propose weighing the potential risks with the 
benefits.111,115 
Questions regarding the appropriateness of carrier identification in newborns extend 
beyond sickle cell. SCT is not the only carrier status discovered incidentally through current NBS 
programs. Heterozygous carriers of the congenital lung disease cystic fibrosis (CF), which is also 
included on the RUSP, may be identified through NBS.9 With a carrier rate of one in 25 among 
individuals of Western European descent, CF has been the focus of similar assessments of carrier 
status disclosure through NBS.140,170 In the case of CF, the incidental carrier status is typically 
identified through follow-up diagnostic testing following a positive NBS result.158 While key 
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differences in carrier notification exist between these two conditions – namely the circumstances 
of carrier identification, the degree of provider involvement, and the different populations most 
greatly affected – similar concerns have been raised regarding inadequate education about the 
health and reproductive implications of the carrier state, as well as undue parental anxiety.140,158,171 
Thus, this study’s findings may have broader applicability, extending to carrier status notification 
through NBS more generally. A greater understanding of the effects of such NBS programs is 
becoming increasingly salient, as states’ panels are being further pushed to expand.82 
 With the potential growing for more carrier infants to be identified incidentally through 
NBS, advocates for an increased scope of the public health program suggest that reproductive 
benefit may be designated as one of its primary purposes.117,172 A number of professional groups 
challenge this view, yet they do concede that disclosure of carrier screening results through NBS 
may offer secondary benefits to the infant’s parents.125,173,174 A statement from ASHG calls for 
“additional research to assess the utility of disclosing carrier results generated from NBS for 
reproductive decision-making and cascade testing.”125 This study adds to that body of knowledge 
called for by ASHG. It contends that programs must be robustly supported by educational 
resources, both for families as well as physicians, for carrier identification to more fully realize its 
potential. Through minimizing confusion about the genetic information, parental stress related to 
the notification may be reduced and the information better utilized. Further education may also 
inform the discussions that this survey’s parents reported they intend to have with at-risk family 
members. These conversations are necessary for both the informed reproductive decision-making 
and cascade testing specified by the ASHG statement.125  
As it was informed by previous studies of Kladny et al., this study also further clarifies 
how genetic counselors may support SCT notification programs in better attaining their goals.22,24 
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As noted by one SCD patient advocate, a key barrier to increasing sickle cell awareness and 
informing reproductive choice is the “racial and cultural differences between the patient and 
members of the healthcare community…that impede effective communication and therapeutic 
relationships.”162 With the genetic counseling field’s particular emphasis on acknowledging 
clients’ social and familial dynamics, culture, and religion, genetic counselors may be particularly 
adept at overcoming these racial and cultural barriers, thereby facilitating the informed choice and 
adaption to risk that drives SCT notification.175 However, the historical involvement of genetic 
counseling in sickle cell screening is complex and has not always been positively regarded: It is 
important that the profession look to this past as a tool to improve its interaction with affected 
communities, rather than as discouragement toward future involvement. Through direct 
engagement with the parents and communities affected by SCD, genetic counselors’ services may 
be better directed to the communities’ needs and desires. Genetic counselors must also continue 
their efforts to increase the racial and cultural diversity of their own profession.  
The importance of this conclusion further rests in evidence that genetic counseling services 
are inaccessible to many parents following trait notification and when offered, are 
underutilized.21,22,24,73 This study’s findings call for genetic counselors to assess barriers and 
identify mechanisms that may increase access and utilization of their services following trait 
notification. Alternative service modes, such as group counseling or telephone counseling, have 
previously been demonstrated to have success in the sickle cell community.15,24,120 Their wider 
implementation could increase the reach of genetic counselors, as  they work to serve the essential 
public health service of informing and educating individuals about their own health.169 
Genetic counselors may also work to inform other healthcare providers in the discussions 
they have with families about the SCT results. While the educational role of genetic counselors is 
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often directed at patients, it may also extend to healthcare professionals. In particular, this study 
identified PCPs o be key resources for notified parents following the SCT notification. However, 
PCPs report feeling underprepared to discuss positive NBS results with families.149,150,153,160 
Genetic counselors’ help in the development of educational programs to promote skills in 
supportive communication and explaining the genetics of sickle cell in particular provides a 
secondary means to employ their specialized training to positively impact the trait notification 
process for families. Through this role, genetic counselors may better assure proficiency of the 
workforce, which is another essential public health service.169 Arming these providers to counsel 
about the SCT screening results as well as about NBS more generally would significantly increase 
the healthcare provider workforce who is available to assist families made anxious and confused 
by learning of their infant’s positive SCT screen through the NBS letter.  
Finally, partnering with community-based organizations has been shown to be effective in 
increasing knowledge and promoting awareness of personal trait status among at-risk 
populations.15,131 In Pittsburgh, where this study was conducted, the Children’s Sickle Cell 
Foundations (CSCF) is one organization that exists to support families affected with SCD. 
Working with CSCF and other community-based partners, such as public schools, can help bolster 
the resources that are available for families who receive the SCT notification. This study calls for 
the mobilization of such community partnerships, so that the benefits of NBS programs may be 
more fully experienced by the notified families of Western Pennsylvania.169 
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5.0 PUBLIC HEALTH ESSAY:  
EVALUATION OF A QUALITY INITIATIVE TO IMPROVE PENICILLIN 
PRESCRIPTION IN PEDIATRIC SICKLE CELL CLINIC 
5.1 BACKGROUND 
Sickle cell disease (SCD) encompasses a family of inherited blood disorders characterized 
by structurally variant forms of hemoglobin.3,4 It is a chronic condition estimated to affect between 
72,000 to 100,000 individuals in the United States.30 Approximately 300,000 babies are born with 
SCD each year throughout the world.26 In 2006, the World Health Organization (WHO) declared 
SCD to be one of its top global health priorities.26 SCD continues to be a significant public health 
concern in the United States, as well as throughout the world. 
5.1.1  Molecular Genetics of Sickle Cell Disease 
SCD is a genetic condition caused by biallelic pathogenic variants in the hemoglobin beta 
gene (HBB), which results in the production of abnormal forms of hemoglobin. All individuals 
with SCD have at least one copy of the HbS allele.3 In the HbS allele, an adenine to guanine point 
mutation in the sixth codon of HBB results in the substitution of glutamic acid for valine 
(Glu6Val).29,69 This gives rise to Hemoglobin S, or Sickle Hemoglobin. Individuals with SCD may 
have a second copy of the HbS allele or another variant allele that affects HBB gene expression or 
protein structure.3 The HbC allele (Glu6Lys) is the second most common structural HBB variant 
that leads to SCD.31 It also arises due to a point mutation in the sixth codon of HBB, which in this 
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case results in substitution of a lysine residue in place of glutamic acid. Mutations in HBB that 
affect gene expression, rather than protein structure, are denoted as thalassemia alleles. β0 
Thalassemia corresponds to no HBB gene expression, while β+ Thalassemia refers to a mutation 
that results in reduced HBB gene expression.31 
Hemoglobin is the chief oxygen transporter in the blood and is found at particularly high 
concentrations in the red blood cells (RBC).28 The HbS allele results in the production of 
Hemoglobin S (HbS), or Sickle Hemoglobin. HbS is less soluble than normal adult hemoglobin 
(HbA) and polymerizes under low oxygen concentrations. Chains of polymerized HbS distort the 
RBCs.35 The consequences of this deformation on both the RBCs themselves and the surrounding 
vasculature account for the majority of SCD pathophysiology.4 Repeat sickling damages the 
cytoskeleton of the RBCs, so that these cells are removed prematurely from circulation. This 
shortened lifespan results in chronic hemolytic anemia, jaundice, aplastic crises, and delays in 
growth as well as sexual development.3,4 Additionally, sickled RBCs form aggregates that block 
blood flow in the microvasculature. This is known as vaso-occlusion and leads to episodes of 
extreme pain, extensive tissue damage, and eventual tissue death due to lack of blood flow. The 
diverse consequences of chronic hemolytic anemia and vaso-occlusion events give rise to the 
multi-systemic involvement of SCD.3,4 
Clinical manifestations of SCD are not present at birth. Rather, symptoms arise during 
infancy, once pathological concentrations of HbS are reached in the RBCs.28 Prior to this time, the 
fetal form of hemoglobin, HbF, predominates, providing a protective effect. At sufficiently high 
cellular concentrations, HbF precludes RBC sickling. It cannot itself polymerize and thus, 
interrupts the polymerization reaction of HbS at high enough concentrations.27 Developmentally 
regulated differential gene expression at the beta-globin locus is responsible for the gradual 
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increase in HBB expression in relation to HBF, which is necessary for the synthesis of HbF.28 The 
gradual switch from fetal to adult hemoglobin expression begins before birth, with HbA 
predominating over HbF in the blood by around six months after birth. This timing correlates 
clinically to the period in which the significant risk for mortality emerges in SCD, between six to 
twelve months of age.3,176 
5.1.2  Infection in Sickle Cell Disease 
Infection is one of the earliest life-threatening complications of SCD.4 Between three and 
six months of age, infants with SCD develop an increased susceptibility to sepsis and meningitis 
due to infection from invasive bacterial species.177 Without intervention, the risk for infection in 
SCD is estimated to be between 30 to 600 times higher than that of an age and race-matched 
population.178 Susceptibility decreases with age, so that the greatest risk presents before age 
five.4,179 In the United States, approximately 30% of affected children under the age of five years 
old died from infection prior to the introduction of effective treatment methods.179–181 
Several early studies helped to clarify this high risk of infant mortality in SCD and attribute 
it to pneumococcal infection. In a retrospective case review of autopsies completed in Memphis, 
Tennessee in the early 1970s, the director of the first comprehensive sickle cell research center, 
Lemuel Diggs, estimated that one-fifth of deaths among those with SCD occurred prior to age 2.182 
One quarter of all deaths occurred prior to age five. In both groups, the primary cause was 
infection. Another early retrospective cohort study of 276 children with SCD born in Jamaica 
between 1952 and 1982 had similar findings. Among these individuals, the highest risk for death 
occurred before age five, and more specifically, between six and twelve months of age. In these 
children as well, infection was the most common cause of death.42 
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Infant mortality was the focus of one of the inaugural projects of the Cooperative Study of 
Sickle Cell Disease (CSSCD). The CSSCD was conceived to be the largest epidemiological study 
of SCD to date with an aim of clarifying the condition’s natural history.78 Through funding 
provided by the Sickle Cell Anemia Control Act, the National Heart, Lung, and Blood Institute 
(NHLBI) of the National Institutes of Health (NIH) sponsored this multi-center study beginning 
in 1978.2 Through the CSSCD, more than 600 newborns with SCD were identified through 
screening performed at birth.183 Upon diagnosis, newborns were enrolled for ongoing clinic 
follow-up for their first two years of life. Data that were collected over the course of this study 
demonstrated a strikingly high frequency of acute events of bacterial meningitis and sepsis in 
infants with SCD.183 A follow-up study through the CSSCD was published six years later in 1995 
and once again found infection to be the primary cause of death in its affected population under 
the age of five years old.176  
5.1.3  Immune Dysfunction  
Vulnerability to infection in infants with SCD is due to immune dysfunction primarily 
relating to the spleen.179,184 As the largest organ of the lymphatic system, the spleen plays a 
multifunctional role in maintaining the body’s immunity.185  
The spleen serves as a mechanical filter for the circulatory system. Old and damaged RBCs, 
as well as bloodborne pathogens, are removed as blood flows through its endothelial slits.178,184 
Macrophages metabolize the waste, aiding in the prevention of infection by circulating 
microorganisms.185 Additionally, the spleen is integral to the humoral and cell-mediated pathways 
of the adaptive immune system. It is the site of maturation for memory B-cells, which are the 
body’s main defense against encapsulated microorganisms.185,186 Memory B-cells are needed for 
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opsonization, a process exclusive to the spleen in which encapsulated bacteria are removed by 
macrophages via phagocytosis.186 Individuals with reduced splenic function, such as those with 
SCD, exhibit a deficiency in memory B cells.187 This contributes to an impaired clearance of 
bacteria and consequently, an increased susceptibility to infection by invasive pneumococcal 
species.  
Functional Asplenia: While the spleen is functionally and morphologically unaffected at 
birth, it is one of first organs impacted during the progression of SCD.4,184 Signs of damage can be 
observed as early as three to four months of age in those with HbSS disease.188,189 The pathological 
course that leads to insufficient splenic function is complex, but is believed to arise secondary to 
vaso-occlusion.184 The deoxygenating conditions of the spleen are a particularly potent stimulus 
for the sickling of RBC.184 Because sickled RBCs are more rigid than round RBCs, they are prone 
to becoming entrapped in the organ’s microvasculature.187,190 Congestion of the splenic filtration 
system by sickled RBCs can lead to pooling of blood and acute or chronic enlargement of the 
spleen. The latter, known as splenomegaly, is one of the most common complications of SCD.4 
Congestion of the splenic filtration system can further compromise the spleen’s ability to remove 
bacteria from circulation. This leads to an increased risk of invasive pneumococcal disease 
(IPD).191  
Complete loss of splenic function is known as functional asplenia and is a common 
development in the natural history of SCD.189,192 Also termed autosplenectomy, it is a consequence 
of repeat vaso-occlusion events, which cause splenic tissue ischemia, infarction, and eventually 
fibrosis. Over time, the spleen atrophies and is rendered non-functional.184 Among those with 
HbSS disease, functional asplenia is typically exhibited between six months and five years of 
age.4,192 In one study performed through the CSSCD, approximately 14% of infants with HbSS 
   
 111 
disease demonstrated partial or fully compromised splenic function by six months old; by age five, 
the prevalence had increased to nearly 94%.40 
Surgical Splenectomy: Surgical removal of the spleen may be considered in SCD under 
certain circumstances. Such events include hypersplenia, recurrent or life-threating splenic 
sequestration, and splenic absess.19,193 Hypersplenism is defined as splenomegaly in the presence 
of hematological complications, such as anemia, thrombocytopenia, or neutropenia.194 One large 
cohort study found hypersplenism to be present in approximately 5% of its pediatric population 
with SCD.195 However, prevalence of hypersplenism in SCD may be higher and is hard to 
accurately ascertain due to the difficulty in identifying the condition against the background of 
other common complications of the disease.184 In hypersplenism, the spleen prematurely destroys 
blood cells. Compensatory bone marrow hyperplasia arises in response to blood count deficiencies, 
which can worsen the growth deficiencies commonly experienced in SCD.184,194 Treatment of 
hypersplenism may involve chronic blood transfusions, partial splenectomy, or more typically, 
complete surgical splenectomy. 
A more common indication for surgical splenectomy is recurrent acute splenic 
sequestration crisis (ASSC). ASSC occurs when a sudden enlargement of the spleen leads to a 
drop in circulating hemoglobin concentration and blood volume. The complication follows 
infection as the second primary cause of death in infants and children with SCD.196 For those with 
HbSS disease, lifetime risk of ASSC is estimated to be between 7% and 30%; the risk is highest 
in infancy.39,188,193 In a retrospective case review of 437 ASSC events in children with HbSS and 
HbS-β0 Thalassemia, Brousse et al. found that approximately three-quarters of ASSC events 
occurred prior to age two.39 ASSC appears to become rare after six years of age.188 In ASSC, 
blockage of the splenic vasculature by sickled RBCs results in substantial pooling of blood in the 
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spleen. Blood volume throughout the remainder of the body rapidly drops, which can lead to fatal 
hypovolemic shock unless promptly treated with a blood transfusion.195 Repeat events have been 
found to occur in approximately 50-70% of individuals.39,188 Splenectomy may be considered after 
two occurrences of ASSC in individuals over the age of two years old.19  
The benefits of surgical splenectomy must be weighed against the potential risks. Namely, 
surgical removal of the spleen may be associated with a susceptibility to pneumococcal infection 
that exceeds the already increased risk found in those with SCD. In particular, surgical 
splenectomy is associated with Overwhelming Post-Splenectomy Infection (OPSI).197 OPSI is a 
sudden onset of sepsis or meningitis caused by encapsulated bacteria; death may occur as soon as 
24 to 48 hours after the onset of symptoms. Mortality rates are estimated to be between 50% to 
70%.198 However, these rates are derived from older studies that likely do not reflect advancements 
in care. More recent estimates from retrospective case reviews of OPSI events in England and the 
United States suggest a mortality rate associated with OPSI that is closer to 10%-30%.198,199 
Numerous studies have demonstrated an increased risk of infection and death due to OPSI 
following splenectomy.211,218 In one retrospective review of 413 children who had undergone 
splenic trauma, splenectomized children were shown to have a significantly increased risk for 
overwhelming sepsis, with a 50% mortality rate in the ten events of sepsis that were reviewed.200 
However, this study was not specific to individuals with SCD. The significant increased risk found 
by the study was relative to the general population risk, rather than that of those affected with an 
immune-compromising condition such as SCD. Another review of post-splenectomy sepsis events 
retrieved from the literature between 1966 and 1996 did find that sepsis events among patients 
who had undergone a surgical splenectomy were associated with a significantly increased 
mortality rate in children with hemoglobinopathies, such as SCD.201 
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Considering that autosplenectomy occurs in 94% of all individuals with HbSS disease by 
the age of five, it has been questioned whether surgical splenectomy does increase the risk of IPD 
in children with SCD.40,192 In a number of studies exclusive to individuals with SCD, the incidence 
of infection has not been shown to be significantly elevated following surgical splenectomy. A 
case review performed between 1988 and 1992 of sixteen patients with SCD who had undergone 
a surgical splenectomy did not show a significant increase in incidence of infection or sepsis 
following the procedure.202 Likewise, a retrospective case review of 37 children with HbSS disease 
who underwent splenectomies between 1993 and 2008 found that the overall rate of sepsis in this 
group did not differ significantly before and after surgery.203 Such studies, which examine infection 
rate in the same individuals pre- and post-splenectomy, have been criticized for the potential 
influence that age has been found to have on infection rate in SCD. Specifically, the risk for IPD 
decreases as individuals with SCD grow older. Thus, the measured post-splenectomy risk for 
infection may be diminished by the protective effect of a patient’s increased age.183 An additional 
limitation of such studies that examine infection rate exclusively in individuals who have had a 
splenectomy is that they may insufficiently capture an increased risk for these individuals relative 
to other individuals with SCD. This would be the case if splenectomy itself is not a predisposing 
factor to infection, but rather a surrogate marker for some other cause for a greater susceptibility 
to infection. 
Studies have attempted to address these shortcomings by comparing the infection rate 
among those with SCD who have had surgical splenectomies with age and sex matched controls 
who did not. Two such studies, which were performed as retrospective case-control studies, 
reported favorable post-splenectomy outcomes. They found no significant difference in infection 
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rate between those who received a splenectomy, both pre- and post-surgery, and those who did 
not.204,205 
In spite of unclear evidence, current clinical guidelines consider splenectomy to put 
individuals with SCD at a lifelong increased risk for IPD.19,206 Specifically, lifelong use of 
penicillin is recommended for affected individuals following surgical splenectomy to protect 
against this presumed increased risk of infection.206  
5.1.4  Management of Infection Risk 
In order to address the increased risk for IPD, penicillin prophylaxis and pneumococcal 
vaccination have become the standard of care for all children with SCD. Early implementation of 
these measures before two months of age has been enabled through universal newborn screening 
and has resulted in significantly improved health outcomes for those with SCD.207  
Penicillin: The Prophylactic Penicillin Study (PROPS) laid the initial groundwork for 
reducing infection-related infant mortality in SCD through the strong evidence it provided for the 
utility of penicillin to prevent IPD. PROPS was a multi-center, randomized, double blind, and 
placebo-controlled study conducted between August 1983 and June 1985 through the CSSCD.5Its 
aim was to assess the efficacy of penicillin for reducing mortality risk owing to IPD. Two hundred 
fifteen children with HbSS disease, aged three to 36 months, were enrolled into either the penicillin 
or control groups. Those in the experimental penicillin group (n = 105) received twice daily 125 
mg penicillin V potassium, and those in the placebo control group (n = 110) received twice daily 
50 mg doses of Vitamin C. In the initial findings, the experimental group exhibited an 84% 
decrease in IPD, as compared to the control group: Two of the 105 patients in the experimental 
group experienced a pneumococcal infection, compared to thirteen of the 110 patients in the 
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placebo group (p = 0.0025).5 Additionally, there were no fatalities among those taking penicillin, 
while three fatalities occurred in the control group. The strength of these findings in support of 
penicillin prophylaxis resulted in the study’s termination eight months early. The results from the 
PROPS trial, which were published in 1986, established that penicillin prophylaxis could 
significantly reduce the risk of infection due to encapsulated bacteria in children with HbSS 
disease.73,208 The study’s authors recommended that penicillin prophylaxis be initiated by two 
months of age.  
Newborn Screening: This evidence-based intervention for SCD established by the PROPS 
study provided an impetus for universal screening of infants for SCD. In the United States, this 
proceeds through newborn screening (NBS). NBS is a national public health program that aims to 
detect congenital conditions in newborns for which prompt intervention has been demonstrated to 
improve long-term health outcomes.1,94  
In 1987, which was the year following publication of the PROPS study, New York became 
the first state to screen newborns for SCD.2 Other states began adding hemoglobinopathies to their 
NBS programs, with New Hampshire becoming the last state to do so in 2006.2 This was prompted 
by the inclusion of hemoglobinopathies on the Recommended Uniform Screening Panel (RUSP), 
which was published that year to guide the composition of state’s screening panels.9 The RUSP 
recommends screening for four core hemoglobinopathies: HbSS disease, HbSC disease, HbS-β0 
Thalassemia, and HbS-β+ Thalassemia.96 Currently all 50 states, as well as the District of Columbia 
and Puerto Rico, screen for these upon birth.2 Other variant hemoglobin traits are detected 
incidentally during the screening process and are designated as secondary conditions by the 
RUSP.96 Consequently, all newborns in the United States are screened for variant hemoglobin 
traits, such as Hemoglobin D and Hemoglobin E, along with the more common HbS and HbC 
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traits. These variant hemoglobin traits may contribute to SCD if they are in trans with the HbS 
allele.3  
Upon a positive screen for a hemoglobinopathy, infants in Pennsylvania are referred to a 
hematology specialist for diagnostic testing and comprehensive care. For infants with a confirmed 
diagnosis, the priority is initiation of penicillin. This should begin by two months of age.5,19 Prior 
to age three years old, the recommended dose for infants remains the dosage prescribed in the 
PROPS trial, at 125 mg of penicillin V potassium twice a day. After age three years old, the dosage 
is doubled to 250 mg twice daily to account for increased body mass.19  
Pneumococcal Immunization: In the context of penicillin prophylaxis, pneumococcal 
immunization further reduces the risk IPD in children with SCD. The 23-valent polyvalent 
polysaccharide S. pneumonia vaccine (PPSV23) was introduced in 1983, and its administration is 
currently recommended to all those with SCD at the ages of two, five, and ten years old.209 The 
vaccine consists of 23 purified capsular polysaccharide antigens and has been shown to cover 
between 73-90% of pneumococcal strains.210 When administered in addition to daily penicillin, 
PPSV23 has been found to result in a 50% reduction of invasive pneumococcal disease in children 
with SCD.210 However, epidemiological studies have shown that PPSV23 vaccination and 
penicillin alone confer insufficient protection from fatal pneumococcal infection.79,210,211 Many of 
the polysaccharides used in the vaccine fail to evoke a immune response in children with SCD, 
especially those younger than two years old.210 The risk of IPD in children with SCD taking 
penicillin who have received the PPSV23 vaccination has still been found to be ten-times higher 
than that of the general population.211  
In 2000, the seven-valet pneumococcal conjugate vaccine, Prevnar 7 (PCV7), was 
introduced and recommended for all children under age two.212 PCV7 addresses the mechanism of 
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poor immunogenic response exhibited by PPSV23, as it consists of purified polysaccharide 
conjugated to protein carriers in order to induce a greater immunological response than 
polysaccharides do alone.210 Several epidemiological studies demonstrated that a significant 
reduction in IPD in those with SCD followed the vaccine’s introduction.79 In a retrospective review 
of 2,026 affected children in Tennessee, the rates of pneumococcal disease were compared before 
introduction of the vaccine (1995 to 1999) and after (2001 to 2004).177 In children under age two, 
a 90.8% reduction in cases was observed in the post-vaccination time period. In children under the 
age of five years old, the effect was even greater, with a decrease of 93.4%. Additionally, a 
population-based retrospective analysis of 1,242 hospitalizations for IPD in children with SCD 
between 1994 and 2007 in Georgia showed that hospitalization rate owing to infection decreased 
three-fold over the study period.211 The study’s authors attributed this reduction to the additional 
protection conferred by PCV7.  
In February 2010, the Food and Drug Administration approved a thirteen-valent 
pneumococcal conjugate vaccine, Prevnar 13 (PCV13) to replace PCV7. PCV13 is more 
comprehensive, covering additional six serotypes (1, 3, 5, 6A, 7F and 19A) to those covered by 
PCV7 (4, 6B, 9V, 14, 18C, 19F and 23F).212 Consequently, it provides coverage for strains not 
covered by PCV7 that have been implicated in a substantial proportion of the IPD cases that have 
presented following the introduction of PCV7.212 While few epidemiological studies are yet 
available to show an additional impact on infection rate afforded by PCV13, immunogenicity 
studies have indicated that the supplementation of six serotypes does indeed confer additional 
protection against pneumococcal disease.212–215 In the United States, the PCV13 vaccine is 
currently recommended along with PPSV23 for all children with SCD.212 Administration of 
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PCV13 is recommended at the age of two months old, with additional doses at four months, six 
months, and finally between 12 to 15 months old.216 
Effect of Intervention: Since the introduction of prophylactic measures as enabled by 
NBS, childhood mortality rates in SCD have significantly reduced.79 The Dallas Newborn Cohort 
(DNC) has provided a unique perspective on the efficacy of this intervention, as recruitment for 
the study began after the inclusion of hemoglobinopathies into the states’ NBS program.217 
Consequently, the DNC is one of the largest cohorts to date of individuals diagnosed with SCD 
(specifically HbSS disease, HbSC disease, HbS-β+ Thalassemia, and HbS-β0 Thalassemia) who 
have been provided with comprehensive care since birth. 
A 2010 publication describing mortality events in the DNC, which included 940 study 
participants at the time, found that bacterial sepsis was no longer the leading acute cause of death, 
as it had been in the DNC’s initial 2004 review.79 The authors noted this to be a temporal shift in 
mortality patterns associated with the introduction of PCV7 in 2000. From this year to that of the 
study’s publication in 2008, no deaths had occurred due to Streptococcus pneumoniae sepsis in 
the 940 participants, compared to four events in the 711 individuals who had been followed over 
the previous 8-year span of 1991 to 1999. This contributed to the marked change in overall death 
rates seen among those with HbSS disease and HbSβ0 Thalassemia specifically. In Era 2 (1991-
1999) an incidence of 0.72 deaths per 100 patient years was observed in patients under age two. 
This decreased to 0.32 deaths per 100 patient years in Era 3 (2000-2007). A similar reduction was 
seen in the death rate of children between two years old and five years old: 0.35 deaths per 100 
patient years were observed in Era 2, compared to 0 deaths per 100 patient years observed in Era 
3.79 Finally, the study found that the a greater proportion of participants were living into adulthood, 
with 93.9% (95% CI: 90.3% to 96.2%) of those with HbSS disease and HbS-β0 Thalassemia 
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surviving to age 18, compared to 85.6% (95% CI: 73.4% to 94.8%) of those in the previous 
study.79,218 
Age-Related Infection Risk: Evidence from epidemiological studies suggests that risk for 
IPD in children with SCD significantly diminish after the age of five years old.178,179 Findings of 
a follow-up study by the CCSD Prophylactic Penicillin Study Group, referred to as PROPS II, first 
evaluated this reduction in risk as it pertained to the potential ongoing benefit of penicillin 
prophylaxis.219 Following the same study design as its predecessor, PROPS II was a double blind, 
placebo-controlled trial that specifically aimed to measure the effect of penicillin in children with 
SCD above the age of five years old. This follow-up study recruited 400 patients with HbSS 
disease who had been receiving penicillin prophylaxis for at least two years prior to their fifth 
birthday and who had also received the PPSV23 vaccine. Those who had received a surgical 
splenectomy or had previously experienced a severe pneumococcal infection were excluded due 
to their higher risk for infection. An insignificant relative risk of infection was found to exist for 
those in the placebo group, as compared to those receiving penicillin (p = 0.5, 95% CI: 0.1–2.7). 
Additionally, in both the treatment and control groups, infection rates due to pneumococcal 
bacteremia or meningitis were significantly less compared to those younger patients in both the 
treatment and placebo groups of the PROPS I trial. Specifically, rates of 0.33 pneumococcal 
bacteremia or meningitis episodes per 100 person-years in the penicillin group and 0.67 episodes 
per 100 person-years in the placebo group were observed in the older patient population that 
comprised PROPS II, compared to 1.5 episodes per 100 person-years in the penicillin group and 
9.8 episodes per 100 person-years in the control group of the PROPS I trial. These findings 
contributed to the clinical recommendation that penicillin be discontinued after the age of five 
years old in individuals without other risk-increasing factors.208  
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5.1.5  Current Guidelines 
In 2014, an expert panel commissioned by the National Heart, Lung, and Blood Institute 
(NHLBI) of the US National Institutes of Health (NIH) put forth an updated set of Evidence-Based 
Management guidelines for SCD.19 These guidelines were developed based on available scientific 
evidence and expert consensus and are generally consistent with the American Academy of 
Pediatrics (AAP).206  
In its consideration of penicillin prophylaxis, the committee evaluated one observational 
study and three randomized-control trials, including the original PROPS I trial.5,219,220 The studies 
included 951 individuals under the age of five years old, among whom 95% had HbSS disease, 
5% had HbSC disease, and 1% had HbS-β0 Thalassemia. Across these studies, daily penicillin was 
found to be associated with a significant reduction in risk for IPD. The risk reduction in mortality 
was not found to be significant; however, the evidence regarding mortality was deemed to be low 
quality and imprecise due to the small total number of mortality events. As a result of their 
evaluation, the committee put forth strong recommendations supported by moderate-quality 
evidence that twice-daily oral penicillin be administered to children with HbSS disease up to age 
five.19 
While the guidelines state that there is strong and clear evidence for the provisional 
discontinuation of penicillin after the age of five, the committee presented weak recommendations 
with moderate-quality evidence that penicillin should be discontinued in children with HbSS 
disease after age five years old.19 The recommendation applies to only those individuals who have 
not had a splenectomy or IPD. The committee also emphasized the necessity of assuring that the 
recommended pneumococcal vaccination series had been completed prior to penicillin 
   
 121 
discontinuation; in the case that it had not, this should be completed as soon as possible and prior 
to discontinuing penicillin.  
Specific guidelines regarding pneumococcal vaccination were also presented in the NIH 
document. A strong recommendation with moderate quality evidence was made for the 
administration of PCV13 and PPSV23 according to the time-courses specified by the Advisory 
Committee on Immunization Practices of the Centers for Disease Control and Prevention (CDC).19 
Children with SCD were recommended to follow the time course for individuals with immune-
compromising conditions published in the “Childhood and Adolescent Immunization 
Schedule.”209 According to these guidelines, the PCV13 series should begin shortly after birth for 
infants with SCD. Additionally, the first does of PPSV23 should be administered at age two. The 
second dose should be given at the age of five, rather seven, as it is more generally advised. This 
is to provide adequate protection following discontinuation of penicillin at age five.  
Guidelines for other SCD Types: In the NHLBI management guidelines, strong 
recommendations for penicillin prophylaxis were made only for those with HbSS disease and HbS-
β0 Thalassemia.19 For those with other SCD forms, namely HbSC disease and HbS-β+ 
Thalassemia, the summary puts forth a weak recommendation with low-quality evidence that 
clinicians consider not prescribing penicillin for infants and children who have not had 
splenectomy or IPD. However, the guidelines acknowledge that many clinicians do prescribe 
penicillin universally for those with all forms of SCD and generally recommend that consultation 
by an SCD specialist should guide care. In a subsequent review article on the prevention and 
management of infection in SCD, this was criticized as lack of strong support for universal 
penicillin prophylaxis in SCD by the NHLBI.221 This review by Sobota et al. recommended 
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identical use of antibiotics in those with HbSC disease until further research determined the safety 
of doing otherwise.  
Little research specific to forms of SCD beyond HbSS disease drives a lack of consensus 
regarding the prophylactic use of penicillin for SCD types outside of HbSS disease and HbS-β0 
Thalassemia.19,33,222 Current guidelines for the management of these other forms of SCD have been 
generalized from studies either exclusive to or a majority of those with HbSS disease.19 Both the 
PROPS I and PROPS II studies were performed in children with HbSS disease exclusively, for 
example.5,219 The paucity of data comes from the lower prevalence of these other forms of SCD as 
compared to HbSS disease, which accounts for approximately 64% of hemoglobinopathies.26 
HbSC disease is the second most common form of SCD, yet it comprises only approximately 16% 
of hemoglobinopathies in the world.26 
Data that are available indicates that in HbSC disease and HbS-β+ Thalassemia, 
complications are typically less frequent and present later than in HbSS disease.4,33,184 These have 
been considered to be more mild forms of SCD, and research suggests that the spleen typically 
remains unaffected for longer in individuals with these SCD forms.41,223 Notably, this may allow 
for the development of humoral immunity and protection against fatal bacterial infection. One 
multi-centered, prospective study found that in their cohort of 201 patients with HbSC disease, 
none developed functional asplenia prior to age four. By 12 years old, 55% of the HbSC patients 
still had not demonstrated pathological splenic dysfunction.224 Based on these findings, Lane et al. 
raised concerns that antibiotic use may be unnecessary in this population and in fact may hinder 
the natural acquisition of antibodies needed to confer protection later in life, when asplenia did 
appear to develop.224 The findings are consistent with other studies, which indicate that the 
   
 123 
susceptibility to infection in milder SCD forms follows a similarly delayed timeline.179,225 This has 
led to questioning of the appropriateness of penicillin prophylaxis in these other SCD types.  
One large epidemiological study in the DNC indicates that penicillin prophylaxis in these 
forms of SCD may not be necessary. In this cohort, children with HbSC disease and HbS-β+ 
Thalassemia do receive penicillin prophylaxis. It is prescribed for those with HbSS disease and 
HbS-β0 Thalassemia.217 In a 2010 report on survival statistics in the cohort, which consists of 
30.2% (284/940) individuals with HbSC disease, the four recorded deaths owing to pneumococcal 
sepsis that occurred between 1983 and 2007 were in individuals with HbSS disease and HbS-β0 
Thalassemia. None of the deaths in those with HbSC disease were determined to be related to 
SCD, and 98.4% of individuals with HbSC disease survived past age 18.79  
5.1.6  Issues with Prophylaxis 
Despite the enabling of penicillin prophylaxis and pneumococcal vaccination through 
NBS, remaining issues reduce its effectiveness. In their guidelines of SCD management, the 
NHLBI expert panel concedes that risk of pneumococcal infection remains a top concern in SCD 
primarily due to increasing emergence of resistant pneumococcal strains and inadequate 
immunization.19  
Antibiotic Resistance: While the importance of penicillin for children with HbSS disease 
under age five is not debated, its use in situations where it is necessity is less clear and should be 
weighed against potential risks. Namely, excessive antibiotic use may encourage the emergence 
of antibiotic resistant pneumococcal strains. The prevalence of resistant pneumococcal strains does 
appear to be increasing.226 One study of resistant strains in North America found an increase from 
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5% prevalence in 1989 to over 35% in 1997. One-quarter of strains isolated were moderately 
resistant, and 11% were found to be highly resistant.227 
The emergence of resistant pneumococcal strains supports the discontinuation of penicillin 
once infection risk in SCD has subsided. Resistant strains not covered by penicillin or the current 
pneumococcal vaccination protocol lead to decreased effectiveness of the prophylactic measures 
relied on by high-risk populations, such as those with SCD prior to this age. A concerning trend 
of increasing incidence of IPD in those with SCD following introduction of the PCV7 and PCV13 
vaccines has been a focus of recent studies. In 393 pneumococcal samples obtained from children 
with SCD in the eight years following PCV7 introduction, nearly 90% of isolated strains were not 
covered by either penicillin or the recommended vaccination course at the time.228 In another study 
that looked at cases of IPD one decade after the introduction of the PCV7 vaccine, the frequency 
of IPD was found to have risen most significantly in the last two years of the study, indicative of 
an upward trend in infection rates.229 The majority of IPD cases were found by this study to occur 
with serotypes not covered by penicillin or the PCV7 and PPSV23 vaccines. Finally, a 2014 review 
of literature published since the early 2000s presented a number of additional retrospective case 
review studies that demonstrated an increasing incidence of IPD in immune-compromised 
individuals in what the authors termed the post-PCV era.230 
Immunization Compliance: Penicillin alone confers incomplete protection against IPD 
for children with SCD.231,232 Pneumococcal immunization with both PCV13 and PPSV23 is 
integral to the prophylactic measures recommended by current guidelines.19 These evidence-based 
guidelines additionally support the conditional discontinuation of penicillin in children with SCD 
over the age of five only in the case that complete pneumococcal vaccination can be assured.19,216 
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Consequently, insufficient or unverified pneumococcal immunization remains a barrier to 
appropriate discontinuation of penicillin.  
A number of studies have found deficient vaccination rates in those with SCD, calling for 
strategies to improve these rates. In an audit of the immunization status of 58 individuals with SCD 
at an urban medical center, just over half (56%) of those with SCD had completed the 
recommended vaccination schedule for S. pneumoniae.233 In another comparative study of patients 
with SCD who were seen at a hematology clinic between 2004 and 2009, only 21.5% were found 
to be vaccinated against pneumococcus upon admission.234 Finally, a case-control study involving 
enrollees in Michigan Medicaid and Children’s Special Health Care Services compared the 
pneumococcal vaccination rates in 179 patients with SCD born between 2001 and 2005 with 537 
controls who did not have SCD. The controls were also Medicaid beneficiaries and were matched 
based on age, race, and county. While vaccination rates in the SCD cohort at every age group were 
significantly higher than the controls, they were lower than national averages, as reported in the 
National Immunization Survey data: 72% versus 84% at three months of age, 54% versus 74% at 
five months, and 73% versus 92% at 24 months. These rates were deemed by the study authors to 
be insufficient for the high-risk population of children with SCD. The authors, Nero et al., called 
for further studies to identify barriers to pneumococcal vaccination, so that successful interventions 
could be implemented to address under-vaccination in children with SCD.235  
A variety of strategies have been investigated to increase vaccination adherence in the SCD 
population. These include provider and parent education, reminders provided by a patient 
navigator, and enhancements to the Electronic Health Record (EHR).234,236 The latter has been the 
focus of a number of interventions, which have generally demonstrated promise in the ability of 
EHR technology to increase immunization rates.234,236–238 In one case, Fiks et al. demonstrated in 
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their urban pediatric population that EHR-based clinical reminders significantly improved routine 
childhood vaccination rates by two years of age.238 While this study was not specific to 
pneumococcal vaccination or SCD, the population possessed similar demographics, specifically a 
high percentage of minority patients (>80%) and of individuals with Medicaid coverage (>85%), 
that more closely pertains to the SCD population than to the more general population engaged by 
the National Immunization Study.232 The EHR alert based intervention assessed by Fiks et al. 
increased routine pediatric immunization rates from 81.7% to 90.1% post-intervention.238 
A 2015 interventional study conducted in a pediatric SCD clinic also leveraged the EHR 
system in its aim to increase influenza vaccination rates.236 Focusing on the inaccessibility of 
influenza vaccination information in the EHR clinic note, the intervention revised the Sickle Cell 
Encounter Note to make the patients’ immunization eligibility more prominent to allow for easier 
provider recognition during the clinic visit. It additionally integrated the clinic’s Sickle Cell 
Registry into the EHR to enable targeting of the high-risk population. Following this quality 
improvement effort, influenza vaccination rates in the study’s pediatric population significantly 
increased, from a rate of 45% to 71% (p < 0.0001). Although a number of strategies in addition to 
those involving the EHR were included in their intervention, Sobota et al. acknowledged the utility, 
relative simplicity, and inexpensiveness of the EHR improvements as a tool to increase in vaccine 
compliance rate.236 
Finally, a 2016 Quality Initiative (QI) at an urban academic medical center in Philadelphia, 
Pennsylvania focused on the EHR to address inadequate adherence to pneumococcal vaccination 
in its immune-compromised population of children who had received kidney transplants.239 The 
two vaccines of interest in the study are also those currently required for children with SCD: 
PCV13 and PPSV23.209 Following a period of immunization record collection from outsides 
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sources, documents were scanned into the patients’ charts, and PCV13 and PPSV23 immunization 
dates were entered into the immunization section of the EHR. A space for manual entry of the 
patients’ PCV13 and PPSV23 vaccines was also added to the progress note template. Lastly, an 
algorithm for identification of vaccine candidates was created, so that an alert advising the provider 
to consider pneumococcal vaccination would be displayed on the progress note during their clinic 
visit. Progress was measured as a decrease in missed vaccine opportunities. A significant drop 
noted in the first six months of the QI, and at the end of their one-year evaluation period, the 
percentage of fully vaccinated patients had increased from 10% to 52%. However, the majority of 
this improvement was obtained in the first six months and was attributed primarily to the active 
efforts of the nurse to obtain records. It was noted that in absence of these dedicated staff hours, 
the rate of missed vaccine opportunities returned to baseline. Thus, continued active record 
collection was identified as a more crucial component of the intervention than EHR enhancements, 
which alone had minimal effect on sustained improvement of vaccination rates.239  
5.1.7  Description of a Quality Initiative to Improve Appropriate Penicillin Prescription 
The Pediatric Sickle Cell Clinic at University of Pittsburgh Medical Center (UPMC)-
Children’s Hospital of Pittsburgh (CHP) is one of six referral centers in Pennsylvania responsible 
for following up on positive NBS results for SCD. The Clinic is specifically responsible for 
newborns born in 19 different counties in the western portion of Pennsylvania. Each year, an 
average of 10 to 12 infants are born with SCD in its designated region. The Clinic currently follows 
conservative guidelines, prescribing penicillin to infants with all SCD disease types. After the age 
of five years old, the clinic seeks to discontinue penicillin for all patients given: 1) no personal 
history of IPD, 2) no surgical splenectomy, 3) at least one dose of both PCV13 and PPSV23 
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vaccines received, and 4) parental approval. Those who have received PCV7 in place of PCV13 
must receive the latter vaccine to be considered up-to-date. Penicillin prescription may be 
discontinued at any time after the age of five years of age for whom the preceding criteria are met, 
and prophylaxis is no longer considered indicated. 
In the spring of 2017, The Pediatric Sickle Cell Clinic at CHP identified concerns with 
inadequate documentation of PCV13 and PPSV23 vaccination in its active patient population. One 
consequence of insufficient vaccine documentation was an inability to discontinue penicillin 
prophylaxis for many of the clinic’s patients over the age of five. A system for documenting 
vaccinations had been lacking since the medical records were gradually transitioned from paper to 
electronic health records beginning in the early 2000s. Several barriers to maintaining updated 
immunization status in the EHR were identified. These included a significant number of missing 
outside immunization records, poor integration into the EHR of the clinic’s previously hand-
written notes documenting immunization, and the lack of a standardized entry space in the EHR 
to note immunization status.  
In May 2017, a Quality Initiative (QI) was implemented at the Pediatric Sickle Cell Clinic 
that focused on a manual effort to collect missing records as well EHR enhancements in order to 
address issues with immunization documentation. The long-term goal of the QI was to improve 
the clinical care of its pediatric SCD population through increasing pneumococcal vaccination and 
also decreasing inappropriate penicillin use. In the initial stage, the Sickle Cell Clinic Research 
Nurse Coordinator collected missing immunization records for all active patients from primary 
care providers, the Pennsylvania State Immunization Registry, and any additional outside sources 
as they were identified. All faxed records were placed in a binder to be referenced by the Pediatric 
Sickle Cell staff. This binder continued to be updated with new faxed immunization records 
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following the QI. In June 2017, enhancements were made to the EHR to facilitate immunization 
documentation. Specifically, clinic notes could now be entered into an electronic document with 
dedicated space to enter vaccination status, date of administration, and recommended action steps 
was added to the Sickle Cell Clinic Visit Note. This information was set to auto-populate with 
future clinic visit notes as well. Vaccination records that had been retrieved from the initial 
collection step of the QI were entered in this space in the EHR. A system to regularly forward 
these notes to the pediatrician was also implemented, in order to recruit additional efforts in 
maintaining immunization compliance in the sickle cell clinic’s population.  
Through these actions, patients eligible for either pneumococcal vaccination or penicillin 
discontinuation were identified. This was addressed at their following clinic visits. For those 
individuals of the appropriate age who had not yet received the PCV13 and/or PPSV23 vaccines, 
the clinic’s providers discussed the vaccine with the patient and his or her parents or caregiver. 
Vaccinations were administered either in clinic or by their primary care provider per family choice 
and with consent. For those individuals for whom prophylaxis was no longer indicated, penicillin 
was discontinued if the family was in agreement. These actions steps were recorded in the Clinic 
Note. 
5.1.8  Aims of the Quality Initiative Assessment  
For those individuals with SCD who have no disqualifying medical history, current clinical 
guidelines recommend that penicillin prophylaxis be discontinued after the age of five years old, 
when it has been demonstrated to no longer confer significant protection against pneumococcal 
infection.19 Up-to-date immunization, which currently consists of PCV13 and PPSV23, is required 
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prior to stopping penicillin. Incomplete or unverified vaccination is a barrier to appropriate 
cessation of prophylaxis.  
While current literature generally supports that penicillin be stopped after the age of five 
years old, it inadequately addresses the clinical experience of implementing this recommendation. 
Specifically, limited data exist regarding strategies for achieving this current clinical 
recommendation. This assessment addresses this current deficit of the literature by describing and 
evaluating a QI project that was carried out in the SCD specialty clinic of an urban academic 
medical center with rural outreach to 18 additional counties, which had the goal of decreasing 
inappropriate penicillin prescription in its patients over five years old. As an evaluation of the 
effects of the QI on vaccination and penicillin prescription rates, this work builds on previous 
findings, which support the use of the EHR to enhance medical care in the SCD patient population. 
Specifically, this assessment aims to show that enhancements to the Sickle Cell Clinic Visit note, 
as housed in EHR, improve rates of vaccination documentation and compliance, and ultimately 
reduce excess penicillin prescription in the pediatric patient population.  
 
As an evaluation of the QI, this assessment aims to: 
1) Characterize the patient population engaged by the QI, who were those patients seen at the 
Pediatric Sickle Cell Clinic at UPMC-CHP during the 18 months that spanned the 
implementation and sustained evaluation period of the QI. Basic demographic and medical 
information of all patients seen by the clinic during this time will be gathered from 
electronic databases maintained by the Pediatric Sickle Cell Clinic at CHP. Descriptive 
statistics will be applied to this data in order to describe the study population, as it may 
specifically relate to the effectiveness of the QI. 
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2)  Statistically measure the degree of change in PCV13 and PPSV23 vaccine documentation, 
as it was available at the date of the clinic visit via a retrospective chart review of the EHR 
and paper immunization records. Data will be analyzed in age-appropriate subsets of 
patients, according to the vaccine schedule recommended by the CDC, for change in 
documentation rates between those time periods spanning implementation of the QI.  
3)  Statistically measure the degree of change in PCV13 and PPSV23 vaccination rates via a 
retrospective chart review. Vaccination status at the date of the clinic visit will be recorded 
as reported by the most current medical records available at the time of data collection. 
Data will be analyzed in age-appropriate subsets of the patient population to assess for 
change in immunization rates over the four designated time periods of the study.  
4)  Statistically measure the degree of change in appropriate penicillin prescription in this 
patient population over the age of six years old. Appropriate penicillin prescription will be 
defined as its prescription for patients who do not meet the clinic’s established criteria for 
stopping penicillin; it will additionally be defined as penicillin not being prescribed for 
patients who do meet the criteria for penicillin prescription. This data will be analyzed in 
two ways. First, criteria will be applied that require documentation of immunization at the 
date of the clinic visit for appropriate penicillin discontinuation. A second set of criteria 
will not incorporate vaccine documentation as a criterion. This will be done in order to 
isolate the effect that missing immunization documentation had on penicillin prescription. 
 
Through Aims 2 through 4, it is expected that this assessment will show that the QI resulted 
in significant increases in the metrics of vaccine documentation, immunization compliance, and 
appropriate penicillin prescription. It is anticipated that a significant increase in all three described 
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rates will be seen in the time period that directly follows the QI, as compared to the baseline 
established prior to implementation of the QI. It is also anticipated that these increases will be 
sustained in the time periods following the QI. Ultimately, this assessment is anticipated to show 
that enhanced clinical care may be achieved through specific efforts to increase accessibility of 
immunization records, both through manual staff efforts as well as modifications of the EHR. 
5.2 METHODS  
This QI was submitted and approved by the UPMC Quality Initiative Review Committee 
under project identification number 1528 (Appendix J). 
5.2.1  Data Collection 
Data for this project were retrieved from two sources: Cerner, which is the EHR system of 
CHP, and the Sickle Cell Database (SCDB). The SCDB is an online database that contains 
information on all inactive as well as active patients with a diagnosis of SCD who have been seen 
by the Pediatric Hematology Department of CHP since 1999. Each patient is assigned a unique 
identifying number in the SCDB that is distinct from his or her Medical Record Number. A portion 
of the information in the SCDB is pulled automatically from Cerner; this includes patient date of 
birth, medical record number, race, ethnic background, and insurance coverage. Additional 
information is manually collected from Cerner and entered into the SCDB by clinic staff each 
fiscal quarter. This information includes the SCD genotype, dates of all clinic and Emergency 
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Room visits, in-patient admissions, and active prescriptions for penicillin and hydroxyurea for all 
patients active that quarter.  
For this project, all Sickle Cell Clinic visits that occurred in four separate time periods were 
pulled from the SCDB. As the specific actions of the QI’s intervention took place between May 1, 
2017 and June 30, 2017, a time frame of February 1, 2017 through October 31, 2018 was 
designated to measure pre-intervention rates as well as data at several time periods following the 
QI intervention to assess initial impact and sustainability/further improvements over time. The 
four time periods were defined as Pre-Intervention (February and April 2017), Post-Intervention 
(July, August, and September 2017), Sustain 1 (January, February, and March 2018), and Sustain 
2 (July, August, September 2018). All time periods were three months in length, with the exception 
of the Pre-Intervention time period. This period was two months in length as the data for this time 
period were previously collected for an initial assessment of the QI and additional data were not 
available.  
Each routine Sickle Cell Clinic visit that occurred in the four time periods of the QI project 
provided one data point. A unique clinic visit was characterized by a patient name and visit date 
associated with a Clinic Note. All patients with clinic visits included in this dataset had a diagnosis 
of SCD confirmed at the clinic. Appointments pulled from the SCDB other than routine Pediatric 
Sickle Cell Clinic visits, such as those for transfusions or bone marrow transplant evaluations, 
were removed from the dataset.  
A total of 527 routine clinic visits for 180 patients comprised the complete data set. 118 
clinic visits were represented in the Pre-Intervention time period, 193 in the Post-Intervention time 
period, 135 visits in the Sustain 1 time period, and 120 visits in the Sustain 2 time period. A smaller 
dataset was generated from the complete dataset, where only one clinic visit per patient was 
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represented in each time period. In cases where there were multiple clinic visits in one time period 
for the same patient, the latest chronological clinic visit in the time period used. In this data set, 
there were 85 clinic visits in the Pre-Intervention time period, 121 clinic visits in the Post-
Intervention time period, 103 clinic visits in the Sustain 1 time period, and 97 clinic visits in the 
Sustain 2 time period. In Aims Two through Four, parallel analysis for both the complete dataset 
and this smaller dataset were performed and compared in order to evaluate for the influence that 
multiple visits by the same patient had on the analysis. 
For every patient in the complete dataset, age at clinic visit, insurance type, race, ethnicity, 
and SCD type were also obtained through the SCDB. Data pulled from the SCDB were exported 
into a Microsoft Excel spreadsheet and stored on a secure server maintained by CHP. The 
remainder of the data were manually collected from the EHR via a retrospective chart review by 
twelve members of the CHP clinic staff. Data for the Pre-Implementation time period were 
collected from clinic notes scanned into the Outpatient Documents section of Cerner. Data for the 
remaining three periods were collected from the new EHR Sickle Cell Clinic Note, which was a 
product of the QI. Once collection was complete, the combined data were reviewed by one 
individual to ensure that the coded variables had been recorded accurately and consistently across 
all twelve reviewers. Following this final review, patients’ names were removed from the dataset 
used for analysis, while their unique identifying number from the SCDB remained. 
5.2.2  Coded Variables 
All data collected through manual review of the EHR Clinic notes were coded as 
categorical variables (Yes/No) for the purpose of this analysis.  
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PCV13 Documented: PCV13 vaccination status was recorded as documented (“Yes”) for 
that clinic visit if that visit’s clinic note verified that it either had not been administered or had 
been administered at that visit or at any time prior. If confirmation of vaccination status was not 
written in the clinic note or was noted as “pending,” PCV13 vaccination status was recorded as 
not documented (“No”). Vaccination status noted to have been provided verbally by the patient 
without medical records was also coded as not documented (“No”). As PCV13 vaccination is not 
to be administered until after two months of age, individuals younger than this age were not 
included in the analysis of this variable.209 
PPSV23 Documented: Similar rules were applied to the coding for PPSV23 vaccine 
documentation status. In this case, clinic visits of individuals who were under two years of age 
were not included in this analysis, as PPSV23 administration is not appropriate prior to this age.209  
PCV13 Given: The PCV13 vaccine was recorded to have been given (“Yes”) if at least 
one dose had ever been correctly administered prior to or on the date of the clinic visit. This 
criterion was retrospectively applied. Thus, if it were noted in a future clinic note that PCV13 
vaccination had been administered on a date prior to the clinic visit date of analysis, the variable 
was coded as “Yes.” During the final review process, the latest Sickle Cell clinic note was 
examined for vaccine status for those individuals for whom it had not yet been confirmed. This 
was done to obtain the most accurate vaccination status possible. 
If PCV13 was noted to not have been administered or its administration could not be 
verified at the time of final data collection, PCV13 was recorded as Not Given (“No”). This 
variable was also recorded as “No” in the case that PCV13 was administered incorrectly, i.e. prior 
to two months of age or concurrently with the PPSV23 vaccine. Additionally, for individuals who 
had received PCV7 in place of PCV13, this variable was recorded as “No.” PCV13 is the more 
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comprehensive pneumococcal conjugate vaccine introduced to replace PCV7, and the clinic seeks 
to administer PCV13 to those who had previously received PCV7. Only individuals over the age 
of two months old were included in analysis of this variable. 
PPSV23 Given: Coding for administration of the PPSV23 vaccine was performed with the 
same criteria for that of PCV13. For PPSV23 administration, age appropriate analysis 
corresponded to individuals aged two years of age and older. 
Invasive Pneumococcal Disease: This variable was coded as “Yes” if the Clinic Note 
documented a past medical history of IPD. It was coded as “No” if this medical history was not 
noted in the clinic note.  
Surgical Splenectomy: This variable was coded as “Yes” if the clinic note documented a 
past medical history of surgical splenectomy. In all other cases, it was recorded as “No.”  
Parental Preference: If discontinuation of penicillin prescription was identified to be 
appropriate but was continued based on parental preference, this variable was coded as “Yes.” 
Otherwise, it was coded as “No.” 
Penicillin Prescribed: Penicillin was recorded as prescribed (“Yes”) if the patient was 
actively prescribed penicillin at the end of that clinic visit. This was indicated by the inclusion of 
penicillin on the active medication list for that clinic visit note and also noted in the space for 
“Functional Asplenia Risk Assessment” in the clinic visit note. In the case that these two sources 
were conflicting, it was noted by the reviewer. These cases were examined during the final data 
review, and the most likely scenario was recorded, with input from a sickle cell clinic provider. 
Individuals taking amoxicillin were also recorded as “Yes,” as amoxicillin is prescribed for those 
with a penicillin aversion or allergy. For clinic visits where a prescription for penicillin was not 
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present in the clinic visit note, or it was noted as discontinued at that visit, this variable was 
recorded as penicillin not prescribed (“No”).   
Penicillin Prescribed Appropriately: To achieve the Fourth Aim, two additional 
variables were generated to reflect the appropriate prescription of penicillin: “Appropriate 
Penicillin Prescription: Documentation” and “Appropriate Penicillin Prescription: No 
Documentation.” Both variables were coded as “Yes” when penicillin was prescribed at the clinic 
visit and it was indicated, or when penicillin was not prescribed at the clinic visit and it was not 
indicated. The two variables differed by the criteria used to determine whether or not prescription 
of penicillin was indicated. As the QI focused on age appropriate discontinuation of penicillin 
prophylaxis, analysis of this variable was restricted to those patients six years of age or older at 
the time of the clinic visit. While current recommendations are that penicillin be discontinued after 
age five, the Pediatric Sickle Cell Clinic interprets this to mean that penicillin discontinuation is 
appropriate any time between the age of five and six years old. Thus, penicillin prescription prior 
to the age of six was still considered to be appropriate for this QI project. 
The first, “No Documentation” was coded as “Yes” when penicillin was prescribed at that 
clinic visit and one or more of the following criteria were met: 1) medical history of a disqualifying 
medical event (IPD or of surgical splenectomy), or parental preference to stay on penicillin, and 
2) pneumococcal vaccination was not complete. This variable was also coded as “Yes” when 
penicillin was not prescribed at that clinic visit and the following criteria were met: 1) no medical 
history of a disqualifying medical event (IPD or of surgical splenectomy) and no parental 
preference to stay on penicillin, and 2) pneumococcal vaccination was complete (Figure 4).  
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Figure 4. Flowchart for "No Documentation" Criteria 
 
The second variable, “Appropriate Penicillin Prescription: Documentation,” differed from 
the first through the addition of an extra criterion: whether or not vaccination was completely 
documented at the relevant clinic visit (Figure 5). Because vaccine status was retrospectively 
applied, the previous variable (No Documentation) was not based on what was known at the time 
of the clinic visit when penicillin was being prescribed. This second variable used criteria that 
evaluated whether or not penicillin was appropriately prescribed given knowledge that was 
accessible in the medical records at the time of that clinic visit. Comparison of these two variables 
allowed for an evaluation of the proportion of penicillin prescription resulting from missing 
vaccination documentation. 
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Figure 5. Flowchart for "Documentation" Criteria 
5.2.3  Data Analysis  
Data analysis was performed using Microsoft Excel and RStudio for Mac Version 1.1.456. 
Descriptive statistics were used to characterize the demographics of the intervention’s population 
(Aim 1). Chi-squared analysis was performed to compare rates of vaccine documentation (Aim 2), 
vaccine administration (Aim 3), and appropriate penicillin prescription (Aim 4) across the four 
different time periods. A p-value under 0.05 was used to define statistical significance. 
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5.3 RESULTS 
5.3.1  Aim 1: Description of the Patient Population 
A total of 180 patients with a confirmed diagnosis of SCD were seen for 527 routine 
appointments at the Pediatric Sickle Cell Clinic at CHP in the four time periods that comprised the 
time period used to assess the QI (Table 9). The mean±SD age of patients taken at the midpoint of 
the year was 10.5±6.2 years (range 0.15 to 21.4 years). 73.3% (132/180) were above the age of 
six, the age by which penicillin was to be discontinued. The majority of patients identified as 
African American (97.2%, 175/180) and received Medical Assistance (84.4%, 152/180).  
More patients were affected by an SCD type categorized as severe (61.1%, n = 102), 
designated here as HbSS disease and HbS-β0 Thalassemia, as compared to all other SCD types 
(38.8%, n = 70). The most common SCD form was HbSS disease, with 57.2% (103/180) of the 
patient population, followed by HbSC disease with 32.8% (59/180). Smaller proportions of 
patients had HbS-β+ Thalassemia (5%, 9/180) and HbS-β0 Thalassemia (3.9%, 7/180). 
Additionally, there was one patient each (0.6%) with HbSE disease and HbS-Hereditary 
Persistence of Fetal Hemoglobin (HbS-HPFH). Three (1.7%) patients had a medical history of 
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Table 9. Demographics of the Patient Population 
 Severe SCD 
Types1 Other SCD Types
2 Total 
Age    
     Mean ± SD 9.1±6.0 11.6±6.3 10.5±6.2 
     Range 0.15-20.89 0.25-22.45 0.15 – 21.4 
     Under age 6 28.2% (31) 24.3% (17) 26.7% (48) 
Sex    
     Female 48.1% (53) 41.4% (29) 45.6% (82) 
     Male 51.8% (57) 58.6% (41) 54.4% (98) 
Race    
     Asian 0.9% (1) 1.4% (1) 2.0% (2) 
     African  
    American 97.2% (107) 97.1% (68) 97.2% (175) 
     White 2.0% (2) 1.4% (1) 1.7% (3) 
Ethnicity    
     Hispanic/Latino 0.9% (1) 3.1% (2) 98.3% (177) 
     Not Hispanic/            
     Latino 99.1% (109) 96.9% (68) 1.7% (3) 
Insurance    
     Private 13.6% (15) 15.7% (11) 14.4% (26) 
     Medical  
    Assistance 85.5% (94) 82.3% (58) 84.4% (152) 
     No Insurance 0% (1) 1.4% (1) 1.1% (2) 
Total 0.9% (110) 97.1% (70) 180 
1 SCD types HbSS disease and HbS-β 0 Thalassemia 
2 SCD types HbSC disease, HbS-β+ Thalassemia, HbSE Disease, and HbS-HPFH 
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5.3.2  Aim 2: Immunization Documentation 
PCV13 documentation rates were analyzed for patients two months of age or older at the 
date of their clinic visit, as according to the appropriate time course for PCV13 administration. As 
measured by percent clinic visits with PCV13 status documented in the clinic note, the PCV13 
documentation rate was 7.7% (9/117) at baseline. This corresponds to over 90% of clinic visits 
during the Pre-Intervention period that were missing documentation of whether or not the patient 
had received at least one dose of the PCV13 vaccine. Immediately following implementation of 
the QI, PCV13 documentation rate increased to a rate of 85.1% (160/188). This change between 
the Pre-Intervention and Post-Intervention time periods was found to be highly significant, as 
measured by chi-squared analysis (p < 0.001, Table 10). Documentation rates continued to increase 
in the three time periods that followed the QI. Specifically, PCV13 documentation was confirmed 
for 85.1% (160/188) of clinic visits in the Post-Intervention period, 89.6% (120/134) in the Sustain 
1 period, and 96.7% (116/120) in the Sustain 2 period (Table 10, Figure 6). The change in 
documentation rates achieved between baseline and the final period of this project’s assessment 
(Sustain 2) was 89%; this change that was also found to be highly statistically significant (p < 
0.001).  
PPSV23 vaccine documentation rates demonstrated a similar pattern over the project’s time 
course. At a rate of 81.4% (131/161), PPSV23 documentation Post-Intervention was significantly 
greater compared to the Pre-Intervention rate of 10.5% (11/105, p < 0.001) (Table 11). 
Documentation rates continued to increase in the time periods that followed the QI. In the two 
final periods, PPSV23 status was documented for 87.2% (96/110) of clinic visits in the Sustain 1 
period and for 94.0% (94/100) in the Sustain 2 period. PPSV23 vaccine documentation rates 
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increased by 83.5% between the Pre-Intervention and Sustain 2 time periods, which is highly 
significant (p < 0.001). 
Complete (“Up-to-Date”) vaccination documentation status rates were defined differently 
depending on age and CDC immunization guidelines: for individuals between two months and two 
years old, complete vaccination documentation was considered as having PCV13 status 
documented at least once, and for individuals older than two years old, both PCV13 and PPSV23 
statuses needed to be documented at the date of the clinic visit. This rate increased as well, 
paralleling those of the individual vaccine documentation rates. The baseline complete 
documentation rate was 6.8% (8/117) of all clinic visits in the Pre-Intervention time period. 
Following the QI, this rate increased to 81.4% (153/188) of clinic visits in the Post-Intervention 
period, 86.6% (116/134) in the Sustain 1 period, and 94.2% (113/120) in the Sustain 2 period 
(Table 10, Figure 6). Consistent with the other vaccination documentation findings, a significant 
increase in complete pneumococcal vaccine documentation was demonstrated between the Pre and 
Post-Intervention time periods (p < 0.001), as well as between the first and last time points 
measured in this QI project (p < 0.001). Specifically, we found an increase of 74.6% more clinic 
visits with complete pneumococcal vaccination documentation between the Pre-Intervention and 
Post-Intervention time periods, and an increase of 87.4% was found between Pre-Intervention and 
the final time period, Sustain 2.
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Table 10. Vaccine Documentation Rates by Time Period 
Time Period 
Documentation Rate 
PCV13 PPSV23 Complete 
Pre-Intervention 7.7% (9/117) 10.5% (11/105) 6.8% (8/117) 
Post-Intervention 85.1% (160/188) 81.4% (131/161) 81.4% (153/188) 
Sustain 1 89.6% (120/134) 87.2% (96/110) 86.6% (116/134) 





Table 11. Change in Vaccine Documentation Rates Across Time Periods 
Vaccine Time Periods N DF Chi-Square P-value 
PPSV23 
1 versus 2 305 1 171.8 <0.001* 
1 versus 4 237 1 184.6 <0.001* 
PCV13 
1 versus 2 266 1 125.5 <0.001* 
1 versus 4 205 1 139.7 <0.001* 
Both 
1 versus 2 305 1 157.8 <0.001* 
1 versus 4 237 1 177.3 <0.001* 
Time Periods: 1: Pre-Intervention; 2: Post-Intervention; 3: Sustain 1; 4: Sustain 2 
* Statistically significant change 




Figure 6. Vaccine Documentation Rates by Time Period 
 
Vaccine Documentation rates, as recorded in the Sickle Cell Clinic Notes, across the four time periods (1: 
Pre-Intervention; 2: Post-Intervention; 3: Sustain 1; 4: Sustain 2). Analysis was restricted to children over 
the age of two months old for both PCV13 and Complete Documentation, and to children over the age of 
two years old for PPSV23 status. For all three metrics (PCV13, PPSV23, and Complete Documentation), 
significance was found in documentation rates between Pre-Intervention and Post-Intervention, as well as 
between the three periods that followed the QI (Post-Intervention, Sustain 1, Sustain 2).  
* p < 0.001: Pre-Intervention versus Post-Intervention 
# p < 0.001: Pre-Intervention versus Sustain 2 
5.3.3  Aim 3: Immunization Rate 
Analysis of pneumococcal vaccination rates was performed using the same age-specific 
data subsets that were used for vaccination documentation. These were determined according to 
the immunization schedule as published by the CDC.209 
A 10.3% increase in PCV13 immunization rates occurred across the four time periods 
analyzed for this QI project. The Pre-Intervention rate of 75.2% (88/117) increased to 85.8% 
(103/120) by the final time point, Sustain 2 (Table 12, Figure 7). However, PCV13 immunization 
rates did not show a consistent increase across the four time periods. PCV13 immunization rates 
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time period (Sustain 1), and rose again in the final time period (Figure 7). The change in PCV13 
vaccination rates as not found to be significant when measured between the Pre-Intervention and 
Post-Intervention time periods (p = 0.080), as well as between the Pre-Intervention and Sustain 2 
periods (p = 0.057, Table 13) 
PPSV23 vaccination rates continually increased across all four time periods yet remained 
consistently lower than PCV13 vaccination rates in the corresponding time periods. The baseline 
rate for PPSV23 vaccination was 58.1% (61/105) in the Pre-Intervention time period, grew to 
66.5% (158/188) Post-Intervention, and continued to increase to 73.6% (81/110) in the Sustain 1 
and 81.0% (81/100) in the Sustain 2 time periods. The change in PPSV23 vaccination rates 
between the Pre-intervention to Post-Intervention time periods (8.4%) was not statistically 
significant (p = 0.21). However, the PPSV23 immunization rates significantly increased between 
the baseline and final time point (p < 0.001). As it was measured between the Pre-Intervention and 
Sustain 2 time periods, the total change in PPSV23 vaccination rates over the total time course of 
this QI project was 22.9%. 
Complete vaccination rates were determined similarly to complete documentation rates, as 
previously described in Aim 2. Vaccination was considered to be complete as long as one dose of 
PCV13 had been documented as appropriately administered to children between two months old 
and two years old, and one dose each of PCV13 and PPSV23 had been documented as 
appropriately administered to children two years of age and older. This rate increased across the 
four time periods: Pre-Intervention: 54.7% (64/117); Post-Intervention: 63.8% (120/188); Sustain 
1: 67.9% (91/134); Sustain 2: 75.0% (90/120). While the initial increase in rates from Pre-
Intervention to Post-Intervention was not significant, (p = 0.14), a significant change was found 
between the first and final time periods of this project (p = 0.002). 
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Table 12. Pneumococcal Vaccination Rates by Time Period 
Time Period 
Immunization Rate 
PCV13 PPSV23 Complete 
Pre-Intervention 75.2% (88/117) 58.1% (61/105) 54.7% (64/117) 
Post-Intervention 84.0% (158/188) 66.5% (107/161) 63.8% (120/188) 
Sustain 1 79.1% (106/134) 73.6% (81/110) 67.9% (91/134) 





Table 13. Change in Pneumococcal Vaccination Rates Across Time Periods 
Vaccine Time Periods N DF Chi-Square P-value 
PPSV23 
1 versus 2 305 1 3.06 0.080 
1 versus 4 237 1 3.62 0.057 
PCV13 
1 versus 2 266 1 1.57 0.210 
1 versus 4 205 1 11.57 <0.001* 
Both 
1 versus 2 305 1 2.14 0.140 
1 versus 4 237 1 9.85 0.002* 
 Time Periods 1: Pre-Intervention; 2: Post-Intervention; 3: Sustain 1; 4: Sustain 2 
 * Statistically significant change 
 




Figure 7. Pneumococcal Vaccination Rates by Time Period 
Pneumococcal vaccination rates by time period (1: Pre-Intervention; 2: Post-Intervention; 3: Sustain 1; 4: 
Sustain 2). Analysis was restricted to children over the age of two months old for both PCV13 and Complete 
Vaccination, and to children over the age of two years old for PPSV23 status.  
* p < 0.001: Pre-Intervention versus Post-Intervention 
# p < 0.05: Pre-Intervention versus Post-Intervention. 
5.3.4  Aim 4: Appropriate Penicillin Prescription 
As it relates to the final aim of this QI project, rates of appropriate penicillin prescription 
were examined across the four time periods. Analysis was limited to patients who were at least six 
years of age at their clinic visit date, as this is the age at which penicillin prophylaxis could be 
appropriately stopped if all discontinuation criteria were met.  
When immunization documentation status was included in the criteria for appropriate 
discontinuation of penicillin (“Documentation”), the Pre-Intervention rate of appropriate penicillin 
prescription was determined to be 54.1% (46/85) (Table 14). This translates to 45.9% of clinic 
visits where penicillin was prescribed for patients for whom it was not indicated. While a lack of 
penicillin prescription when it was indicated would qualify as inappropriate penicillin prescription, 
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this situation did not represent any actual cases in this data set (n = 0). For all patients for whom 
penicillin was indicated, it was prescribed. 
Under the second set of criteria (“No Documentation”), vaccine documentation status at 
the date of the clinic visit was not a factor in determining whether or not penicillin prescription 
was appropriate. This allowed for a retrospective analysis of whether or not penicillin prescription 
would have been appropriate had vaccine documentation been complete at the clinic visit. In this 
case, a lower rate of appropriate penicillin prescription was found, as would be expected under 
these more stringent criteria. Pre-Intervention, 34.1% (29/85) of clinic visits were found to have 
appropriate prescription of penicillin. This means that in the majority of visits, penicillin was being 
inappropriately prescribed.  
Under both criteria, the rates of appropriate penicillin prescription significantly increased 
in the Post-Intervention time period (Figure 8). Under the criteria that considered documentation, 
appropriate prescription rates increased from 54.1% to 82.7% (p < 0.001) (Table 15). Applying 
the retrospective criteria (“No Documentation”), rates increased from 34.1% to 79.7% (p < 0.001). 
Under both criteria, appropriate penicillin prescription continued to increase across the time 
periods and was appropriately prescribed at an identical rate of 94.0% (78/83) in the final time 
period of this QI project (Sustain 2). This represented a statistically significant change in rates of 
appropriate penicillin prescription under both criteria (p < 0.001). 
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Table 14. Appropriate Penicillin Prescription Rate by Time Period 
Time Period 
Prescription Rate 
Documentation No Documentation 
Pre-Intervention 54.1% (46/85) 34.1% (29/85) 
Post-Intervention 82.7% (110/133) 79.7% (106/133) 
Sustain 1 90.1% (86/95) 89.5% (85/95) 




Table 15. Change in Appropriate Penicillin Prescription Rate Across Time Periods 



















168 1 65.50 <0.001* 
* Statistically significant change 
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Figure 8. Appropriate Penicillin Prescription Rates Across Time Periods 
Percent clinic visits with appropriate use of penicillin across the four analyzed time periods. The solid line 
represents the application of retrospective analysis (“No Documentation”), while the dashed line represents 
the medical history information that was currently available at the date of the clinic visit 
(“Documentation”).  
* p < 0.001: Pre-Sustain versus Post-Sustain, “Documentation” 
# p < 0.001: Pre-Intervention versus Sustain 2, “Documentation” 
** p < 0.001: Pre-Sustain versus Post-Sustain, “No Documentation” 
## p < 0.001: Pre-Intervention versus Sustain 2, “No Documentation”  
5.4 DISCUSSION 
The results of this assessment demonstrate that a QI focused on increasing documentation 
of pneumococcal immunization can lead to improvements in penicillin prescription in a pediatric 
sickle cell clinic. More broadly, it suggests how a modification of the EHR that increases access 
to important information during clinic visits may improve care. While previous research has 
explored the use of the EHR to increase vaccination rates, this report on a QI project is the first, to 
our knowledge, to show how utilization of the EHR may contribute to more judicious use of 
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implemented in the United States via NBS, this assessment, which focuses on a strategy to 
discontinue penicillin use when it is no longer recommended, has implications for public health.  
In the second aim, this assessment found that documentation of pneumococcal 
immunization status in the EHR significantly increased after a QI that involved: 1) staff time 
dedicated to collecting outside records, 2) the creation of a centralized source for storing paper 
records, and 3) enhancements to the EHR Sickle Cell Clinic Note. The rate of clinic visits with 
complete immunization documentation was less than 10% in the Pre-Intervention time period and 
grew to 81.3% post-intervention. A continued increase in documentation rates over the one year 
that followed the intervention was also demonstrated. This finding supports this strategy’s ability 
to sustainably improve immunization documentation in the medical records of SCD patients. 
The increase in documentation rates that immediately followed the intervention is 
consistent with findings of similar interventions. In their evaluation of a QI to improve 
pneumococcal vaccine rates in an immuno-compromised pediatric population, Malone et al. found 
that vaccination rates significantly increased after staff hours were allocated for requesting missing 
records.239 In the absence of this dedicated time, however, their progress metric returned to 
baseline over the following year. While this project similarly demonstrated significant 
improvements in its goal immediately following the intervention, the improvement was sustained 
and increased over the year of analysis. 
Several reasons may explain the discordance between these two studies’ findings regarding 
the sustainable effect of a QI that prominently featured staff efforts for record collection. Most 
notably is the difference in what was measured and analyzed. Malone et al. examined the percent 
of clinic visits for which the opportunity for immunization was not missed; whereas in the case of 
this assessment, progress was first measured by the change in proportion of clinic visits with 
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verified pneumococcal vaccination documentation. This assessment’s initial progress measure is 
more directly related to the clinical nurse’s efforts of collecting records. Additionally, the progress 
measure used by Malone e al. was a measure of incidence. On the other hand, this intervention’s 
progress measure was cumulative in nature: Once documentation is obtained for a patient, it will 
hopefully continue to be present in all subsequent visits as long as the current clinic procedures 
are followed. This is a specific feature of the Sickle Cell Clinic note. A more universal means of 
creating a lasting record of immunization status would be to upload immunization updates to the 
state immunization website. Of note, as the majority of patients were represented at least twice in 
the dataset across the four time periods, use of this measure likely exaggerates the true ongoing 
improvements that can be attributable to this intervention. Additionally, the effort to collect 
immunization records that occurred during the dedicated staff time was made for all active patients 
in the clinic. If a patient whose records were successfully obtained during the initial staff effort of 
record collection was not seen until a later time period of the evaluation, this delay would 
inaccurately convey a sustained effect of the initial intervention. However, continued effort is 
needed to enter this data into the patient’s EHR at the later date it is received. Finally, the continued 
increases in documentation rates likely reflect the impact of time. As obtaining records often 
required sending multiple fax requests to outside medical systems and waiting for records to be 
returned, documentation rates are expected to increase over time, as was seen in Aim 2.  
The demonstrated continued increase in documentation rates is unlikely to be solely due to 
the two-month effort by the Sickle Cell Clinic nurse, however. As not all missing records were 
identified and collected during the two months of the intervention, the findings do support a 
sustained ability to obtain immunization records. Additionally, as the Sickle Cell Clinic at CHP is 
the region’s SCD specialty clinic, it sees all newborns identified through NBS, as well as 
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individuals with SCD who move to the region. These are both sources of new patients. Patients 
coming from external medical systems are more likely to be missing records and have medical 
records that are more difficult to obtain. Thus, an ability to not only sustain, but increase 
immunization status documentation in the clinical note over time indicates that the other 
components of the intervention, such as the enhancements to the EHR, also positively impacted 
documentations rates. To more fully understand the sustained impact of the intervention on vaccine 
documentation, later times points need to be assessed. 
 As another goal of the QI, pneumococcal vaccination rates increased over the time 
analyzed by this assessment. This increase, as measured in Aim 3, was found to be statistically 
significant for PSV23 status as well as complete pneumococcal vaccination status. Baseline 
immunization rates in the Pre-Intervention time period were measured to be 58.1% for PPSV23 
and 54.7% for complete vaccination; this increased to 81.0% for PPSV23 and 75% for complete 
vaccination in the final time period evaluated.  
The Pre-Intervention PCV13 immunization rate of 75.2% demonstrated here is consistent 
with the 73% rate of PCV13 immunization found by Nero et al in the Michigan pediatric SCD 
population at 24 months of age.232 While this current assessment identified documentation, rather 
than immunization, as a larger barrier to discontinuing penicillin at an appropriate age, its findings 
of a baseline pneumococcal vaccination rate similar those of Nero et al support the conclusion 
made by Nero et al., that the SCD population in the United States is under-vaccinated. This 
conclusion was based on findings of vaccination rates that were significantly lower than national 
averages in the respective age groups. However, Nero et al. found vaccination rates of children 
with SCD to be higher than those rates in age, race, and geography-matched controls. Race-based 
health disparities in the United States are well-documented, and such lower rates of immunization 
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found by Nero et al. supporting race and geography-based barriers to immunization are consistent 
with this.139 Of note, immunization status evaluated by Nero et al., pertained only to the PCV13 
vaccine. In this assessment, the baseline documented PPSV23 and complete vaccination rates were 
lower than those of PCV13, at 58.1% and 54.7% respectively. While results of this QI 
demonstrated that true vaccination rates are likely to be higher than what is reflected in the medical 
documentation, this further indicates that children with SCD may be insufficiently protected 
against pneumococcal infection. 
In light of inadequate documented baseline immunization rates, this assessment 
demonstrated an ability of the QI to significantly increase these rates by an average of 
approximately 18% between the initial and final time points. This is consistent with other QI 
interventions described in the literature.234,236,238 Thus, this assessment adds to this body of work, 
which suggests that use of the EHR to increase visibility of vaccine status during clinic visits and 
assist with identifying eligible patients can significantly improve immunization rates. Given the 
populations of this along with the other studies, these findings may hold particular relevance for 
urban and/or high-risk populations. 
Documentation of PPSV23 vaccination rates remained lower than PCV13 rates throughout 
the time span of this project’s assessment. The PPSV23 vaccine has been approved by the FDA 
since 1983, while PCV13 was not introduced until 2010.212 One concern of the clinic was that older 
patients lacked PCV13 coverage, due to having received the PCV7 vaccine in its place and then 
not receiving the PCV13 when it became available. PCV13 vaccination rates that exceeded 
PPSV23 may also be explained by the prioritization of PCV13 in individuals who were in need of 
both. This prioritization is a result of two factors: first, PCV13 confers superior protection against 
pneumococcal infection, and second, PPSV23 may be administered sooner after PCV13 
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administration (2 months) than vice versa (12 months). Additionally, as different age criteria apply 
to the two vaccines, the age composition of the patient populations analyzed for PCV13 and 
PPSV23 immunization status differed. Age or another related characteristic may be confounding 
the results. It may indicate that older individuals may be less likely to be adequately immunized. 
This could be explored in further research. Finally, the measure of vaccination status used in this 
assessment was not direct. Its accuracy is limited by what information was available in the most 
current clinic note. As the vaccine was not noted to have been received if relevant records were 
never obtained, the findings in Aim 3 finding likely reflects incomplete documentation, in addition 
to actual vaccination rates. However, as is demonstrated in Aim 2, the differences in 
documentation rates of the PPSV23 and PCV13 vaccines were minimal and are unlikely to fully 
account for the differences found in PCV13 and PPSV23 vaccination rates. 
As the ultimate goal of the QI, this assessment aimed to demonstrate how efforts to increase 
pneumococcal immunization documentation and compliance rates may affect appropriate 
penicillin prescription in the pediatric SCD population. The results of Aim 4 support that such an 
intervention has a positive effect on appropriate prescription, which for the purpose of this 
assessment, was defined as its prescription when indicated and a lack of its prescription when not 
indicated. In review of the final data, inappropriate penicillin prescription was only represented by 
cases of excessive penicillin prescription; this is when penicillin was prescribed despite clinical 
guidelines that suggest that penicillin is no longer necessary. In no cases was penicillin not 
prescribed despite being indicated, which is reassuring given the strong recommendation for 
penicillin prophylaxis by the NIH guidelines that is based on the PROPS study.19 
Prior to the intervention, penicillin was appropriately prescribed to the clinic’s patients 
over six years old in 54.1% of clinic visits when using criteria considered immunization 
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documentation. This rate was just over one-third of clinic visits (34.1%) when retrospective criteria 
were applied. While the former criteria reflect the actual clinical requirements for penicillin 
prescription, the latter set of criteria was used to emphasize the effect that missing documentation 
had on unnecessary penicillin use. The difference between these rates, which was 20.0% at 
baseline, represents the minimum rate of inappropriately sustained penicillin prescription that can 
be attributed to the immunization documentation missing in the EHR. The strength of the 
intervention’s effect on immunization documentation is illustrated by a convergence of these two 
criteria’s rates across the four time periods. By Sustain 2, the two rates were equal, which suggests 
that this QI removed missing records as a barrier to appropriate use of penicillin, although this may 
also be related to an artifact of data collection. This final rate was significantly higher (94.0%) 
than either baseline rate but was not 100%. This illustrates the role of other factors, such as 
discussing stopping penicillin with eligible patients, in prescribing penicillin appropriately. An 
evaluation of additional barriers, as well a direct analysis of the effect that insufficient 
pneumococcal immunization has on penicillin prescription, is a potential topic for future studies. 
5.4.1  Limitations 
A significant limitation of this assessment was its reliance on indirect means of measuring 
key variables, namely vaccination status and disqualifying medical events. Data for these variables 
were obtained from the patients’ medical records. A fact that was central to this intervention is that 
medical records may be contradicting, incorrect, or not up to date. The data analyzed here can only 
be as accurate as its EHR source  
The possible human error involved in collecting and recording this data introduces an 
additional potential source of error. A number of steps were taken to minimize possible sources of 
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inaccuracy. Immunization status was obtained from the latest Sickle Cell clinic note and applied 
retrospectively to clinic visits of previous time periods if it been missing from those clinic notes. 
This was done in order to most accurately reflect this variable of vaccination status for all data 
points. Additionally, cases with unclear notes regarding penicillin prescription were reviewed a 
second time by a separate reviewer. This individual also performed a final review of the collated 
data for inconsistencies and ambiguous data points and referred back to the clinic note for the most 
likely scenario. In spite of these efforts, immunization statuses likely remain underestimates of the 
true rates, because in the case of insufficient documentation, the vaccine was marked as not 
received. This is supported by the difference between documentation rates and actual 
immunization rates seen in Aims Two and Three, where many more patients had received the 
vaccine than was indicated by their medical records. Finally, only the clinic visit notes being 
reviewed for data collection were used to determine if the patient had experienced a disqualifying 
medical event (surgical splenectomy or IPD). Any such events that were not documented in the 
clinic visit note, but had occurred and were dictating penicillin prescription, would lead to a greater 
calculated rate of inappropriate penicillin prescription. 
An additional limitation of this assessment has already been discussed in relation to Aim 
2: the use of prevalence, rather than incidence, measures to evaluate for effects of the intervention. 
The presence of the same patients multiple times in the dataset means that both previous and new 
cases were evaluated for the audited time periods. As all of the variables were chronic in nature, a 
change made in a patient’s vaccination, vaccine documentation, or penicillin prescription status 
that was brought about by the intervention was reflected in all subsequent data points for that 
patient. Using an incidence metric as did Malone et al., would add additional valuable insight into 
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effect of the QI. However, this metric would have less statistical power and would also not have 
allowed for analysis of the sustained effect of the QI for individual patients.  
One hundred eighty patients were represented in the sample population. In 2017, the SCDB 
records the Sickle Cell clinic as having 221 active patients. At approximately 80% of the total 
patient population, this is a sufficiently large sample size to be considered representative. There is 
still a possibility for sampling bias. Many patients in the dataset are represented by more than one 
data point per time period. Patients with more data points are those who visited the clinic more 
frequently during the audited time period; they are also likely to be those who visit the Sickle Cell 
clinic more often than the average patient in general. These patients may differ in ways that make 
them not representative of the total pediatric patient population seen by the Sickle Cell Clinic. As 
these characteristics may relate to the probability of having pneumococcal vaccines documented 
or received, or to the other criteria used to determine penicillin prescription, such as history of a 
surgical splenectomy, this may have introduced systematic error into the way the three metrics of 
this QI’s success were measured.  
To analyze for the effect of this, a smaller dataset with each patient represented once per 
time period was analyzed in parallel to the larger dataset, as described in the methods section. A 
comparison of the two indicated a minimal effect of duplicate or triplicate patient visits in sample, 
with similar patterns and rates of improvement across the four time periods demonstrated by both 
datasets. Consequently, the larger dataset was utilized for this assessment. This choice was 
validated by Malone et al, who also used individual clinic visits, rather than unique patients, to 
analyze the effect of a QI with a similar structure and goal.239 
It should be noted that the clinic, which is located in an urban center, is a specialty center 
that draws upon a large and diverse geographical area of patients in the western Pennsylvania 
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region. The unique characteristics of the pediatric Sickle Cell Clinic at CHP may indicate 
limitations of this QI’s effectiveness to wider use, such as in primary care, non-academic, and/or 
rural care facilities. However, as described in Aim 1, the general demographic characteristics of 
the patient population seen at the Pediatric Sickle Cell Clinic at CHP are similar to other studies 
involving the SCD population in terms of racial background, distribution of SCD types, and 
insurance coverage.232,236 As was previously discussed, the clinic’s immunization records were 
largely lost after a move from paper to electronic records. Consequently, baseline documentation 
rates in this clinic’s population may be lower than average. The effect of a similar QI in other 
clinics with higher baseline rates of vaccine documentation may not be as dramatic as was found 
in this assessment. 
5.4.2  Public Health Relevance 
As enabled through NBS, penicillin prophylaxis for infants with SCD significantly reduces 
their risk for potentially fatal pneumococcal infection. These initial services of diagnosis and 
immediate care often receive significant attention and resources in NBS. However, the public 
health program is intended to be comprehensive and span an individual’s lifetime. This involves 
six primary components, which are education, screening, follow-up, diagnosis, treatment and 
management, and evaluation of programs for continuous quality improvement.167,168 
In the NBS program, follow-up is comprised of both short-term and, in some states long-
term, services. The latter begins once an infant has received a definitive diagnosis through the 
program and the necessary disease management or treatment has been initiated.86 Services should 
be provided into adulthood in order to maximize the benefit of diagnosis through the program.85 
In the case of SCD, long-term health care includes complete pneumococcal vaccination as well as 
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cessation of penicillin after the age of five years old, when it has no longer been shown to provide 
significant benefit.19,226 As this assessment demonstrates the effectiveness of a QI in increasing 
pneumococcal vaccination rates and discontinuing inappropriate penicillin prescription in children 
with SCD, it adds to current knowledge about how to successfully implement NBS services in the 
SCD patient population.  
In 2008, a statement was put forth by the SACHDNC, an organization that was created to 
guide the US Department of Health and Human Services Secretary on NBS tests, policies, and 
guidelines. The statement came in response to studies which found that long-term follow-up in 
NBS is variably and inconsistently applied.84,240,241 To clarify the role of this core service in NBS 
programs, the SACHNDNC specified that long-term follow-up should include “the assurance and 
provision of quality chronic disease management, condition-specific treatment, and age-
appropriate preventative care throughout the lifespan of individuals identified with a condition 
included in newborn screening.”85 Additionally, it should ensure care coordination and 
“continuous quality improvement,” as well as “active surveillance and evaluation of data related 
to care and outcomes.” The project described by this assessment was carried out at a specialty 
sickle cell clinic to provide such services to children identified to have SCD through the NBS 
program. 
First, this project demonstrates the value of the EHR to a pediatric sickle cell clinic’s ability 
to coordinate their patients’ care. The Sickle Cell Clinic of CHP is contracted with the Department 
of Health of the Commonwealth of Pennsylvania to follow-up on newborns identified with SCD 
through NBS in Western Pennsylvania and seeks to ensure their comprehensive, multidisciplinary 
care until their transition into adult care. This is in line with the intent of the NBS program to 
provide such care to individuals diagnosed through the program through the provision of both 
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primary care and specialty health care services.242,243 The EHR is an invaluable tool for the care 
coordination that is necessary for this service, as it facilitates communication by providers across 
different clinics and health care systems.234,238,244 This QI leveraged concerted efforts in collecting 
and updating the vaccination records of the clinic’s pediatric SCD population, as well 
modifications to the EHR, to better enable this communication, thereby allowing for deficient 
pneumococcal vaccination status to be identified and provided by the specialty clinic or the child’s 
pediatrician. This resulted not only in increased pneumococcal vaccination rates, but a decrease in 
inappropriate penicillin prescription. Finally, the QI promoted conversations between the family 
and the clinicians about discontinuing penicillin if indicated. This is consistent with another goal 
of a medical home, which is to engage in family-centered and culturally effective care.126,242  
As it is another component of NBS, quality improvement was the primary focus of this 
assessment.85 Quality improvement in NBS can be enabled by data-systems such as the EHR, 
which capture clinical care data that can be analyzed in order to inform clinical decisions and 
policies. This assessment engaged in record collection from the EHR in order to identify deficient 
vaccination documentation as a significant barrier to the age-appropriate cessation of penicillin for 
children with SCD. The data review also demonstrated that the interventions engaged in by the QI 
served as an effective means of addressing this barrier. 
Finally, the importance of this assessment, which presents a strategy for discontinuing 
penicillin, is further emphasized by evidence that excessive antibiotic use may contribute to the 
emergence of resistant pneumococcal strains.227 Increased resistance diminishes the effectiveness 
of prophylaxis in the SCD population.226 As a primary intention of the NBS program for SCD is 
to reduce morbidity and mortality due to IPD, responsible implementation of this public health 
program calls for stopping penicillin when it is no longer recommended.245 
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While more evidence is needed, a number of additional populations, such as those with less 
severe SCD types and those who have received a surgical splenectomy, have been explored in the 
literature review as potential recipients of excess penicillin prescription. The findings of this 
assessment suggest that adoption of similar strategies by other SCD clinics may allow for more 
judicious use of penicillin. Ultimately, greater utilization of similar interventions may minimize 
the unintended, and likely deleterious, consequences of excessive penicillin prophylaxis in high-
risk, immune-compromised populations. 
5.5 CONCLUSION 
In the 18-month time span evaluated by this assessment, all three metrics of improvement 
that the QI sought to improve, pneumococcal vaccine documentation, immunization rates, and 
appropriate penicillin prescription, were found to increase from baseline rates. Significant 
increases in vaccination documentation status, as well as appropriate penicillin prescription were 
found in the time period immediately following implementation of the QI. These changes were 
sustained or increased in the time periods that followed. While vaccination rates did not appear to 
significantly increase immediately after the intervention, complete vaccination rates were found 
to have significantly increased, by approximately 20%, by the final time period. This is consistent 
with improvements in vaccination rates that have demonstrated by other interventions that utilize 
the EHR in an urban, pediatric population.234,236–238 Baseline pneumococcal vaccination rates that 
were consistent with, or even lower, than other literature focusing on the SCD population indicate 
a need to implement such interventions in high-risk population.232 The importance of protection 
against pneumococcal infection and its connection to resistant strains further fuels this QI’s 
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ultimate goal, which was to address excessive penicillin prescription. To further contribute with 
this effort, additional research is needed to more fully explore the barriers to pneumococcal 
vaccination and penicillin discontinuation, so that possible interventions may be implemented to 
address these concerns in the SCD population. 
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  TRAIT NOTIFICATION NEWBORN SCREENING LETTERS 
B.1 Sickle S Trait Letter 
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B.2 Hemoglobin C Trait Letter 
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 INFORMATION BROCHURE 
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 WAIVER OF INFORMED CONSENT 
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The survey sent for HbC trait screening results was identical except “Sickle S trait” was replaced 
with “Hemoglobin C trait.” 
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  PROMIS SCORING TABLE 
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 MAIL AND TELEPHONE SURVEY RESPONSES 
H.1 Knowledge Questionnaire





1. Did the video make it clear
that there is a difference
between sickle cell trait and
sickle cell disease? This is not a
question that can be answered
correctly or incorrectly (Yes)
Mail 100% 0% 0% 
Telephone 91.4% 6.1% 2.5% 
Total 95.2% 5.3% 2.1% 
2. Can a child with sickle cell
trait ever develop sickle cell
disease?
(No)
Mail 76.9% 7.7% 16.1% 
Telephone 70.4% 16.1% 13.6% 
Total 71.3% 14.9% 13.8% 
3. Do both parents have to have
sickle cell trait for a baby to be
born with sickle cell disease
(Yes)
Mail 53.9% 38.5% 7.7% 
Telephone 65.4% 33.3% 1.2% 
Total 63.8% 34.0% 2.1% 
4. If one parent has sickle S trait
and one parent has hemoglobin
C trait, could they have a baby
with disease? (Yes)
Mail 61.5% 15.4% 23.1% 
Telephone 51.9% 21.0% 27.2% 
Total 53.2% 20.2% 26.6% 
5. If you have sickle cell trait,
could your brother or sister also
have sickle cell trait? (Yes)
Mail 69.2% 23.08% 7.7% 
Telephone 75.3% 21.0% 3.7% 
Total 74.5% 21.3% 4.3% 
180 
6. Can you choose which genes
are passed onto your children?
(No)
Mail 100% 0% 0% 
Telephone 92.6% 2.5% 4.9% 
Total 93.6% 2.1% 4.3% 
7. Can you “catch” sickle cell
disease like a cold? (No)
Mail 100% 0% 0% 
Telephone 100% 0% 0% 
Total 100% 0% 0% 
      Mail: n = 13; Telephone: n = 81; Total: n = 94 
H.2 Sharing
Have you or 





Method Yes No Unsure 
Partner 
Mail 100% 0% 0% 
Telephone 96.3% 3.7% 0% 
Total 96.8% 3.2% 0% 
Child 
Mail 100% 0% 0% 
Telephone 98.8% 0% 1.2% 
Total 98.9% 0% 1.1% 
Child’s 
Doctor 
Mail 100% 0% 0% 
Telephone 88.8% 7.4% 3.7% 
Total 90.4% 6.4% 3.2% 
Own Doctor 
Mail 76.9% 15.4% 7.7% 
Telephone 70.4% 27.2% 2.5% 
Total 71.3% 25.5% 3.2% 
 Mail: n = 13; Telephone: n = 81; Total: n = 94 
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  SELECTED MAIL AND TELEPHONE RESPONSES 
Mail: 
 
I checked sometimes in those 3 boxes because that is how I felt when I first found out she had the 
trait. But now that I learned about it and read about it I feel much better 
 
The letter made me feel generally uncertain…about the present and the future. I could tell it was 
intended as notification and tried to reassure me that nothing is wrong, but it is still very 
intimidating to be contacted by the Hematology/Oncology department of Children's Hospital... 
 
My husband is Hispanic and we know I do not carry the Hemoglobin S trait; how do we go about 
getting him and members of this family tested for the Hemoglobin S trait? His country never tested 




I read it over and over. I was glad they put that number on there. I was very worried. 
 
Doctor called and told me to take him in immediately, that his “hemoglobin levels are low.” 
 
My husband has it and he knows biology and was able to explain it to me. 
 
I have three children with it [hemoglobin c trait]. It’s not a big deal. 
 
I was bawling my eyes out for the first ten minutes. I was confused about it [trait] and the disease, 
that it is not the disease. Also, the timing with all the hormones. 
 
Everyone in my family has sickle cell. 
 
It did scare me when I saw that letter. What’s going on? Then I read it and was reassured, that 
it’s something to think about when she is finding her life partner and having babies.  
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  QUALITY INITIATIVE REVIEW COMMITTEE APPROVAL LETTER 
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